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Background: People with cystic fibrosis frequently have low levels of adherence to inhaled medications.
Objectives: The objectives were to develop and evaluate an intervention for adults with cystic fibrosis
to improve adherence to their inhaled medication.
Design: We used agile software methods to develop an online platform. We used mixed methods to
develop a behaviour change intervention for delivery by an interventionist. These were integrated to
become the CFHealthHub intervention.We undertook a feasibility study consisting of a pilot randomised
controlled trial and process evaluation in two cystic fibrosis centres.We evaluated the intervention using
an open-label, parallel-group randomised controlled trial with usual care as the control. Participants were
randomised in a 1 : 1 ratio to intervention or usual care. Usual care consisted of clinic visits every 3 months.
DOI: 10.3310/pgfar09110 Programme Grants for Applied Research 2021 Vol. 9 No. 11
Copyright © 2021 Wildman et al. This work was produced by Wildman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
vii
We undertook a process evaluation alongside the randomised controlled trial, including a fidelity study,
a qualitative interview study and a mediation analysis. We undertook a health economic analysis using both
a within-trial and model-based analysis.
Setting: The randomised controlled trial took place in 19 UK cystic fibrosis centres.
Participants: Participants were people aged ≥ 16 years with cystic fibrosis, on the cystic fibrosis
registry, not post lung transplant or on the active transplant list, who were able to consent and not
using dry-powder inhalers.
Intervention: People with cystic fibrosis used a nebuliser with electronic monitoring capabilities.
This transferred data automatically to a digital platform. People with cystic fibrosis and clinicians could
monitor adherence using these data, including through a mobile application (app). CFHealthHub
displayed graphs of adherence data as well as educational and problem-solving information. A trained
interventionist helped people with cystic fibrosis to address their adherence.
Main outcome measures: Randomised controlled trial – adjusted incidence rate ratio of pulmonary
exacerbations meeting the modified Fuchs criteria over a 12-month follow-up period (primary outcome);
change in percentage adherence; and per cent predicted forced expiratory volume in 1 second
(key secondary outcomes). Process evaluation – percentage fidelity to intervention delivery, and participant
and interventionist perceptions of the intervention. Economic modelling – incremental cost per quality-
adjusted life-year gained.
Results: Randomised controlled trial – 608 participants were randomised to the intervention (n = 305)
or usual care (n = 303). To our knowledge, this was the largest randomised controlled trial in cystic
fibrosis undertaken in the UK. The adjusted rate of exacerbations per year (primary outcome) was 1.63
in the intervention and 1.77 in the usual-care arm (incidence rate ratio 0.96, 95% confidence interval
0.83 to 1.12; p = 0.638) after adjustment for covariates. The adjusted difference in mean weekly
normative adherence was 9.5% (95% confidence interval 8.6% to 10.4%) across 1 year, favouring the
intervention. Adjusted mean difference in forced expiratory volume in 1 second (per cent) predicted
at 12 months was 1.4% (95% confidence interval –0.2% to 3.0%). No adverse events were related to
the intervention. Process evaluation – fidelity of intervention delivery was high, the intervention was
acceptable to people with cystic fibrosis, participants engaged with the intervention [287/305 (94%)
attended the first intervention visit], expected mechanisms of action were identified and contextual
factors varied between randomised controlled trial sites. Qualitative interviews with 22 people with
cystic fibrosis and 26 interventionists identified that people with cystic fibrosis welcomed the objective
adherence data as proof of actions to self and others, and valued the relationship that they built with
the interventionists. Economic modelling – the within-trial analysis suggests that the intervention
generated 0.01 additional quality-adjusted life-years at an additional cost of £865.91 per patient,
leading to an incremental cost-effectiveness ratio of £71,136 per quality-adjusted life-year gained.
This should be interpreted with caution owing to the short time horizon. The health economic model
suggests that the intervention is expected to generate 0.17 additional quality-adjusted life-years
and cost savings of £1790 over a lifetime (70-year) horizon; hence, the intervention is expected to
dominate usual care. Assuming a willingness-to-pay threshold of £20,000 per quality-adjusted life-year
gained, the probability that the intervention generates more net benefit than usual care is 0.89.
The model results are dependent on assumptions regarding the duration over which costs and effects
of the intervention apply, the impact of the intervention on forced expiratory volume in 1 second
(per cent) predicted and the relationship between increased adherence and drug-prescribing levels.
Limitations: Number of exacerbations is a sensitive and valid measure of clinical change used in many
trials. However, data collection of this outcome in this context was challenging and could have been
subject to bias. It was not possible to measure baseline adherence accurately. It was not possible to
quantify the impact of the intervention on the number of packs of medicines prescribed.
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Conclusions: We developed a feasible and acceptable intervention that was delivered to fidelity in the
randomised controlled trial. We observed no statistically significant difference in the primary outcome
of exacerbation rates over 12 months. We observed an increase in normative adherence levels in a
disease where adherence levels are low. The magnitude of the increase in adherence may not have
been large enough to affect exacerbations.
Future work: Given the non-significant difference in the primary outcome, further research is required
to explore why an increase in objective normative adherence did not reduce exacerbations and to
develop interventions that reduce exacerbations.
Trial registration: Work package 3.1: Current Controlled Trials ISRCTN13076797. Work packages 3.2
and 3.3: Current Controlled Trials ISRCTN55504164.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 9, No. 11. See the NIHR Journals Library website for further project information.
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Plain English summary
People with cystic fibrosis need medication to stay well. They take some medication using anebuliser. This is a machine that helps people to inhale medicine as a mist. Nebulisers are used to
take medication that prevents health problems occurring. People do not always take all the doses of
their nebuliser treatments and they often believe that they take more than they do. Our research
aimed to develop a new intervention called ‘CFHealthHub’. This was a website and mobile application
to show people with cystic fibrosis their actual medication use, and training for health-care
professionals to help people to take more of their medication.
We used feedback from patients and staff in three cystic fibrosis centres to develop CFHealthHub.
We tested it in a small study. We then improved the intervention before using it in a larger study. We
focused on whether or not people with cystic fibrosis had fewer spells of being ill in hospital and
whether or not they took more of their treatments.
A total of 19 cystic fibrosis centres took part in the main study. The study recruited 608 people with
cystic fibrosis. They were in the study for 12 months. All participants received their usual treatment.
Half were also given the CFHealthHub intervention. Numbers of nebuliser treatments taken by people
with cystic fibrosis were automatically measured. People with cystic fibrosis completed questionnaires
about their general health during the study. We interviewed 22 people with cystic fibrosis and 26
health-care professionals delivering the intervention about their views of CFHealthHub.
We found that CFHealthHub did not reduce spells of being ill in hospital. However, we found that
those who used CFHealthHub took more of their nebuliser medication. People with cystic fibrosis
felt that the new intervention was helpful and valued the relationship they had with health-care
professionals delivering the intervention. We found that the intervention may be good value for money
for the NHS. However, this depends on how long the intervention is effective for and whether or not
increasing adherence also increases the numbers of prescriptions for medicines.
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The World Health Organization states that poor adherence to medication is a worldwide problem
associated with poor health outcomes and increased costs to health-care systems. This is particularly
problematic in chronic conditions including cystic fibrosis. Existing nebulised therapies for cystic
fibrosis are effective but only when adherence levels are high. Low levels of adherence are associated
with poor health outcomes, including increased rates of pulmonary exacerbations and rapid lung
function decline. Objectively measured adherence levels in cystic fibrosis are estimated to be as low as
30–40%, as measured on dose-counting nebulisers. Subjective estimates of adherence levels are higher,
at around 80%.
To date, behaviour change interventions designed to increase adherence in cystic fibrosis have
demonstrated little success. This may be because interventions have not targeted the most appropriate
factors, because there is a lack of studies using a theory- and evidence-based approach to intervention
development and because interventions tend to assume that one size fits all, despite evidence that the
factors affecting adherence may be person-specific. Indirect or subjective measures of adherence have
also limited the reliability of adherence measurements in these studies.
This programme aimed to develop a theory- and evidence-based intervention that targets specific
capability, opportunity and motivational issues faced by people with cystic fibrosis, to support people
with cystic fibrosis to increase adherence to nebulised medications and, through that, to reduce the
number of exacerbations that they experience.
Objectives
The aim was to develop and evaluate an intervention to support adherence to inhaled medications for
people with cystic fibrosis.
Our specific objectives map to three work packages:
1. to develop a mechanism for objective measurement of adherence through (1) development of a data
capture and transfer infrastructure that can collect time- and date-stamped data and (2) display this
data both on a ‘CFHealthHub’ website, for use by people with cystic fibrosis and their clinicians,
and on a CFHealthHub mobile application, for people with cystic fibrosis, and (3) develop the
CFHealthHub web interface with patients and clinicians
2. to develop an evidence-based behaviour change intervention to increase adherence to nebulised
cystic fibrosis medications that works concurrently with the CFHealthHub digital platform
3. to evaluate the CFHealthHub intervention (platform plus behaviour change intervention) in terms of
(1) clinical effectiveness, (2) acceptability and (3) cost-effectiveness and to examine the processes
that drive these outcomes.
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Developing the technology and infrastructure to collect adherence data
A data capture and transfer infrastructure was constructed that collected time- and date-stamped
nebuliser utilisation data from chipped nebulisers and displayed these data on a CFHealthHub website
for use by both people with cystic fibrosis and their clinicians. A mobile application was developed to
display data for use by people with cystic fibrosis. Agile software development methods were used to
develop the CFHealthHub website and application. Sprint cycles were released, iteratively incorporating
technical requirements identified by the research team and the nebuliser supplier. This continued
throughout the feasibility study (work package 3.1). Decisions on which changes to implement were
made by the research team, in consultation with the patient and public involvement panel.
Website and mobile application iterations were conducted over 18 months. The priority was to
display to people with cystic fibrosis and their care team objective adherence data captured from
dose-counting nebulisers. Technical architecture was developed to enable this, along with role-based
interfaces for clinicians/interventionists, members of the research team and people with cystic fibrosis.
Alongside adherence data display, the following behaviour change intervention website features
were developed and integrated: ‘My Education’ and ‘Problem-solving’, ‘My Toolkit’, a screening tool
to support intervention tailoring, peer videos, ‘Action Planning’, ‘Coping Planning’, ‘Party Planning’,
‘Day Planning’, push notifications, click and touch analytics, and export functionality. The final version
of the platform was completed for the launch of the full-scale randomised controlled trial.
Work package 2
Understanding the illness perceptions and treatment beliefs of people with cystic
fibrosis (work package 2.1A)
Eighteen face-to-face semistructured qualitative interviews were conducted with people with cystic
fibrosis in one UK cystic fibrosis centre to explore perceptions of their condition, their treatments, the
acceptability of visual displays of their recent medications adherence, and perceived barriers to and
facilitators of adherence to their treatments. The perceived barriers to and facilitators of adherence to
treatments were interpreted using the theoretical domains framework. Key contextual issues related
to desires to feel normal, varying levels of openness about their condition, health beliefs, treatment
burden, tiredness and emotions. Specific barriers to and facilitators of medication adherence covered
all 14 theoretical domains. Ways of improving the acceptability of adherence graphs were identified.
Findings fed into the intervention development in work package 2.2.
Patient story video interviews to develop the CFHealthHub intervention
(work package 2.1C)
A purposive sample of 14 people with cystic fibrosis with high levels of adherence (> 80%) or sustained
increases in adherence level were interviewed face to face to identify positive experiences of overcoming
barriers to adherence. Interviews were video-recorded and extracts selected. A series of ‘talking heads’
video clips were integrated into the behaviour change intervention as a resource on the CFHealthHub
platform (work package 2.2).
Behaviour change intervention development (work package 2.2)
A four-stage process to plan, design, create and refine the behaviour change intervention was
conducted. A mixed-methods approach, combining theory and evidence in the capability, opportunity,
motivation – behaviour model and behaviour change wheel and the ‘person-based approach’, was
used to iteratively develop the behaviour change intervention part of the intervention, alongside
the development of the digital platform. This incorporated findings from work package 1, work
package 2.1A, work package 2.1C and the feasibility study in work package 3.1 as well as two additional
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studies: (1) an early prototype of the intervention was tested on five people with cystic fibrosis, who
were interviewed after 1 week and 1 month, and (2) 22 participants received four intervention sessions
from a physiotherapist/interventionist and were given access to CFHealthHub over five iterative cycles
of development. Participants were interviewed and six undertook ‘think aloud’ interviews, which were
recorded, during use of the CFHealthHub website. Changes to the intervention were considered based
on the feedback, and refinements were made for each new iteration of the intervention.
An intervention manual and training programme for interventionists was produced and used in the
feasibility study (work package 3.1). The training programme comprised face-to-face and online elements
and included assessments of competence. Further amendments were made to the intervention and the
training programme in response to findings from the feasibility study process evaluation before use in
the full-scale randomised controlled trial (work package 3.2).
Work package 3
Feasibility study (work package 3.1)
A pilot open-label, parallel-group randomised controlled trial with concurrent mixed-methods process
evaluation was conducted. Interventionists were recruited in two UK cystic fibrosis centres. Participants,
recruited at both centres, were people aged ≥ 16 years with cystic fibrosis, on the cystic fibrosis registry,
not post lung transplant or on the active transplant list, who were able to consent and not using dry-
powder inhalers. They were given a nebuliser with time- and date-stamped inhalation data transfer
capability and randomised on a 1 : 1 allocation. Intervention arm participants received the behaviour
change intervention with access to CFHealthHub platform; control arm participants received usual care.
Feasibility was determined on recruitment of > 48 participants (75% of target) in 4 months, valid
exacerbation data available for > 85% of those randomised, change in per cent adherence (a secondary
outcome for the full-scale randomised controlled trial), and positive perceptions of the intervention
from qualitative interviews with intervention (n = 14) and control (n = 5) participants, interventionists
(n = 3) and multidisciplinary team members (n = 5). Recruitment (n = 64) and retention (94%) targets
were met. Five serious adverse events (not related to the intervention) were identified. At study
completion, mean change in adherence was 10% (95% confidence interval –5.2% to 25.2%).
In the qualitative interview study there was evidence of the expected behaviour change mechanisms of
action and mechanisms of action associated with effective telehealth interventions for self-management
support: relationships, visibility and fit. The intervention was tailored to individuals but there were
challenges in how the intervention fitted into some patients’ busy lives when delivered through a
desktop computer. Interventionists identified that patients with moderate adherence rates were more
likely to benefit.
The feasibility study led to 25 key changes to randomised controlled trial procedures and the intervention.
These included a longer recruitment accrual window, development of an application for mobile
telephones, changes to the interventionist training and manual to emphasise ‘active ingredients’, and
increased numbers of protocolised intervention review sessions.
Full-scale randomised controlled trial (work package 3.2) and process evaluation
(work packages 3.3 and 3.4)
A full-scale, open-label, parallel-group randomised controlled trial with concurrent mixed-methods
process evaluation to examine the clinical effectiveness of the final CFHealthHub intervention.
The intervention was delivered by physiotherapists in 13 out of the 19 centres and nurses, psychologists,
a pharmacist and a dietitian in other centres. Some centres had two interventionists that shared the role,
sometimes from different clinical disciplines.
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Work package 3.2
People with cystic fibrosis from 19 UK cystic fibrosis centres, aged ≥ 16 years, on the cystic fibrosis
registry and not post lung transplant or on the active transplant list, who were able to consent and not
using dry-powder inhalers, were given a nebuliser with time- and date-stamped inhalation data transfer
capability. Participants were randomised on a 1 : 1 allocation to the intervention (n = 305) or usual
care (n = 303). One participant randomised to the intervention arm withdrew on the day of consent,
prior to baseline data collection. The primary outcome was adjusted incidence rate ratio of pulmonary
exacerbations meeting the modified Fuchs criteria over a 12-month follow-up period. Key secondary
outcomes were adjusted between-group differences in medication adherence, forced expiratory
volume in 1 second (per cent) predicted and body mass index at 12 months. The adjusted incidence
rate ratio of exacerbations at 12 months was 0.96 (95% confidence interval 0.83 to 1.12; p = 0.638).
The adjusted mean difference in normative adherence was 9.5% (95% confidence interval 8.6% to
10.4%; p < 0.001) across 1 year, favouring the intervention. The adjusted mean difference in forced
expiratory volume in 1 second (per cent) predicted was 1.4% (95% confidence interval –0.2% to 3.0%;
p = 0.082) at 1 year, favouring the intervention. There was an adjusted mean difference in body mass
index of 0.3 kg/m2 (95% confidence interval 0.1 to 0.6 kg/m2; p = 0.008), favouring the intervention.
Work package 3.3
The process evaluation consisted of (1) a fidelity study (including analysis of click analytics in
CFHealthHub), (2) a survey of usual care consisting of an 11-item questionnaire completed by staff at
each randomised controlled trial site at baseline (n = 20) and follow-up (n = 19), (3) a survey of user-
perceived helpfulness of different intervention components at 12 months completed by 257 out of
305 intervention arm participants, (4) a qualitative study of interviews with 22 intervention users,
26 interventionists recruited to deliver the intervention in the randomised controlled trial and five
members of the multidisciplinary team in five sites, (5) a mediation analysis to assess the mechanisms
of action of the intervention and (6) trial monitoring data. Triangulation of the process evaluation
components identified the following key findings:
l interventionist fidelity to the intervention was high at 18 out of 19 randomised controlled trial sites
l the intervention was substantially different from usual care because, although usual care varied
between randomised controlled trial sites, access to objective adherence measurements was described
as infrequent and ad hoc
l the intervention was acceptable to people with cystic fibrosis – all components were rated as mostly
helpful, with first intervention sessions, adherence graphs/tables and face-to-face intervention sessions
rated among the most helpful components
l some people with cystic fibrosis did not like the patient stories (videos) or setting formal action plans
l participants engaged with the intervention, including the tailored education and problem-solving,
and personalised target setting and rewards
l the mean adherence between 6 and 12 months was primarily mediated by awareness of medication
usage (overall, 37% of the total effect mediated, 95% confidence interval 24% to 51%), with habit
formation (9% of the total effect mediated, 95% confidence interval 3% to 16%) the second most
important factor.
The qualitative research identified additional mechanisms of action, including how interventionists
spending time with people with cystic fibrosis and listening to wider life concerns could help to build
relationships and trust that facilitated adherence improvement, and how changes occurred if the
intervention was delivered at the right time in patients’ lives. People with cystic fibrosis with different
baseline adherence rates responded differently to the intervention. Context varied between
randomised controlled trial sites in terms of the engagement of the multidisciplinary team with the
intervention and the strengths of the interventionists in each site.
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Health economic analysis (work package 3.5)
We undertook two related economic analyses to assess the cost-effectiveness of the intervention:
(1) a short-term within-trial economic evaluation that compared health gains and costs for the intervention
and usual care arms using patient-level data from the 1 year primary outcome window of the randomised
controlled trial and (2) a model-based analysis that compared the intervention versus usual care over a
lifetime horizon using multiple sources of evidence. The base case results for the within-trial analysis
(including multiple imputation of missing data) indicated that the intervention generated 0.01 additional
quality-adjusted life-years at an additional cost of £865.91 per patient; the corresponding incremental
cost-effectiveness ratio was £71,136 per quality-adjusted life-year gained. The health economic model
suggested that the intervention could generate 0.17 additional quality-adjusted life-years and cost
savings of £1790 compared with usual care; this assumes a lifetime horizon and that the treatment
effect lasts for 10 years. Therefore, the adherence intervention is expected to dominate usual care.
Sensitivity analyses indicated that the conclusions of the economic analysis were sensitive to assumptions
regarding (1) the duration over which health effects and costs of the adherence intervention apply,
(2) the impact of the intervention on the patient’s forced expiratory volume in 1 second (per cent)




The CFHealthHub was successfully developed. In the full-scale randomised controlled trial there was
no statistically significant reduction in the primary outcome of the number of pulmonary exacerbations
at 12 months. Clinically and statistically significant improvements in the key secondary outcome of
normative adherence were observed. The magnitude of the increase in adherence, at 10% on average,
may not have been large enough to affect exacerbations. The intervention was delivered with fidelity,
and key mechanisms of action, including self-monitoring, were observed. The health economic model
suggested that the intervention is expected to generate additional health gains of 0.17 quality-adjusted
life-years and cost-savings of £1790 over the patient’s remaining lifetime. This finding is dependent on
assumptions regarding the duration over which costs and effects of the intervention apply, the impact
of the intervention on forced expiratory volume in 1 second (per cent) predicted and the relationship
between increased adherence and drug-prescribing levels.
Limitations
Number of exacerbations is a sensitive and valid measure of clinical change used in many trials.
However, data collection of this outcome in the context of this trial was challenging and could have
been subject to bias. It was not possible to measure baseline adherence accurately. It was not possible
to quantify the impact of the intervention on the number of packs of medicines prescribed. As a
consequence, there remains uncertainty regarding the relationship between improving adherence on
overall treatment costs incurred by the NHS.
Implications for practice
An infrastructure for measuring objective adherence data was established that could be used in routine
care. The availability of these data may be useful for accurate diagnosis and medicines optimisation.
The CFHealthHub intervention provided an effective method to support people to increase their adherence.
Although subject to uncertainty, adopting the CFHealthHub intervention may produce small improvements
in health for the NHS.
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Recommendations for future research in priority order
l Given the non-significant difference in the primary outcome, further research is required to explore
why an increase in objective normative adherence did not translate into reduced exacerbations, and
to develop interventions that reduce exacerbations.
l The existing intervention could be adapted or tailored to address the needs of people with cystic
fibrosis with different levels of baseline adherence, including those with low levels of baseline
adherence who often have complex problems.
Trial registration
The trial was registered as follows with the NHS Research Ethics Committee, Health Research
Authority and International Standard Randomised Controlled Trials Number registry:
l work package 2.1A – a study of the views of people with cystic fibrosis about their condition and
treatments (Hampshire A Research Ethics Committee 14/SC/1455; Integrated Research Application
System 171049).
l work package 2.1C – a study to produce videos for the CFHealthHub website (Camden and Kings
Cross Research Ethics Committee 15/LO/0944; Integrated Research Application System 182367).
l work package 2.2B – a study to develop a behaviour change intervention to help people with cystic
fibrosis manage treatment adherence (South Yorkshire Research Ethics Committee 15/YH/0332;
Integrated Research Application System 184477).
l work package 2.2B(1) – a study to understand how to use the eTrack (PARI GmbH, Starnberg,
Germany) nebuliser and Bi-neb nebuliser to help people with cystic fibrosis to manage their
inhalation treatments (West of Scotland Research Ethics Committee 5 15/WS/0089; Integrated
Research Application System 177900).
l work package 3.1 – a feasibility study comprising an external pilot randomised controlled trial and
process evaluation (London Brent Research Ethics Committee 16/LO/0356; Integrated Research
Application System 199775). Current Controlled Trials ISRCTN13076797.
l work packages 3.2 and 3.3 – a randomised controlled trial and parallel process evaluation to determine
the efficacy of CFHealthHub and manuals and to conduct a parallel process evaluation (London Brent
Research Ethics Committee 17/LO/0035; Integrated Research Application System 218519). Current
Controlled Trials ISRCTN55504164.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 11. See the NIHR Journals Library website for further project information.
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Cystic fibrosis (CF) is the commonest inherited, life-limiting disease in white populations. In 2018,
222 new cases of CF were diagnosed, totalling 10,509 people with cystic fibrosis (PWCF) in the UK,
with a median age at diagnosis of 2 months.1 Although CF is a multisystem disorder, the upper and
lower airways and digestive system are more commonly affected.2,3 Gene mutations lead to clinical
manifestation of the disease whereby secretions in the lungs become congealed and sticky.4 In > 80%
of cases, PWCF experience respiratory failure due to lung damage.5 In the UK, the median predicted
survival for a child born with CF is currently 47.3 years.1
Cystic fibrosis management
Preventative medications both preserve lung function and reduce pulmonary exacerbations.6–12 Typical
treatments for CF target airway clearance, reduction in bacterial infection and inflammation. Patients
self-manage their disease through a complex, time-consuming daily regimen of treatments that include
inhaled therapies delivered via a nebuliser.13,14 As with other long-term conditions, adherence levels to
medication are low. Estimates by the World Health Organization suggest that 30–50% of prescribed
medicines are not taken as intended.15 In CF, observed objective adherence rates to nebulised therapies
are 36% in adults16 and 67% in children,17 despite self-reported rates of adherence of 80%.16 Treatments
work only if they are taken; poor adherence predicts periods of exacerbation requiring intravenous
antibiotics (IVAB).18,19 Exacerbations carry both the burden of systemic side effects and significant
mortality;20,21 frequent exacerbations are linked with accelerated decline in lung function and increased
3-year risk of lung transplant or death.22
The cost of non-adherence
The cost of pulmonary exacerbations is high. The total UK spend in 2012 for CF was estimated to be
£100 million, £30 million of which was spent on inhaled antibiotics and mucolytics (Paul McManus, Lead
Pharmacist, South Yorkshire and Bassetlaw Area Team, NHS England, 2015, personal communication).
In the UK, CF patients received 171,907 days of IVAB, with 93,455 days occurring in hospital, at an
estimated cost of £27 million (Stephanie McNeil, Chief Statistician, UK Cystic Fibrosis Registry, 2016,
personal communication). Medicines possession ratio (MPR) data suggests that PWCF with good
adherence (MPR > 80%) have lower health-care costs than PWCF with poor adherence (MPR < 50%).
Hospital admissions for IVAB are responsible for most of the excess costs.23,24 At the heart of enabling
preventative therapy is the task of making adherence visible and allowing this key metric to be available
to both PWCF and their clinical teams to move from rescue to prevention.
Potential for cost savings
In the early stages of the programme grant reported here, Tappenden et al.24 conducted an early, model-
based cost–utility analysis in adults with CF with chronic Pseudomonas aeruginosa infection in a project
funded separately from the programme grant. Therapies included nebulised or dry powder inhaled
antibiotics prescribed by the NHS and Personal Social Services (PSS) over a lifetime horizon. The analysis
suggested that an intervention such as ‘CFHealthHub’ had the potential to generate cost savings.
Aims
We developed a complex intervention with several components25 to support adherence to medication
for PWCF, in line with identified research priorities.26,27
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Objectives
Our specific objectives map to three overarching work packages (WPs):
1. to develop a mechanism for objective measurement of adherence through (1) development of
a data-capture and transfer infrastructure that could collect time- and date-stamped data and
(2) display this data both on a CFHealthHub website, for use by both PWCF and their clinicians,
and on a CFHealthHub mobile application (app), for PWCF, and (3) develop the CFHealthHub web
interface with patients and clinicians
2. to develop an evidence-based behaviour change intervention (BCI) to increase adherence to nebulised
CF medications that works synonymously with the CFHealthHub digital platform
3. to evaluate the CFHealthHub intervention (digital platform plus BCI) in terms of (1) clinical
effectiveness, (2) acceptability and (3) cost-effectiveness and to examine the processes that drive
these outcomes.
These objectives were met through three WPs from intervention development to evaluation, details of
which are outlined in Figure 1.
Key changes to the original programme
Interventionists
We adapted our initial plans to employ physiotherapists as interventionists because, early in the programme,
CF clinicians identified that it was challenging to recruit physiotherapists because of workforce
shortages. Intervention training was adapted to ensure that a range of health-care professionals could
deliver the intervention competently through the use of tests and certification. Consequently, any
member of the multidisciplinary team (MDT) could be trained to deliver the CFHealthHub intervention.
Additional funding from NHS England allowed us to increase the amount of interventionist time from
0.8 to 1.0 whole time equivalent at randomised controlled trial (RCT) sites in England.
Primary outcome
The definition of the primary outcome – number of exacerbations – was changed from the standard
Fuchs criteria (IVAB plus 4/10 symptoms)28 to the modified Fuchs criteria (IVAB plus 1/10 symptoms)
to increase the sensitivity of the primary outcome, in line with other, recent CF research.29
Number of centres and treatment costs
As a way of paying treatment costs, the NHS England patient activation quality improvement scheme
authorised the CF Commissioning for Quality and Innovation (CQUIN). The CQUIN was offered to all
26 adult CF centres in the UK, adoption of which was a means of engaging with quality improvement
by delivering the full-scale RCT in our programme. A total of 19 sites participated in the RCT, nine of
which were funded by the CQUIN and 10 by a combination of local and central Department of Health
and Social Care commissioning.
Fidelity
Fidelity checklists together with audio-recording sessions were used to assess treatment fidelity.
CFHealthHub also records exactly what intervention components have been prescribed at each
session, and the extent of participants’ independent engagement with the intervention. Interventionists
were trained to audio-record all intervention delivery sessions of which a purposive sample were
assessed based on the type and time point (phase) of the session administered. Data were analysed
and rated for fidelity by two independent assessors for inter-rater reliability.
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Changes to work packages
The WPs completed are shown in Figure 1. Changes to WPs included:
l Combining distinct WPs together – WP 2.1B was completed as part of integrating the findings of
WP 2.1A with WP 1 to develop the CFHealthHub portal.
l Creating a smaller, distinct WP [WP 2.2B(1)] within WP 2.2B to allow us to recruit an initial set of
participants to start refining the intervention.
Patient and public involvement
Active involvement of the patient and public involvement (PPI) panel was integral to the design and
implementation of key aspects of the ACtiF (Development and evaluation of an intervention to support
Adherence to treatment in adults with Cystic Fibrosis) programme. PPI was embedded in the early
intervention development phase, the feasibility and RCT phases and the dissemination of the programme
findings. As outlined by Shippee et al.,30 patient and service user involvement was considered in each of
the three phases of our research: preparatory, execution and translational.
Specific objectives were to:
l seek iterative cycles of advice and feedback from PWCF and the wider clinical community during
the development of the CFHealthHub intervention, including from our PPI panel
l receive guidance on key research procedures and materials used in the feasibility study and
full-scale RCT
l contribute to discussions on a dissemination strategy, including the most effective methods of
communicating programme findings to the CF community.
Service user initiation
Dan Beever, a co-applicant on the ACtiF programme, is a PWCF and was the PPI panel chairperson
throughout the programme. Dan Beever was involved in providing patient input to research design
at the bid stage. The remaining panel consisted of five PWCF and two parents of PWCF. The initial
PPI panel consisted of PWCF members from the Sheffield CF centre who were involved during the
intervention development phase. To establish a more diverse panel, membership was extended to
PWCF from across the country. A leaflet campaign was used to recruit patients, carers and other
people with an interest in CF through sites involved in WP 2.1C. In addition, the opportunity was
advertised on the People in Research website (URL: www.peopleinresearch.org/; accessed 12 May
2021), and contact made with some individuals known to Dan Beever. Roles and responsibilities of the
group were discussed at the first meeting. During the course of the programme, the study manager
provided regular updates on programme progress to allow co-learning30 and maintain engagement.
Development phase (work packages 1.1 and 2.2)
A number of frameworks and approaches that were used during the intervention development phase
necessitated input from the PPI panel. Use of the agile software development approach required
iterative cycles of development and feedback from both the research team and the PPI panel. This
included giving feedback on the proposed input of the educational content, the CFHealthHub landing
page and demo versions of the CFHealthHub website and giving advice on practical issues of sharing
data on the platform. The PPI panel ensured that the CFHealthHub user guide was accessible and
coherent. Frameworks to guide decision-making and prioritisation of work implementation in this
process required PPI input to understand which tasks were the most important and relevant to PWCF.
Our PPI panel also contributed to discussions on the themes identified in the qualitative research
conducted in WP 2.1 to provide context and additional insights. Feedback on the content and nature
of PPI meetings was continuously sought from the panel. Alterations were made to agenda items to
include agenda items that the panel wished to discuss, for example ongoing progress.
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Feasibility and randomised controlled trial phases (work packages 3.1 and 3.2)
The PPI panel advised on research procedures, in preparation for both the feasibility study and the
full-scale RCT. This included input on the best way to contact participants to arrange consent visits and
collect prescription data as well as discussions on the most appropriate terminology and communicative
approaches to use during intervention sessions and on the CFHealthHub digital platform. The panel
advised and provided input on the essential trial documents and their administration with participants.
One important element was testing the participant-administered questionnaires, with feedback on
completion times and appropriateness of both questionnaire and text message wordings to participants.
Dissemination phase
The PPI panel advised the research team on dissemination strategies across the clinical community and
participants. Co-learning facilitated sharing knowledge in a multidirectional way between the study
management team and the PPI panel. The RCT findings were presented to the PPI panel members on
the Trial Steering Committee (TSC), who provided input on the way in which these findings should be
presented to PWCF. One of the PPI panel members with expertise in managing communications
assisted with the development of a formal dissemination strategy for feedback of results to multiple
stakeholders in multiple ways. The PPI panel agreed the dissemination plan.
Challenges and successes
We had regular contact with the PPI panel but input was limited by the inability of the group to attend
face-to-face meetings because of infection control requirements. Visual conferencing facilities were a
challenge to use in practice and this was not pursued owing to technical issues. Recruitment of the PPI
panel was a challenge but we were able to expand recruitment from the initial Sheffield CF centre to
several other CF centres through our leaflet campaign. Involvement was much more frequent in the
earlier intervention development phase than during the evaluation phase. Two members of the PPI
panel also became members of the TSC and, as such, were able to provide oversight to the programme
as a whole.
One of the key successes of our PPI panel was their continued input and engagement, which was sustained
throughout the duration of the programme. This is in part a result of having a patient co-applicant on
the ACtiF grant who acted as the PPI panel chairperson. Dan Beever’s contributions were of particular
value in the recruitment of the PPI panel, as well as in maintaining the interest and engagement of
the panel throughout the duration of the programme. A short survey was distributed to members of
the panel at the end of the RCT phase to seek their views on their involvement during the course
of programme. Three completed responses were received, all reflecting positively on involvement,
particularly in terms of contributions being valued by the research team.
Specific impacts
l When PPI panel members used the prototype website they found it difficult to locate appropriate
patient videos, so suggested that these be tagged with labels for ease of use (change recommended
14 September 2016). This change was made to the intervention.
l We asked for advice from the panel around contacting potential RCT participants to arrange
consent visits. The group recommended sending a text message to the potential participant the day
before the planned telephone contact to prepare them, followed by a telephone call the next day,
leaving a voicemail message if there was no answer (discussions held 23 June 2017 and 2 October
2017). This approach was used.
l A guide was produced for people using the intervention. The panel recommended a number of
changes, for example referring to it as a ‘guide’ rather than as a ‘how to guide’ and being clear that
the ‘problem-solving’ related to solving problems with adherence and not with using the intervention
(changes recommended 13 November 2017). These changes were made to documentation.
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Work package 1: developing the
technology and infrastructure to collect
adherence data
A digital platform – CFHealthHub – was created to provide the technical components of thecomplex intervention to support adherence to treatment in PWCF. CFHealthHub provided the
front-end user-facing components of the intervention (a website and mobile app) and the back-end
server infrastructure for secure receipt and storage of adherence data. The technical development
was defined by two high-level phases: (1) technical scoping and configuration of the infrastructure and
(2) development of the digital components of the BCI.
The digital platform was developed iteratively over an 18-month period, with the first phase conducted
with 27 participants from August 2015 to April 2016, followed by a two-centre feasibility study conducted
with 64 participants across two CF centres in 2016–2017. The digital platform was finalised and
became feature complete for the full-scale RCT launch in October 2017. The first phase of the technical
development involved high-level requirements capture for the project. The top priority identified was to
enable the display of objective adherence data to the interventionists and PWCF through the CFHealthHub
website. Discussions with the nebuliser supplier led to the configuration of a secure data-transfer
mechanism, enabling nebuliser devices to submit data in real-time to the study server, hosted at the
University of Manchester (Manchester, UK). To display the adherence data in CFHealthHub it was
necessary to develop a manual entry point for the prescription information through the CFHealthHub
website. The website was developed to display the objective adherence data in a variety of graphical
and tabular formats.
After the website was designed to display the objective adherence data, an intensive co-design process
was launched to refine the display of data and to incorporate, develop and refine the BCI components.
This involved multiple project stakeholders reviewing successive prototypes and wireframes of designs,
and iterative website software releases. Input from the PPI panel and from the qualitative research
contributed to the design and refinement process. Development of the mobile app drew heavily on the
earlier website development reviews, but designs were tailored for smaller screen sizes. Mobile-specific
engagement strategies (e.g. push notifications to encourage engagement with the CFHealthHub digital
platform) were also incorporated.
The technical architecture of the digital component of the intervention is shown in Figure 2.
The software development was conducted by the mobile health (mHealth) team at the Health
eResearch Centre, University of Manchester, with design expertise provided by user experience (UX)
company Keep It Usable (Manchester, UK). Later phases of the design work were completed in-house
at the Health eResearch Centre.
For more details on WP 1, see Appendix 1.
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FIGURE 2 Technical architecture of the digital component of the intervention.
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Work packages 2.1A and 2.1B:
a qualitative study – understanding the
illness perceptions and treatment beliefs
of people with cystic fibrosis
Aims
The aims of WPs 2.1A and 2.1B were to explore PWCF’s perceptions of their illness and their
treatments, perceptions of barriers to and facilitators of medication adherence using nebulisers,
and the acceptability of visual displays of their recent medication adherence.
Methods
Sarah J Drabble undertook 18 face-to-face semistructured qualitative interviews with PWCF in the
Sheffield CF centre. Sarah J Drabble is a female research associate with a doctoral degree, psychology
training and experience in qualitative research. The proposal stated that 20–24 interviews would be
undertaken. Our research physiotherapist Marlene Hutchings approached people who met our
sampling strategy criteria to obtain permission to pass on their details to our qualitative researchers.
She did this in a variety of ways, such as face to face and by e-mail. A total of 21 PWCF agreed to
have their details passed on, 20 of whom gave informed consent for an interview. A total of 18 of
these were available for interview. We used purposive sampling to identify adults with different
objectively measured adherence levels. We knew their objectively measured adherence rates because
the Sheffield CF centre had introduced measurement using chipped nebulisers. In addition, we undertook
maximum diversity sampling by asking the research physiotherapist to approach adults of different
genders, ages and socioeconomic backgrounds.
The stance taken was phenomenological in that we were interested in patient experiences of CF and
adherence. The participants did not know Sarah J Drabble prior to the research. She was clear with
participants that she had no prior experience of CF. Interviews were undertaken in people’s homes.
Usually only the participant was present, although in two interviews the participant’s partner was
present. The topic guide used for the interviews is included as Report Supplementary Material 7.
This developed over time after the first couple of interviews. We audio-recorded the interviews and
made field notes after each interview. Interviews lasted 65–147 minutes (mean 99 minutes).
We used framework analysis31 deductively to code high and low levels of adherence behaviour into the
theoretical domains framework (TDF)32 and inductively to identify perceptions of CF and treatments
and to explore the acceptability of the adherence graphs. Two researchers coded the data using
NVivo (QSR International, Warrington, UK). There was no participant checking but the findings were
discussed with the PPI panel.
We followed consolidated criteria for reporting qualitative research (COREQ) guidance
(see Report Supplementary Material 4).
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Findings
The detailed findings were published in two journal articles33,34 and are briefly summarised here with
illustrative quotations.
Perceptions of cystic fibrosis and treatments
Key contextual issues
l Being normal: PWCF wanted to fit in and be like other people
I just think I’m not doing it today just because I just want to be normal for a day or I just don’t want
to do it.
Participant (P)3, very low level of adherence
l Openness about having CF and adherence: some PWCF discussed having CF with friends but others
did not
I do tell people you know. I’m quite open minded I like to let people know if I’m not OK.
P4, very low level of adherence
I think the telling of people – I have this big thing about they’d treat me differently.
P17, high level of adherence
l Forgetting: talk of ‘forgetting to take medication’ could be used to exercise control in the context of
the moral obligation to adhere to treatment (see Drabble et al.33)
[. . .] probably when I’m socialising and going out and things you know so if I go out an earlier time
I might forget to have it.
P4, very low level of adherence
l Health belief: some PWCF were driven to keep healthy until a cure was found (high-level adherers),
whereas others experimented on themselves and actively decided which treatments worked for them
My nebulisers. I’ve just sort of tested them. Just not took them until next time I’ve been in clinic just to
see what effect it would have. Like my lung capacity and stuff like that.
P16, high level of adherence
l Treatment burden: varied within the sample and could be all consuming for those with more severe
CF symptoms and other health conditions
This time my weight had gone up but my lung function had gone down, so I am trying to find that balance.
P10, low level of adherence
l Tiredness: CF and daily life activities caused fatigue, leading to non-adherence
When you’re using a lot of effort just to breathe, then it takes away your efforts on other places, other parts.
P11, moderate level of adherence
l Emotions: some of our interviewees described how adherence behaviour was often emotionally
driven depending on their feelings about aspects of their lives. How they felt about their CF could
affect their motivation to adhere to treatments
If I get up and it’s one of those days I can’t be [bothered] to do anything, I just won’t do it.
P2, very low level of adherence
WORK PACKAGES 2.1A AND 2.1B
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Barriers to and facilitators of medication adherence using the theoretical
domains framework
Factors influencing adherence to treatment included all 14 domains of the TDF,34 most of which varied
by adherence level:
1. skills
2. memory and decision-making
3. behavioural regulation
4. environmental context and resources
5. social influences
6. beliefs about consequences
7. beliefs about capability
8. reinforcement




Factors identified by PWCF in higher and lower adherence level categories are summarised in Table 1.
Acceptability of adherence graphs
People with CF in the sample generally found the charts interesting and easy to understand. They
found the different ways of looking at adherence, overall, by week or by time of day, useful because
they could see different patterns in their adherence:
I like the graph idea, if it gives you a visual aid. This is basically what you’ve done since your last visit.
P11, moderate adherence
They identified ways of improving the visual attractiveness of the charts. We also identified that there
was a need for the research team to identify an approach to measuring adherence in the context of
multiple and changing prescriptions.
Conclusions
The findings from this WP shaped the intervention in three ways. First, the findings on the perceptions
of CF and treatment identified aspects of any intervention that were important to attend to, and in
particular that an intervention should not increase treatment burden. Second, the findings from the
TDF domains identified how different people faced different barriers so that it was important to tailor
the intervention to individuals; these findings also helped to identify key content for different components
of the intervention. Third, the findings on acceptability of the graphs offered confidence that PWCF
welcomed the graphs and identified ways of improving the presentation of data in these graphs.
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TABLE 1 Theoretical domains framework factors identified by PWCF in higher and lower adherence level categories
Factor Quotation
Identified by PWCF in higher adherence level categories
Believing that complete adherence was
unachievable
In a way you sort of think you can’t remember every time
P18, high level of adherence
Concerns about bacterial resistance to
treatment
I’m on antibiotics. Sort of the more you take them, the less effective
they get
P16, high level of adherence
Having a habit for treatment It has got to a stage since that that in my head now, routine. I don’t
need a checklist
P15, high level of adherence
Fear about becoming ill Just that fear, know I could be unwell some days. Just sort of striving to
do it really
P16, high level of adherence
Identified by PWCF in lower adherence level categories
Feeling worse as a result of treatment What runs through my head like especially the Promixin [Profile Pharma
Ltd, Chichester, UK; colistimethate sodium] is that 3 months where I
took it and still end up on [i.v. therapy]. And then end up having a
reaction to the i.v. [therapy] from of it
P5, very low level of adherence
Being rebellious or disorganised If I don’t see no point in doing it, I won’t do it no matter what
anybody says
P7, low level of adherence
Feeling that treatment was difficult
when tired
I think Fridays I’m always tired from the whole week so I just always
went to bed early or so I might just put it off
P6, low level of adherence
Finding stressful events a barrier to and being
in hospital a facilitator of adherence
I was really good at taking it then [in hospital] because I have got a
watchful eye over me
P5, very low level of adherence
Forgetting When I remembered to tick it off it were alright but ‘cos I put it in the
cupboard at side of me bed I just forgot about it
P3, very low level of adherence
Avoiding thinking about CF I know it will all affect me in the long run but I just don’t think about it
P6, low level of adherence
Declining support He does look after me but when I’m alright and walking around and
stuff I don’t want him to have to do that
P3, very low level of adherence
Feeling in conflict with health-care
professionals
I’ve had a doctor tell me before [laughs] if you took your nebuliser you
wouldn’t be on [i.v. therapy]. But he said it so confrontational
P5, very low level of adherence
i.v., intravenous.
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Work package 2.1C: patient story video
interviews for use in the CFHealthHub
intervention
Aim
The aim of this qualitative study was to develop a series of patient story videos capturing PWCF
talking about their experiences of managing nebulised medication as part of their overall CF treatment.
The videos produced would be part of the BCI on the website.
Design
A qualitative study was undertaken by the Health Experiences Research Group at the University of
Oxford (Oxford, UK). They used purposive sampling based on objectively measured adherence to
nebulised medication, lung function and sociodemographic characteristics. Inclusion criteria for PWCF
were as follows:
l age ≥ 16 years
l not on the active transplant list
l not post lung transplant or in the palliative phase of the disease.
All participants had high and/or improved levels of adherence.
Methods
In-depth qualitative interviews were carried out with 14 PWCF from five UK CF centres. A total of
14 participants (aged 20–57 years) were interviewed between November 2015 and August 2016 by a
female senior qualitative researcher from the Health Experiences Research Group (Susan Kirkpatrick).
The researcher did not establish a relationship with participants prior to the research. Participants
knew that the aim of the research was to create videos. The approach taken was phenomenological
in that participants talked about their experiences. Face-to-face interviews were conducted in
participants’ homes and video-recorded. Interviews lasted between 45 and 60 minutes. A topic guide
was used to explore participants’ experiences of living with CF, to reflect on times when their nebuliser
adherence level had been lower and to reflect on how and why they had improved their use of
nebulised medication. Written consent was obtained by the researcher for participation in an interview
and for selected clips being used on the website prior to editing and publication.
Analysis
Interview transcripts were analysed thematically using NVivo. The research team reviewed each
transcript to select suitable content for inclusion on the CFHealthHub website. Criteria for inclusion
of content was the identification of talk about making positive changes to adherence or reflecting on
times of difficulties and how these had been overcome. These video clips were checked by participants.
DOI: 10.3310/pgfar09110 Programme Grants for Applied Research 2021 Vol. 9 No. 11
Copyright © 2021 Wildman et al. This work was produced by Wildman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
13
Results
We created a library of short ‘talking heads’ videos that are hosted on the CFHealthHub website as
part of the complex intervention. Emerging topics from the transcripts were identified and those
selected were arranged into video categories, for example ‘Coping with feeling low’ and ‘Juggling
treatment and life’. There was a total of 66 videos across 16 different categories (Table 2). The
descriptions of the categories were created by the PPI panel.
Conclusions
This WP produced a series of ‘talking head’ video clips from qualitative interviews with PWCF in which
PWCF shared their experiences and passed on knowledge to others about how they adhered to their
treatments. These were used as part of the intervention.
TABLE 2 Video categories
Categories Examples of video descriptions created by PPI panel
Advice to younger self PWCF talks openly about the risks of underestimating his condition, missing treatment
and how you are the person who can make the biggest positive change
Coping with feeling low There will always be peaks and troughs with CF; it’s important to keep motivated
Juggling treatment and life PWCF talks about how seeing adherence data motivates him and supports what he
wants to achieve in life
Going to university PWCF talks about what motivated him to do his treatment and not rely on i.v. therapy
The importance of nebulisers PWCF discusses thinking long term and doing your treatment to help you live a
normal life
Keeping motivation up Treatments are not a chore; you should look at them like drinking water – just
something you have to do
Having a routine PWCF explains that the key to doing her treatment is organisation and accepting that
everyone slips once in a while
Finding support PWCF shares her views on why it’s important to talk to others with CF
Nebuliser tips Not cleaning your nebuliser will increase your treatment times
Having a normal life PWCF talks about what routine works for her, being a mum with CF
Being normal PWCF explains that doing her nebulisers allows her to be well enough to do the fun
things in life, rather than just seeing them as a burden
Advice to others PWCF talks about how to find a way to make nebulisers fit into your life
Late diagnosis PWCF explains that, after discovering that he had CF later in life, the nebulised
medicines he started to take completely changed his life for the better. The stark
improvement in health after beginning his treatment is all the motivation he needs to
take them
Growing up with CF PWCF talks about the positive relationship with his CF team. Even though he
was critical of them when he was younger, he reflects that they were only trying to
help him
General tips PWCF provides a tip to help when coughing in a public place
Talking to others PWCF talks about the benefit of talking to other people with CF – being able to offer
your experience. Hearing stories from those who are much older with CF has also
made him feel much more positive about life expectancy
i.v., intravenous.
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Work package 2.2: development and
refinement of the CFHealthHub
intervention
This section outlines the process of planning, designing and creating, refining and documenting theintervention35 that the team undertook with input from the PPI panel and alongside the technical
development of the digital platform (see Work package 1: developing the technology and infrastructure to
collect adherence data).
Intervention development combined a ‘theory- and evidence-based’ approach36 [the behaviour change
wheel (BCW) approach]37 with a ‘target population-based’ approach [the person-based approach
(PBA)].38 The BCW considers capability, opportunity and motivation in relation to behaviour
(i.e. nebuliser adherence) and, through a series of stages, systematically selects intervention functions
and behaviour change techniques. The PBA utilises mixed methods with people from the target population
(i.e. adults with CF) to inform all of the intervention development stages in an iterative process.
Stage 1: planning the intervention
We undertook a needs analysis informed by the qualitative research undertaken in WP 2, a literature
review and PPI panel input and determined which capability, opportunity and motivation barriers the
intervention should address. The qualitative research helped us to understand the context of PWCF’s lives.
Stage 2: designing and creating the intervention
We used the BCW approach to identify what ways to enact the intervention, and identified suitable
behaviour change techniques, drawing on relevant theory and evidence. We embedded these in a
prototype CFHealthHub website. We considered how the intervention could be tailored to meet the
needs of patients with different needs. We considered the competencies required by interventionists
and developed job descriptions and a prototype training manual.
Stage 3: refining the intervention
Refinement of the prototype intervention took place iteratively based on feedback from users. We
undertook two studies with participants who were PWCF aged ≥ 16 years and on the CF registry.
Participants were provided with an eTrack (PARI GmbH, Starnberg, Germany) nebuliser and Qualcomm
(San Diego, CA, USA) hub and were given access to the CFHealthHub digital platform. Five participants
took part in the first study, which assessed the ability of the system to successfully record and
display nebulisations. Participants were interviewed 1 month later about their experiences and views.
We made changes to the intervention based on this feedback. A total of 22 participants took part in
the second study. During the intervention development phase our research physiotherapist delivered
the intervention of four sessions to each participant. We conducted 18 semistructured telephone
interviews with participants in different cycles of the software development to ask about acceptability,
appearance and functionality of the digital platform and suggestions for improvements. We identified
during this work the need for ‘talking heads’ videos of other PWCF to help participants learn
how to improve their adherence (see Work package 2.1C: patient story video interviews for use in the
CFHealthHub intervention). We also conducted six in-depth think-aloud interviews with participants
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while they were using the platform and these were screen- and audio-captured. We interviewed the
physiotherapist delivering the intervention about their views. All of this feedback was used to improve
the prototype digital platform and training manual.
Stage 4: documenting the intervention
At the end of this process we created an intervention manual that outlined the components of the
intervention, the features and functions of the CFHealthHub digital platform and the proposed
structure of delivery by health-care professionals/interventionists. An associated training programme
for interventionists was also developed.
The CFHealthHub intervention
The CFHealthHub intervention is described in detail in Appendix 2 using template for intervention
description and replication (TIDieR) guidelines.39 The intervention comprises a web platform and app,
which display graphs and tables of objectively measured nebuliser adherence and include modules of
behaviour change techniques designed to increase motivation for adherence, to address capability and
opportunity barriers and to build habits for treatment taking, and an intervention manual including
procedures and worksheets for delivery by a health-care professional (interventionist).
The content of the website/app is tailored to individual participants’ needs based on their nebuliser
medication prescription and their responses to the Beliefs about Medicines Questionnaire40 and
displays individual real-time adherence data and personalised information in a ‘Toolkit’ area.
Participants are supported to interact with the digital platform content and tools in sessions by trained
interventionists following a manualised delivery procedure, with a person-centred communication style.
Six sessions (one ‘first intervention’ visit, 40–60 minutes; two ‘intermediate’ reviews, 5–15 minutes
each; two ‘main’ reviews, 30–45 minutes each; one ‘phase’ review, 20–30 minutes) were usually
delivered over a 12-week phase of delivery, with phase reviews every 12 weeks thereafter, or every
6 weeks thereafter for participants with objectively measured adherence of < 25%. Participants with a
high level of adherence during the baseline period of the study (> 80%) received two sessions (one first
intervention visit and one phase review), with phase reviews every 12 weeks thereafter. Additional blocks
of sessions (a ‘phase’) were offered when (1) participants requested further support, (2) participant’s
adherence was reduced by 20% in a 4-week period or (3) participants received intravenous (i.v.) therapy for
an exacerbation. First intervention sessions were always delivered face to face, whereas review sessions
were delivered either face-to-face or by telephone, allowing the interventionist to intervene with one set of
sessions or repeat further sets of sessions under certain circumstances. This means that, if used in the real
world, the interventionist-delivered component of the intervention may be used throughout a person’s
lifetime if their adherence drops for any reason.
A full description of the intervention is available in Appendix 2.
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Work package 3.1: feasibility study
comprising an external pilot randomised
controlled trial and process evaluation
Parts of this section are reproduced or adapted with permission from Hind et al.41 This is an OpenAccess article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text.
Aim
The aim was to assess the feasibility of RCT procedures and the intervention.
Methods
Design
This was a pilot, open-label, parallel-group RCT with concurrent mixed-methods process evaluation.
The pilot RCT has been reported in Hind et al.41 The qualitative research from the process evaluation
has been reported in Drabble et al.42 and Hind et al.43
Randomised controlled trial
Participants were PWCF at two CF centres. Inclusion criteria: aged ≥ 16 years and on the CF registry.
Exclusion criteria: post lung transplant or on the active list, unable to consent, or using dry-powder inhalers.
Qualitative research
Sarah J Drabble, Samuel Keating and Alexander Scott interviewed intervention (n = 14) and control
(n = 5) participants, interventionists (n = 3 on two occasions) and CF team members (n = 5) at the two
CF sites. See Work packages 2.1A and 2.1B: a qualitative study – understanding the illness perceptions
and treatment beliefs of people with cystic fibrosis for Sarah J Drabble’s credentials and experience.
Participants were identified from RCT records and sampled purposively in a similar way to WP 2.1.
A total of 49 patients agreed to be approached for interview. We were unable to contact 14 patients
and did not actively invite seven, leaving a sample of 28, among whom 23 consented. People declined
because they were too busy, had withdrawn from the intervention or did not show up for the interview.
Patients were interviewed mainly at home and staff in their workplace or by telephone. The patient
sample comprised nine male and five female patients, aged 17–69 years, across all deprivation levels
and had fewer people with low levels of adherence than we wanted. The topic guide was used in the
process evaluation of the full RCT is shown in Report Supplementary Material 8. All interviews were
audio-recorded and field notes were taken and these were analysed using NVivo. Interviews lasted
between 11 and 102 minutes (mean 56 minutes).
Interventions
Central randomisation using a computer-generated pseudo-random list and random permuted blocks
of varying sizes (2, 4 and 6), stratified by site and number of IVAB days in the previous 12 months
(≤ 14 days and > 14 days) on a 1 : 1 allocation to (1) the intervention arm, which involved linking a
nebuliser with data recording and transfer capability to a software platform and strategies to support
self-management with trained interventionists (n = 32), or (2) the control arm, which involved typically
face-to-face meetings every 3 months with the CF team (n = 32).
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Outcomes and processes
Trial feasibility was defined as recruitment of > 48 participants (75% of target) in 4 months (pilot
primary outcome), valid exacerbation data available for > 85% of those randomised (future RCT primary
outcome), change in percentage of medication adherence (secondary outcome in future RCT), use of
CFHealthHub and positive perceptions of the intervention from qualitative interviews.
Results
The pilot RCT recruited to target, randomising 33 participants to the intervention arm and 31
participants to the control arm during the 4-month period June to September 2016. At study
completion (30 April 2017), 60 (94%) participants (intervention arm, n = 32; control arm, n = 28)
contributed good-quality exacerbation data. Five serious adverse events occurred, none of which was
related to the intervention. The process evaluation identified problems with data connectivity, which
affected adherence data. The mean change in adherence was 10% (95% CI –5.2% to 25.2%) higher in
the intervention arm. Data from CFHealthHub identified that interventionists delivered insufficient
numbers of review sessions to identify and address low levels of motivation. Concentration on
participant recruitment left site interventionists insufficient time for key intervention procedures.
In the qualitative interview study there was evidence of the expected behaviour change mechanisms of
action. Mechanisms of action were similar to those associated with effective telehealth interventions
for self-management support: relationships, visibility and fit.42 PWCF described how building a
relationship with the interventionist helped them to consider ways of increasing their level of adherence
to medication. PWCF in this sample found having their data visible to themselves and others motivating,
particularly if they received praise from others about the progress they had made. The intervention
was tailored to individuals but there were challenges in how the intervention fitted into some patients’
busy lives when delivered through a desktop computer. Interventionists identified that patients with
moderate adherence rates were more likely to benefit from the intervention. PWCF in the control arm
had not seen their adherence data or other parts of the intervention, indicating that the level of
contamination was low.
The feasibility study led to 25 key changes to RCT procedures and the intervention.43 Plans to develop
an app for mobile phones were progressed. Changes were made to CFHealthHub to make it easier for
interventionists to view and edit prescription data and to handle alternating treatment regimens. Other
changes to CFHealthHub included making graphs more easily interpretable and adding descriptions
to videos so that they could be found more easily by PWCF. Changes to the interventionist manual
increased the emphasis on ‘active ingredients’, introduced intervention triggers for reduced adherence
or exacerbations and introduced new habit formation sessions. The need for increased numbers of
protocolised intervention review sessions arose because a focus on RCT recruitment targets gave
interventionists inadequate time to deliver review visits, which were critical for updating personalised
action plans and updating coping plans. For the same reason, we planned for the subsequent
full-scale RCT to have a longer accrual window. Training and job specifications were modified to suit
interventionists from different disciplines and manage expectations about the need for travel and
flexible working.
Conclusions
We concluded that, with improved intervention/research processes and lower monthly participant
recruitment targets, a full-scale RCT and the intervention were feasible.
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Work packages 3.2, 3.3 and 3.4: full-scale
randomised controlled trial with
concurrent process evaluation
Parts of this section are reproduced or adapted with permission from Wildman et al.44 This is anOpen Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text.
Introduction
Having integrated the identified changes into the RCT and intervention protocols, we conducted a full-scale
RCT to determine the efficacy of the CFHealthHub intervention (WP 3.2). Concurrently, we undertook
a process evaluation to explore implementation (including fidelity), mechanisms of action and context
(WP 3.3).45 We report the independent streams of research and the triangulation of the results (WP 3.4).
A logic model was constructed early in the programme and refined throughout to show how the
intervention could affect outcomes (Figure 3).
Design
This was a two-armed, parallel-group, open-labelled, efficacy superiority RCT comparing intervention
with usual care, with concurrent process evaluation. The protocol is available online.46
Methods
Objective
The objective of the RCT was to determine the effect of the CFHealthHub intervention on clinical and
participant-reported outcomes.
Sample size
Sample size estimation was conducted using a between-group difference in mean exacerbations of
0.5 over the 12-month follow-up period, a standard deviation (SD) of 1.5, a design effect of 1.16 to
allow for clustering, an alpha level of 5% and 90% power. After adjusting for 20% loss to follow-up,
the recruitment target was 556 participants (278 per arm). The sample size was predicated on 2.0
exacerbations per year and reducing this by 0.5 to 1.5 per year. This is equivalent to an incidence rate
ratio (IRR) of 0.75 (2.0 ÷ 1.5).
Participants
Potential participants were identified using the UK Cystic Fibrosis Registry. Eligible participants
were aged ≥ 16 years and willing to take inhaled mucolytics and antibiotics via the eTrack nebuliser.
Participants were ineligible if they were post lung transplant, on the lung transplant list, receiving
palliative care, lacking capacity for informed consent or using dry-powder devices to take mucolytics
or antibiotics.
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FIGURE 3 Logic model. a, Optional; depends on participant consent. CHAOS-6, Confusion, Hubbub and Order Scale-6 item; COM-BMQ, capability opportunity motivation – behaviour

















































Intervention participants received the intervention described in Work package 2.2: development and
refinement of the CFHealthHub intervention and Appendix 2. The intervention was delivered by full-time
interventionists employed specifically for the research study to deliver both the intervention and
the RCT (recruitment and some data collection). They were physiotherapists in 13 of the 19 centres
and nurses, psychologists, a pharmacist and a dietitian in other centres. Some centres had two
interventionists that shared the role, sometimes from different clinical disciplines. Control participants
were given an eTrack controller and Qualcomm (San Diego, CA, USA) hub to enable accurate recording
of inhalation data and calculation of adherence levels. They did not have access to CFHealthHub, that
is, its adherence data, behaviour-change tools, educational content and visits from interventionists.
Control arm participants received usual care.
Participants were allocated 1 : 1 to the intervention arm or control arm using a computer-generated
pseudo-random list with random-permuted blocks of randomly varying sizes, via a central, web-based
randomisation system. The allocation sequence was hosted by the Clinical Trials Research Unit at the
University of Sheffield (Sheffield, UK), with the sequence created by a statistician (not otherwise involved
with trial) and held on a secure server. The recruiting health-care professional logged into the server and
entered basic demographic information, then the allocation was revealed. Stratification was by centre and
number of past-year i.v. antibiotic days (≤ 14 days and > 14 days) – a predictor of current-year i.v. days.21
The trial statistician remained blind to treatment allocation until database freeze. Participants and
health-care professionals collecting primary outcome data were not blind to treatment allocation.
The trial statistician remained blind to treatment allocation until database freeze; analyses were
conducted unblinded.
An intention-to-treat approach was used, with all participants included in the arm to which they were
randomised and exclusions being made only in the event of insufficient data for inclusion in the model
for a given outcome. In addition, per-protocol and complier average causal effect (CACE) analyses were
conducted, with protocol compliers defined as participants participating in both a first intervention visit
and a review visit during which adherence graphs and/or charts were accessed.
Outcome measures
The primary analysis consisted of a between-group comparison of pulmonary exacerbation rates over
the 12-month period from consent, with exacerbations defined as meeting at least one of the 12 Fuchs
criteria and being treated by i.v. antibiotics.47 The following sensitivity analyses were conducted to assess
the robustness of the findings, applying the same model as for primary analysis: inclusion of all (including
those not treated with i.v. antibiotics) exacerbations, multiple imputation for missing outcome data,
best-case imputation, per-protocol analysis and CACE analysis (see Report Supplementary Material 1 and 2).
Key secondary outcomes included weekly medication adherence, forced expiratory volume in first second
(per cent) (FEV1%) predicted and body mass index (BMI). To calculate numerator-adjusted normative
adherence, daily doses taken were recorded, capped at the number of doses prescribed if the participant
took more than the prescribed dose, divided by the appropriate daily dose given the participant’s disease
status and treatment regimen, and summarised as weekly means. Lung function and BMI were measured
at baseline and 12-month follow-up visits. Health-related quality of life (HRQoL), beliefs and perceived
behaviours were assessed by way of the following patient-reported measures:
l generic health status – EuroQol-5 Dimensions, five-level version (EQ-5D-5L)
l Patient Activation Measure-13 item (PAM-13)
l Confusion, Hubbub and Order Scale-6 item (CHAOS-6)
l perceptions of treatment adherence – Medication Adherence Data-3 item (MAD-3)
l Self-Report Behavioural Automaticity Index (SRBAI)
l Cystic Fibrosis Questionnaire-Revised (CFQ-R)
l Generalised Anxiety Disorder-7 (GAD-7)
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l specific concerns and necessities – Capability Opportunity Motivation – Behaviour Beliefs About
Medicines Questionnaire (COM-BMQ)
l Patient Health Questionnaire-8 item (PHQ-8).
Patient-reported outcomes were recorded at baseline and 12 months.
Participant safety was assessed by way of adverse and serious adverse event reporting. All randomised
participants were included in safety summaries.
Statistical analysis
The statistical analysis plan is detailed in Report Supplementary Material 1. Analysis is summarised in
this section.
Baseline and safety data were reported using summary statistics.
For the primary outcome (and associated sensitivity analyses), pulmonary exacerbation rates were
compared using the IRR from a negative binomial model adjusted for stratification factors and
including an offset for follow-up time.
Weekly numerator-adjusted normative adherence data were analysed using a longitudinal mixed model
with random slopes and intercepts and adjustment for stratification factors and ‘baseline’ (weeks 1 and
2 post consent) adherence. The treatment effect was quantified using the adjusted between-group
difference in mean normative adherence. Other secondary outcomes were analysed using 12-month
follow-up data adjusted for baseline values and stratification factors. Treatment effects were determined
by adjusted between-group differences in means.
For all models, treatment effects were reported with corresponding 95% confidence intervals (CIs). No
adjustments were made for multiplicity. Adjustment for multiplicity was not specified in the statistical
analysis plan, which was written, in accordance with the Clinical Trials Research Unit at the University
of Sheffield (Sheffield, UK) standard operating procedures, before the data were analysed and was
reviewed and approved by the independent members (which included two statisticians) on the TSC.
There is no consensus on what procedure to adopt to allow for multiple comparisons.48 Therefore, we
followed Altman et al.’s49 recommendation of reporting unadjusted p-values (to three decimal places/
significant figures) and confidence limits, with a suitable note of caution with respect to interpretation.
As Perneger concludes: ‘simply describing what tests of significance have been performed, and why, is
generally the best way of dealing with multiple comparisons.’50
Analyses were conducted in R v3.6.1 (The R Foundation for Statistical Computing, Vienna, Austria) and
SAS® v9.4. (SAS Institute Inc., Cary, NC, USA).
We followed Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines (see Report
Supplementary Material 5).
Process evaluation methods
There were six components in the process evaluation. Each component was undertaken and analysed
separately. The findings from each component were brought together using a triangulation protocol51
adapted for use with qualitative research and RCTs.52 Experts in process evaluation recommend that
the process evaluation is analysed before the RCT results are known.53 All components, except the
mediation analysis, were reported to the team before the RCT results were known, although further
analysis continued on some components after the RCT results were revealed.
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Fidelity
The aim was to explore the fidelity of the intervention in practice. We used the Borrelli checklist54 as
the framework to assess and monitor the fidelity of the intervention delivered in the RCT. Intervention
sessions were assessed for fidelity at certification and for drift. CFHealthHub data on use of different
parts of the website (click analytics) were included in this assessment. Details of the fidelity assessment
methods, together with the fidelity results, are available in Appendix 3.
Usual-care survey
The aim was to understand usual care in each of the RCT sites, and how it changed over the time of
the RCT, to assess how different the intervention was from usual care. We used an 11-item survey at
baseline and at 12 months at each RCT site. Questionnaires were completed by the site interventionist
and/or other members of the MDT. Questions included a mixture of items requiring five-point nominal
scale and free-text responses. Medians, interquartile ranges and percentages by response were
used to summarise categorical items. Free-text responses were summarised by identifying key themes.
To examine change in usual care at sites over the course of the 12-month follow-up, change scores
were calculated. All sites responded to the survey. Details of methods are reported in Appendix 4.
User acceptability survey
The aim was to measure the acceptability of different components of the intervention. We asked
11 questions about the perceived helpfulness of different components of the intervention in the
12-month follow-up questionnaire for those in the intervention arm. The questionnaire was either
posted and handed to PWCF who had had the intervention for completion in the presence of the
interventionist. A total of 257 out of 305 (84%) participants in the intervention arm responded.
Details of methods are reported in Appendix 5.
Trial monitoring data
The aim was to monitor RCT progress in terms of numbers of people approached, reasons for not
agreeing to participate in the RCT and numbers withdrawing from the intervention. This allowed us to
consider reach and engagement.
Qualitative research
The aim was to explore perceptions of the intervention in practice. We sampled patients purposively
using a similar approach to WP 2.3. A total of 84 patients agreed to be approached for interview.
We were unable to contact 37 patients, and did not approach 12, leaving a sample of 35. A total of
32 patients consented and 22 were interviewed. Some patients declined and others said that they were
too busy to participate; three were unwell on the day of the interview and one died. We approached
and interviewed all 26 interventionists. We approached nine MDT members and did not get a response
from four, so interviewed five.
We undertook face-to-face interviews with 22 intervention users in seven CF centres, 26 interventionists
(some sites had more than one) and five members of the MDTwho acted as principal investigators for the
study at five RCT sites. Patients comprised 10 male and 12 female patients, aged 19–58 years, across all
deprivation levels and all adherence levels.
The interviews were undertaken by Sarah J Drabble (see Work packages 2.1A and 2.1B: a qualitative
study – understanding the illness perceptions and treatment beliefs of people with cystic fibrosis for her
credentials) and Elizabeth Lumley, a female clinically trained qualitative researcher educated to
master’s level with no experience of CF research. The relationship between researchers and
participants, and the approach taken, was similar to those in WPs 2.1 and 2.3. The topic guide for
PWCF included questions relating to acceptability of different aspects of the intervention and what
aspects of the intervention, if any, helped them to increase their adherence. The topic guide for
interventionists included questions on the delivery of the intervention, the trial processes and aspects
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of the context (see Report Supplementary Material 2 for both topic guides). Interviews were audio-
recorded and field notes taken. Interviews lasted between 17 and 83 minutes (mean 42 minutes).
We used framework analysis,31 deductively coding to the TDF,32 mechanisms of action including
Vassilev’s telehealth mechanisms of action,55 different components of the intervention and its delivery,
and inductively to context. Three researchers (SJD, EL, AS) coded the data in NVivo. No participant
checking occurred; the findings were discussed with the PPI panel.
Mediation analysis
Structural equation modelling was undertaken on the RCT data to identify the mechanisms by which
the CFHealthHub intervention could have influenced medication adherence. Prior to analysis, a logic
model (see Figure 3) was constructed to map the anticipated mechanistic pathway, along with potential
effect moderators (including two-way interactions) from which a provisional directed acyclic graph
(DAG) was created. The factors were further screened for inclusion prior to fitting the model by
graphically assessing two-way associations and, for potential mediators, by calculating mean differences
between the randomised arms. Factors with little apparent association (defined as an absolute
correlation of < 0.1 or a mean difference < 0.1 SDs) were removed from the DAG prior to model fitting.
Factors identified as potential mediator–outcome confounders were included in the model as fixed-effect
covariates. Pearson’s correlation coefficients with their 95% CI (calculated using Fisher’s z transformation)
were used as a guide to identify relationships between mediators. Model fit statistics comparative fit
index (CFI) and root mean squared error of approximation (RMSEA) were used to select the final model.
In addition, 95% bootstrap CIs were used to estimate the indirect effect of the chosen mediators as well
as the direct and total effect of the intervention on medication adherence. Sensitivity analysis was carried
out, removing intervention arm participants whose follow-up overlapped with the intervention system
being unavailable owing to technical difficulties (i.e. from 20 March to 23 April 2019).
Results
Key results are described in this section. Further results from the statistical analysis plan are reported
in Report Supplementary Material 2. Extra analyses were undertaken that were not specified in the
statistical analysis plan and these are reported in Report Supplementary Material 3.
Participant flow
Participants were recruited from October 2017 to June 2018. Participants were followed up until trial
completion in June 2019. Participant recruitment and disposition is shown in Figure 4.
Reasons for declining participation and premature discontinuation of intervention
Common reasons for declining to participate were unwillingness to change nebuliser (125/566) and
that the trial would be too time-consuming (118/556). There were 54 premature discontinuations
of adherence data collection (control arm, n = 29; intervention arm, n = 25) and 32 premature
discontinuations of intervention delivery. Unhappiness with the device/nebuliser or a preference for
a previous device was reported as a reason for discontinuation (see Report Supplementary Material 2).
Baseline characteristics
One participant withdrew prior to baseline data collection. Participant characteristics at baseline are
shown in Table 3. There were no discernible between-group differences in baseline demographic
characteristics. A difference was observed in ‘baseline’ numerator-adjusted normative adherence,
which was measured in the first 2 weeks post consent. Participants in the intervention arm had slightly
higher FEV1% predicted and fewer i.v. therapy-days in the prior year. In accordance with CONSORT
reporting guidelines, we did not carry out any significance tests of baseline differences. We carried out
an analysis adjusted for covariates. We describe this analysis briefly in the statistical analysis section
and in more detail in the statistical analysis plan. In summary, we adjusted for baseline stratification
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FIGURE 4 The CONSORT flow diagram. a, Exclusions due to missing covariates. Reproduced with permission from
Wildman et al.44 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
TABLE 3 Participant demographics and clinical characteristics at baseline
Variable
Control arm Intervention arm Overall
N Mean (SD)/n (%) N Mean (SD)/n (%) N Mean (SD)/n (%)
Demographic data: numeric
Age (years) 303 30.3 (10.8) 304 31.1 (10.6) 607 30.7 (10.7)
Weight (kg) 303 63.2 (14.2) 304 64.1 (14.1) 607 63.7 (14.1)
Height (cm) 303 167.2 (9.2) 304 167.7 (9.5) 607 167.5 (9.4)
BMI (kg/m2) 303 22.5 (4.2) 304 22.7 (4.2) 607 22.6 (4.2)
continued
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factors (site and previous years’ i.v. therapy-days) and baseline value of the outcome (where available)
in all statistical models.
Primary outcome
The IRRs from the primary and sensitivity analyses comparing exacerbation rates between the
intervention and control arms are presented in Figure 5. The IRR for the main primary analysis was
0.96 (95% CI 0.83 to 1.12; p = 0.638). The point estimate of the IRR is < 1, which favours the
intervention arm. However, the 95% CI for the treatment effect included 1, which is consistent with no
overall difference in exacerbation rates between the two randomised arms. The sample size was predicted
on the assumption of 2.0 exacerbations per year prior to intervention, with a reduction of 0.5 exacerbations
to 1.5 per year. This is equivalent to an IRR of 0.75 (2.0 ÷ 1.5). We observed 1.77 exacerbations in the
control arm and 1.63 in the intervention arm. If we are looking for a 0.5 reduction in exacerbations from
1.8 to 1.3 then this gives an IRR of 0.72 (1.8 ÷ 1.3). Based on our sample size calculation, a clinically
important IRR is between 0.65 and 0.75. Because the lower limit of the estimate (i.e. 0.83) is above this,
our result is not statistically significant, and not clinically significant if we believe an important IRR is ≤ 0.75.
Findings from sensitivity analyses were consistent with the primary analysis, with 95% CIs encapsulating
the null IRR value of 1.
Further details about the exacerbation analysis can be found in Report Supplementary Material 2.
TABLE 3 Participant demographics and clinical characteristics at baseline (continued )
Variable
Control arm Intervention arm Overall
N Mean (SD)/n (%) N Mean (SD)/n (%) N Mean (SD)/n (%)
Demographic data: categorical
Gender
Female 303 154 (50.8) 304 156 (51.3) 607 310 (51.1)
Male 303 149 (49.2) 304 148 (48.7) 607 297 (48.9)
Deprivation
1st quintile 302 51 (16.9) 302 50 (16.6) 604 101 (16.7)
2nd quintile 302 71 (23.5) 302 59 (19.5) 604 130 (21.5)
3rd quintile 302 66 (21.9) 302 63 (20.9) 604 129 (21.4)
4th quintile 302 67 (22.2) 302 63 (20.9) 604 130 (21.5)
5th quintile 302 47 (15.6) 302 67 (22.2) 604 114 (18.9)
Clinical characteristics: numeric
FEV1% predicted 302 58.3 (22.6) 304 60.7 (23.5) 606 59.5 (23.1)
i.v. therapy-days in previous 12 months 303 27.7 (33) 304 24.2 (27.9) 607 25.9 (30.6)
Subjective adherence (%) 298 69 (30.8) 300 69.9 (31) 598 69.4 (30.9)
Numerator-adjusted normative
adherence (weeks 1 and 2 post
consent) (%)
295 45.6 (34.2) 296 54.0 (32.9) 591 49.8 (33.8)
Clinical characteristics: categorical
Chronic Pseudomonas infection 299 175 (58.5) 304 174 (57.2) 603 349 (57.9)
Non-chronic Pseudomonas infection 299 124 (41.5) 304 130 (42.8) 603 254 (42.1)
Reproduced with permission from Wildman.44 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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The mean weekly numerator-adjusted normative adherence over the course of the RCT is shown in
Figure 6. The adjusted between-group difference in mean weekly adherence was 9.5 (95% CI 8.6 to
10.4; p < 0.001) percentage points in favour of the intervention arm. Further details about adherence















































Adjusted difference in means: 9.5% (95% CI 8.6% to 10.4%)
Usual care
Intervention
FIGURE 6 Mean weekly numerator-adjusted normative adherence. Reproduced with permission from Wildman et al.44
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and
formatting changes to the original figure.
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FIGURE 5 Pulmonary exacerbation IRR from primary and sensitivity analyses. Reproduced with permission from
Wildman et al.44 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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Other secondary outcomes
The adjusted mean FEV1% predicted at 12-month follow-up was 1.4 (95% CI –0.2 to 3.0; p = 0.082)
percentage points higher in the intervention arm. The adjusted mean BMI was 0.3 kg/m2 (95% CI
0.1 kg/m2 to 0.6 kg/m2; p = 0.008) higher in the intervention arm. Effect sizes were modest for the
remaining secondary outcomes, but all excluding the patient-reported measure of anxiety (GAD-7)
showed a direction of effect favouring the intervention. Observed follow-up means and adjusted
between-group differences for all outcomes are presented in Tables 4 and 5. Further detail can be
found in Report Supplementary Material 2.
Adverse event data from the 12-month follow-up period are presented in Table 6. A full list is presented
in Appendix 6. There were no serious adverse events deemed related to the intervention.
TABLE 4 Clinical and patient-reported outcome measures: primary outcome
Primary
outcome













Exacerbations 303 526/297.2 1.77 304 482/294.9 1.63 0.96
(0.83 to 1.12)
IRR < 1
a All analyses adjusted for previous year’s i.v. therapy-days and site.
Reproduced with permission from Wildman.44 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 5 Clinical and patient-reported outcome measures: key secondary outcomes
Secondary outcome
Control arm Intervention arm
Adjusted difference









295 34.9 (31.7) 293 52.9 (31.4) 9.5 (8.6 to 10.4) Increase 0.29
FEV1% predicted (%) 282 56.9 (23.0) 274 60.6 (24.2) 1.4 (–0.2 to 3.0) Increase 0.06
BMI (kg/m2) 282 22.6 (4.1) 273 23.1 (4.4) 0.3 (0.1 to 0.6) Increase 0.07
Patient-reported outcomes
Beliefs about medication
Concerns 271 2.1 (0.5) 263 2.0 (0.5) –0.2 (–0.2 to –0.1) Decrease 0.29
Necessities 271 3.5 (0.7) 263 3.7 (0.8) 0.1 (0.0 to 0.2) Increase 0.18
SRBAI (habit) 271 11.7 (4.9) 261 12.9 (4.9) 1.2 (0.5 to 1.8) Increase 0.24
CFQ-R
Physical 274 52.6 (30.6) 264 55.8 (30.2) 2.3 (–1.0 to 5.6) Increase 0.08
Emotion 274 66.5 (24.7) 264 66.6 (22.9) 0.2 (–2.9 to 3.2) Increase 0.01
Social 274 59.6 (20.0) 264 60.5 (20.0) 0.3 (–2.2 to 2.7) Increase 0.01
Eating 274 81.0 (23.2) 264 84.0 (21.5) 1.9 (–1.3 to 5.2) Increase 0.09
Body image 274 65.1 (29.3) 264 67.2 (27.3) 1.7 (–1.4 to 4.8) Increase 0.06
Treatment burden 274 51.6 (19.7) 265 56.6 (19.5) 3.9 (1.2 to 6.7) Increase 0.20
Respiratory 271 56.6 (21.9) 263 58.0 (22.5) 0.7 (–2.4 to 3.8) Increase 0.03
Digestion 272 80.2 (21.6) 263 80.4 (19.4) 1.1 (–1.7 to 3.9) Increase 0.05
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TABLE 5 Clinical and patient-reported outcome measures: key secondary outcomes (continued )
Secondary outcome
Control arm Intervention arm
Adjusted difference





effect sizeN Mean (SD) N Mean (SD)
MAD-3 (medication
adherence)
245 9.9 (3.6) 237 10.8 (3.3) 0.7 (0.2 to 1.2) Increase 0.20
Behavioural question
(effort)
270 3.0 (1.2) 260 3.3 (1.3) 0.3 (0.1 to 0.5) Increase 0.22
Subjective adherence 267 65.6 (32.8) 258 68.6 (31.3) 1.9 (–2.8 to 6.6) – 0.06
CHAOS-6 (routine) 272 9.6 (3.2) 263 9.4 (3.4) –0.2 (–0.6 to 0.3) Decrease 0.05
PAM-13 (health-style
assessment)
274 64.9 (13.0) 265 68.1 (15.6) 3.4 (1.3 to 5.4) Increase 0.23
PHQ-8 (depression) 272 6.4 (5.0) 262 6.3 (5.6) –0.1 (–0.8 to 0.7) Decrease 0.01
GAD-7 (anxiety) 273 4.5 (4.8) 262 4.9 (5.3) 0.3 (–0.4 to 1.0) Decrease 0.05
EQ-5D-5L 272 0.81 (0.18) 264 0.84 (0.15) 0.01 (–0.01 to 0.04) Increase 0.09
a All analyses adjusted for previous year’s i.v. therapy-days, site and the outcome measure value at baseline.
Reproduced with permission from Wildman.44 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
TABLE 6 Non-serious and serious adverse events
Adverse event
Control arm
(N= 303), n (%)
Intervention arm




All AEs 301 (46.9) 341 (53.1) 642 (100.0)
Participants experiencing at least one AE 125 (41.3) 139 (45.6) 264 (43.4)
AEs by category
Expected 242 (80.4) 263 (77.1) 505 (78.7)
New depression requiring treatment 1 (0.3) 5 (1.5) 6 (0.9)
Other 58 (19.3) 73 (21.4) 131 (20.4)
Serious adverse events
All SAEs 64 (47.4) 71 (52.6) 135 (100.0)
Participants experiencing at least one SAE 43 (14.2) 56 (18.4) 99 (16.3)
SAEs by category
Expected 21 (32.8) 28 (39.4) 49 (36.3)
New depression requiring treatment 0 (0.0) 0 (0.0) 0 (0.0)
Other 41 (64.1) 42 (59.2) 83 (61.5)
Unknown 2 (3.1) 1 (1.4) 3 (2.2)
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Subgroup analyses
See later in Implications for randomised controlled trial subgroup and sensitivity analyses.
Extra analyses: longer-term outcomes
The above analysis is based on 12 months; however, some PWCF stayed in the RCT for up to 21 months.
Analysis of the longer-term outcomes up to 21 months post consent back up the results of the primary
analysis using 12-month data [no difference in exacerbations or forced expiratory volume in first second
(FEV1)]. There is a difference in adherence of a similar order to the 12-month analysis.
For exacerbations, there was a total of 1326 exacerbations (control, n = 693; intervention, n = 633)
during that time. The observed exacerbation rate in the extended post-consent follow-up was 1.70 per
year in the control arm and 1.58 per year in the intervention arm (compared with an exacerbation
rate of 1.77 per year in the control arm and 1.63 in the intervention arm in the primary analysis).
The primary analysis model included adjustments for the previous year’s i.v. therapy-days and site,
which were stratifying factors in the randomisation schedule. The estimated treatment effect for
this analysis, the IRR, was 0.97 (95% CI 0.84 to 1.12), which is < 1, favouring the intervention arm.
However, the 95% CI for the treatment effect included 1, which is consistent with no overall difference in
exacerbation rates between the two arms. The estimated treatment effect for the longer-term follow-up is
very similar to the primary analysis, with 12-month post-consent follow-up of 0.96 (95% CI 0.83 to 1.12).
For FEV1, the estimated treatment effect was 0.6 (95% CI –0.2 to 1.4) percentage points and the time
effect was –0.1 percentage points (95% CI –0.2 to –0.0 percentage points) decline in FEV1 per month. The
direction of effect favoured the intervention arm, but the 95% CI included zero, consistent with there
being no difference between arms. There was a small trend for decreasing FEV1% predicted over time
and no significant interaction between randomised treatment arm and time. For adherence, the original
mixed-effects adherence model was applied to the extended follow-up data. Increasing the follow-up
time from 12 to 21 months increased the estimated treatment effect from 9.5 to 11.9 percentage points
(95% CI 11.1 to 12.7 percentage points). The time coefficient was –0.2 percentage points (95% CI
–0.2 to –0.1 percentage points), suggestive of a slight decreasing trend in adherence levels over time.
Process evaluation results
Fidelity (work package 2.3)
For both certification and drift, two persons independently assessed each intervention and the level of
agreement between assessors was high. All interventionists were successfully certified as competent to
deliver the intervention, including the first visit, review visit and phase review. A total of 110 assessments
were assessed to explore drift in fidelity over the duration of the trial and a pass mark threshold of 80%
was set for drift assessments. Among all paired assessments during the RCT, there was 97.2% agreement
when comparing pass/fail decisions at the 80% threshold (207/213 assessments in agreement). That is, the
RCT had good fidelity (overall fidelity by site, range 79–97%), with only one site not achieving over the
mean threshold (> 80%) on drift assessments. See Appendix 3 for further details of the fidelity assessment
methods and findings.
Usual-care survey
Although most CF centres reported using objective adherence data at baseline, this was described
as ad hoc or infrequent at most sites, indicating that our intervention’s systematic approach to
measurement was different from usual care. Change scores indicated that usual care within the sites
was consistent from baseline to follow-up. There was variation in usual care between RCT sites.
See Appendix 4 for further details.
User satisfaction
Among those intervention users completing the satisfaction survey, most rated the following intervention
components as ‘very helpful’: the first intervention meeting (77.4%), adherence graphs/tables (68.5%),
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interventionist support to solve problems (60%) and telephone (58.7%) and face-to-face (67.2%) follow-up
visits with the interventionist (Table 7). Videos of other PWCF were rated as less helpful. There was
variation between RCT sites. See Appendix 5 for further details.
Trial monitoring
Among the participants approached for the RCT, 48% were recruited. A total of 566 declined recruitment,
citing reasons such as not wanting to change the type of nebuliser they used and being too busy
(see Report Supplementary Material 2).
The CFHealthHub digital platform was taken down for emergency technical work for 5 weeks (from
20 March to 23 April 2019). It was not available to participants in the RCT in that period. This affected
the delivery of the intervention for a minority of PWCF in the intervention arm. This was taken into
consideration in the mediation analysis and in a sensitivity analysis for the RCT.
Qualitative research
Process evaluations focus on mechanisms of action, implementation/delivery of the intervention and
context.45 The qualitative research focused on these issues. We report the findings in three parts: one
focusing on a single mechanism of action (‘objective adherence data as proof’) (see Appendix 7), one
focusing on the range of mechanisms of action operating in practice in the intervention, including some
that were not identified in the feasibility study (see Appendix 8), and one focusing on variation in context
and implementation between RCT sites/CF centres (see Appendix 9).
During data collection one of the qualitative researchers noted that PWCF and interventionists
sometimes talked about the adherence data as ‘proof’. This mechanism of action was explored in detail
by analysing codes related to mechanisms of action and identifying different aspects of this mechanism.
TABLE 7 Item-by-item questionnaire response summaries











1. The first meeting with the interventionist
when they showed you CFHealthHub
257 77.4 20.6 1.9 0.0
2. Graphs and tables of your adherence data 257 68.5 28.0 2.7 0.8
3. ‘My Toolkit’ 255 39.6 44.3 14.1 2.0
4. Video about how your treatment works 254 37.8 36.6 20.1 5.5
5. Video clips of other people with CF 252 29.0 36.9 25.8 8.3
6. My treatment on CFHealthHub 252 48.4 40.5 8.3 2.8
7. ‘Problem-solving’ on CFHealthHub 251 33.5 47.8 15.1 3.6
8. Making action plans 255 38.8 41.6 16.1 3.5
9. Interventionist support to solve problems 255 60.0 33.3 4.7 2.0
10. Follow-up telephone calls 254 58.7 33.5 6.3 1.6
11. Follow-up visits (face to face) with the
interventionist
256 67.2 29.3 3.1 0.4
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The objective adherence data were described as offering proof to both self and others about adherence
behaviour. PWCF perceived that this could offer benefits, including improving their relationships with
their clinical team and their families, if objective adherence was higher than believed by these external
parties (see Appendix 7 for further details about the role of proof in improving adherence).
During the feasibility study, we explored the range of mechanisms of action of the intervention. During
the evaluation phase we continued to be interested in this. We had coded data to expected mechanisms
of action and mechanisms of action associated with effective telehealth intervention and analysed these
codes. There was evidence to support expected mechanisms of action around self-monitoring and
self-regulation. Other mechanisms of action were also apparent, for example being monitored by others,
which some interventionists believed affected control participants as well as intervention participants
who mistakenly believed that clinicians could see their adherence data. The relationship between
interventionists and PWCF in the intervention arm appeared to be an important mechanism, as found
in the feasibility study. Open communication, home visits, continuity of relationship and time helped
to build trust between interventionists and PWCF. This trust helped PWCF to talk openly and honestly
about the challenges that they faced adhering to treatment. This meant that the interventionists
understood more about the real-life challenges faced by PWCF and could help them to find ways to
address those challenges. PWCF with high levels of baseline adherence reported gaining reassurance
from the intervention. PWCF with very low levels of baseline adherence had challenging life situations
that made improvement difficult. PWCF with low to moderate levels of adherence could improve
adherence, with action plans to help establish treatment habits, especially if the time was right in their
lives. PWCF found the components of the intervention acceptable, but some did not like the patient
video clips and some struggled with setting formal action plans. (See Appendix 8 for further details
about mechanisms of action).
There was considerable variation between the different RCT sites/CF centres in terms of the
backgrounds of the interventionists delivering the intervention at each site, and the way in which the
MDT engaged with the intervention and interventionist. That is, the context in which the intervention
was delivered varied in the RCT, with the potential to affect implementation. See Appendix 9 for
further details.
Mediation analysis
Awareness, habit, concerns, self-efficacy and effort were selected as mediators from the logic model
(see Figure 3) because these were associated with both intervention and normative medication
adherence. The standardised mean differences of the mediator between the intervention and control
arms ranged from 0.6 to 0.2 and mediator–medication adherence correlation ranged from 0.1 to 0.5.
Two-way interaction graphs showed that treatment effect had a stronger effect on awareness as
baseline prescription increased, and treatment effect on effort was different for men and women.
Hence, baseline prescription and gender were included as moderators. Age, gender and baseline
measures of FEV1, number of nebulisers prescribed, depression score, i.v. therapy-days (binary),
medication adherence, awareness, motivation and chaos were included as fixed-effect covariates.
All selected mediators except awareness had a statistically significant association between each other.
The final mediation analysis model included all the selected mediators, moderators and fixed-effect
covariates, demonstrating a good model fit (CFI 1.00, RMSEA 0.00, 95% CI 0.00 to 0.01). The total
effect of the intervention on mean normative medication adherence was 13.3 (95% CI 9.6 to 17.0).
The direct effect on adherence (i.e. not explained via the selected mediators) was 6.1 (95% CI 2.7
to 9.5). The overall indirect effect of awareness was 5 (95% CI 3.2 to 6.8) and mediated 37.3% of the total
effect, but interacted linearly with mean baseline prescription: awareness mediated 18% of the total effect
for patients using a nebuliser on alternate days and mediated 58% of the effect for those using six per day.
The indirect effect of habit was 1.3 (95% CI 0.4 to 2.1; 9.4% mediated), of self-efficacy was 0.2 (95% CI
–0.3 to 0.7; 1.6% mediated) and of concerns was 0.2 (95% CI –0.3 to 0.7; 1.5% mediated). The indirect
effect of ease of effort was 0.2 (95% CI –0.1 to 0.5; 1.4% mediated) but interacted with sex: effort had
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some mediation for women at 0.4 (95% CI –0.2 to 1.0; 2.8% mediated) but little mediation for men at
–0.03 (95% CI –0.3 to 0.3; –0.2% mediated). Results from the sensitivity analysis showed a similar trend
but with a slightly higher mediating effect as mean baseline prescription increased (14% to 63% for the
baseline prescription range 0.5 to 6.0).
The results from the mediation analysis suggests that the intervention helped improve patient’s awareness
of their medication usage. This increased awareness contributed to an increased medication adherence,
with some evidence to suggest that this effect was more pronounced for patients who used several
nebulisers at baseline. Another pathway in which the intervention could have affected medication adherence
was by facilitating habit formation, resulting in decreased effort required to take medication, thereby
reducing concerns and improving self-efficacy. The total mediated effect of all these mediators was 51%.
See Appendix 10 for further information.
Triangulation for process evaluation
The triangulation grid bringing together all the components of the process evaluation is reported in
Appendix 11. This grid was used to draw key conclusions from the process evaluation. The synthesised
conclusions were as follows:
l Implementation was very good. The intervention was delivered with good fidelity at all RCT sites
with the exception of one. There was one period of 5 weeks towards the end of the RCT when the
CFHealthHub platform was not available; this was considered in both the mediation analysis and
the RCT sensitivity analysis.
l The intervention was acceptable. The majority of PWCF who completed the survey found it very
helpful, particularly the graphs of adherence and the interventionists’ visits. Some caution is
appropriate because not all PWCF completed the survey and PWCF may have wanted to please the
interventionist, who might have been present at the time the questionnaire was completed.
l The expected mechanisms of action were evident (e.g. self-monitoring), and further mechanisms of
action were identified for improvements in adherence to nebulisers. Changes in people’s calibration
of their perceived adherence rates affected improvements in objectively measured adherence rates,
showing the importance of the objective adherence data.
l The intervention was different from usual care.
l The context in which the intervention was delivered differed by RCT site owing to the differing strengths
of the interventionists and the different levels of engagement of MDTs with the intervention.
Implications for randomised controlled trial subgroup and sensitivity analyses
Our proposed RCT subgroup analyses identified from the process evaluation were specified prior to
analysis of the RCT data. Based on the process evaluation, we were keen to understand if RCT results
differed by:
l good versus poor implementation at different sets of sites
l whether or not the CFHealthHub intervention was available (i.e. where it was not available for
5 weeks owing to technical difficulties)
l levels of baseline adherence.
In practice it was not possible to identify a set of RCT sites with poorer implementation because
contextual issues varied greatly between sites. Therefore, we did not undertake this subgroup analysis.
The issue about the lack of availability of the intervention for a few weeks was addressed in a
sensitivity analysis and the mediation analysis (see Report Supplementary Material 2). The lack of
availability of the intervention for 5 weeks did not affect the RCT results.
The baseline adherence subgroup analysis had been specified in our set of a priori RCT subgroup
analyses but these planned subgroup analyses were undertaken on the primary outcome only.
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After our process evaluation we were interested in the relationship between baseline adherence
and the key secondary outcomes of change in adherence rates and FEV1.
Subgroup analyses are shown in Report Supplementary Material 2. There were no statistically significant
subgroup differences in number of exacerbations (primary outcome). Post hoc additional subgroup
analyses are also shown in Report Supplementary Material 2. The only statistically significant subgroup
difference was related to improvement in adherence rates differing by baseline objective adherence
(p < 0.001). PWCF with low and moderate levels of baseline adherence had the biggest improvement
(18% and 15%, respectively) and high-level adherers had the least (3%) improvement and very
low-level adherers had a 10% improvement. Adherence graphs by baseline adherence are displayed in
Report Supplementary Material 2.
Triangulation of randomised controlled trial results and process evaluation
findings (work package 3.4)
Work package 3.4 brings together the findings from the RCT and process evaluation related to outcomes.
See Appendix 12 for more details. The process evaluation cannot identify changes in outcomes compared
with control but can offer insights to support (or otherwise) RCT results, as well as explain how outcomes
might have been achieved. The overall conclusions of this triangulation process were:
l The intervention did not statistically significantly reduce the primary outcome of numbers of
exacerbations. This was not due to implementation problems because the intervention was
implemented with high levels of fidelity.
l The intervention increased adherence rates. This finding was supported by multiple components of
the process evaluation, showing the importance of the objective adherence data to this improvement
as well as habit forming and the relationship with interventionists. Improvements in adherence rates
were greater among those with low to moderate levels of baseline adherence than among those with
high levels of baseline adherence (where ceiling effects may have operated) or those with very low
levels of baseline adherence (who may have struggled with complex lives).
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Work package 3.5: health economic
evaluation
Introduction
This section presents the methods and results of economic analyses undertaken to assess the
cost-effectiveness of the CFHealthHub intervention evaluated within the RCT (Dr Martin Wildman,
Sheffield Teaching Hospitals, 2019, personal communication).
We undertook two related economic analyses to assess whether or not the intervention represents good
value for money for the NHS: (1) a short-term ‘within-trial’ economic evaluation alongside a clinical
trial (EEACT) that compares health gains and costs for the intervention and usual-care arms using
individual patient-level data (IPD) from the trial (Dr Martin Wildman, personal communication) only,
and (2) a model-based analysis that compares the intervention with usual care over a lifetime horizon.
The scope of the analyses is summarised in Table 8. Both analyses evaluate the cost-effectiveness of the
intervention in a population of PWCF aged ≥ 16 years who are taking inhaled mucolytics or antibiotics
from the perspective of the NHS and PSS. The within-trial analysis is restricted to the health outcomes and
costs accrued in the trial follow-up period, whereas the model-based analysis includes the extrapolation of
health outcomes and costs over a lifetime horizon and includes the use of additional evidence beyond that
collected in the RCT.
We used Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guidance
(see Report Supplementary Material 6).56
Within-trial economic evaluation alongside a clinical trial
Within-trial economic evaluation alongside a clinical trial methods
The EEACT was undertaken using IPD from the RCT (Dr Martin Wildman, personal communication)
Quality-adjusted life-year (QALY) gains for each patient were estimated as the ‘background QALYs’
accrued based on EQ-5D-5L assessments measured during routine clinic visits, less health losses
associated with exacerbations (days spent receiving i.v. antibiotics). EQ-5D-5L measurements were
mapped to the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), using van Hout et al.57
TABLE 8 Scope of the economic analyses
Element of analysis Within-trial EEACT Model-based analysis
Population ACtiF trial population: people with diagnosed CF aged ≥ 16 years who are taking inhaled
mucolytics or antibiotics
Intervention CFHealthHub intervention as
per trial
CFHealthHub intervention as it would be rolled out
to the NHS
Comparator Usual care (no adherence intervention)
Economic outcome Incremental cost per QALY gained
Time horizon 1 year (primary outcome window) Lifetime (70 years)
Perspective NHS and PSS
Discount rate 3.5% for health outcomes and costs
Price year 2017/18 (£)
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Background QALYs for each patient were calculated under four assumptions:
1. Mean utility was calculated using an area under the curve approach via the trapezium rule, assuming a
constant rate of improvement/worsening in HRQoL between successive EQ-5D-5L measurements.
2. For patients with a final EQ-5D-5L visit beyond the primary outcome cut-off, the patient’s EQ-5D-5L
score was estimated at day 365 based on assumption 1.
3. For patients with a final EQ-5D-5L visit before the primary outcome cut-off, the patient’s mean
utility during the observed period was assumed to apply during the unobserved period (i.e. mean
utility is ‘stretched’ over the whole primary outcome window).
4. Patients with missing baseline EQ-5D-5L measurements and those with fewer than two EQ-5D-5L
assessments over the primary outcome window were treated as missing.
All QALY losses associated with i.v. days were estimated as the mean loss of utility between the first
and last exacerbation-related EQ-5D-5L measurements (‘visit E3’, which took place approximately
4 weeks after the start of the exacerbation, minus ‘visit E1’, which took place at the start of the
exacerbation) for the whole patient population multiplied by the number of i.v. therapy-days incurred
by each individual patient. Total QALYs gained per patient were calculated by subtracting i.v.-related
QALY losses from the background QALYs.
The EEACT includes the following resource costs: the CFHealthHub adherence intervention (applied
to the intervention arm only); i.v. therapy-days in hospital; i.v. therapy-days at home; i.v drugs and
consumables; visits from health-care practitioners; and nebuliser devices. Resource use estimates were
derived from data collected using a standardised resource use form in the trial as well as expert
opinion. The costs of nebulised drugs were not included in this analysis. Unit costs were taken from
NHS Reference Costs 2017/18,58 the Personal Social Services Research Unit (PSSRU)59 and personal
communication [Misbah Tahir, Clinical Pharmacist, Sheffield Teaching Hospitals NHS Foundation Trust,
2019; Carola Fuchs, PARI GmbH, 2019; Pauline Whelan, Farr Institute, and ACtiF Project Management
Group (PMG), 2019]. The resource and cost inputs applied in the EEACT are presented in Appendix 13.
Missing data were handled using multiple imputation by chained equations over 10 iterations.60
A complete-case analysis was undertaken as a secondary analysis. Total QALY gains and costs (with or
without imputation) were included in a seemingly unrelated regression (SUR) model,61 which adjusts for
baseline imbalances between the two groups in terms of baseline EQ-5D-5L and i.v. therapy-days in
the previous 12 months (a stratification factor in the ACtiF RCT).
Within-trial economic evaluation alongside a clinical trial results
The results of the EEACT are summarised in Table 9. The base-case results for the EEACT suggest that
the intervention generated 0.01 additional QALYs at an additional cost of £865.91 per patient; the
corresponding incremental cost-effectiveness ratio (ICER) is £71,136 per QALY gained. The complete-
case analysis suggests a higher ICER of £109,754 per QALY gained.
The results of this analysis should be interpreted with caution for two reasons. First, the short time
horizon for the EEACT incorporates all of the upfront costs of the intervention but does not include
the potential longer-term benefits that accrue as a result of these. Second, the allocation of the
intervention costs across the trial group is unlikely to reflect the actual per-patient costs of delivering
the intervention in practice, further inflating costs and associated ICERs.
Model-based analysis
Model structure and assumptions
The model-based analysis uses evidence from the RCT (Dr Martin Wildman, personal communication)
and other external sources to estimate the cost-effectiveness of the intervention versus usual care
over a lifetime horizon. The model structure was based on the model used to inform the National
WORK PACKAGE 3.5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36















costs (£) ICER (£)
Complete-case analysis (N = 587)
CFHealthHub 0.77008 0.01002 0.7504104 to
0.7897539







Usual care 0.75015 0.01051 0.7295104 to
0.7707954
11,760.74 825.24 10,139.95 to
13,381.54
– – – – –
Imputed (N = 608)
CFHealthHub 0.771179 0.0098649 0.7518052 to
0.7905527







Usual care 0.7509504 0.0103025 0.7307169 to
0.771184
11,921.04 814.43 10,321.59 to
13,520.48
– – – – –
a The mean QALYs and costs in the results table are descriptive statistics for each treatment arm. These do not match the values presented as incremental QALYs and costs as only






























































































































































































































































































































Institute for Health and Care Excellence (NICE) technology appraisal of dry powder antibiotics.62 The model
adopts a state transition approach, defined according to five health states: (1) FEV1 ≥ 70% predicted,
(2) FEV1 40–69% predicted, (3) FEV1< 40% predicted, (4) post transplant and (5) death (Figure 7). During
each annual model cycle, patients may remain in their current FEV1% predicted state, transition to an
improved or worsened FEV1% predicted state or die. A small proportion of patients in the worst lung
function state (FEV1 < 40%) may undergo lung (or heart and lung) transplantation and do not subsequently
receive further nebulised treatment. HRQoL is modelled according to FEV1% predicted stratum and
transplant history, with QALY losses applied according to the proportion of time spent receiving i.v. therapy.
The model uses a 12-month cycle length over 70 cycles; a half-cycle correction was applied to account
for the timing of events. Total QALYs are calculated as the sojourn time in each health state weighted by
state-specific utility scores, less any i.v.-related QALY losses. The model includes the costs associated with
(1) the adherence intervention (intervention arm only), (2) health state resource use conditional on FEV1%
predicted stratum (based on the trial resource use form used in the trial), (3) i.v. therapy-days at home or in
hospital (including hospital inpatient stays, i.v. drugs and consumables), (4) nebuliser devices, (5) nebulised
drugs and (6) lung or heart and lung transplant.
The model employs the following key structural assumptions:
l At model entry, patients are assumed to be aged 30 years, based on the mean age of patients at
entry into the RCT (Dr Martin Wildman, personal communication).
l Patients in any FEV1% predicted stratum can progress/regress to any other FEV1% predicted stratum
during any model cycle.
l Patients who undergo transplantation cannot revert back to other alive health states; hence, the
only remaining event for these patients is death.
l Mortality risk is conditional on model health state. General population and CF-specific mortality
constraints63,64 are applied to ensure that the survival projection is plausible over the entire time horizon.
l Exacerbation risk is dependent on FEV1% predicted stratum.
l HRQoL is dependent on lung function and whether or not the patient is receiving i.v. therapy
for exacerbations.
l The impact of the adherence intervention is assumed to manifest through two mechanisms: (1) risk
ratios (RRs) of switching FEV1% predicted strata in a given year and (2) a relative rate ratio (RRR)
for the number of i.v. therapy-days incurred (which is, in turn, assumed to be constant across all
three FEV1% predicted states):
l The model assumes that the treatment effects and costs related to the intervention accrue only in
the years in which the intervention is given.
l In the base-case analysis, the intervention is assumed to be given for 10 years; this assumption is
tested in sensitivity analyses.
l The intervention is not assumed to directly affect the probability of undergoing transplantation or death.
l The costs of antibiotics and ‘high-cost therapies’ are independent of adherence to those therapies.









FIGURE 7 State transition model structure.
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Evidence used to inform the model’s parameters
The evidence sources used to inform the model’s parameters are summarised in Table 10; these are
briefly described below. All model parameters are presented in detail in Appendix 15.
Baseline characteristics
Initial patient characteristics (age, sex and the distribution of patients across FEV1% predicted strata at
baseline) were based on pooled data for both arms of the RCT (Dr Martin Wildman, personal communication).
Transition probabilities: usual care
The probabilities of transitioning between the model health states under usual care were informed by
analyses of a bespoke registry data set provided by the Cystic Fibrosis Trust.65 The data set contained
patient-level records for all patients included in the CF registry aged ≥ 16 years who had been
prescribed nebulised mucolytics or antibiotics at any time point (data years 2006–15). The overall data
set included 44,464 records across 7144 patients. We fitted a series of homogenous continuous time
multistate models to the available data using the msm package in R. This method assumes that event
hazards are constant with respect to time; hence, fitting a single model to the available data would
have failed to reflect the increasing risk of death for older patients. To address this structural limitation
in the approach, we fitted five separate multistate models to subsets of the data relating to patients in
the following age categories: 30–34 years, 35–39 years, 40–44 years, 45–49 years and ≥ 50 years.
Annual transition probabilities for each age category were estimated using the msm pmatrix function.
In the economic model, a constraint was applied to ensure that the risk of death for any CF patient in
the model is at least as high as that for the general population.63 A further constraint was applied to all
cycles from the age of 60 years to ensure that the risk of death from any state is at least as high as
that estimated by the flexible parametric survival models reported by Keogh et al.;64 this constraint was
applied to prevent underestimation of the mortality rate caused by limited numbers of older patients in
the registry data set.
TABLE 10 Summary of evidence sources used to inform the health economic model
Parameter Source
Initial patient characteristics (age, sex, baseline FEV1%
predicted)
RCT (Dr Martin Wildman, personal communication)
(data pooled across arms)
Transition probabilities, including transplant and death:
usual care
Multistate models fitted to CF registry data65 (including
general population63 and CF-specific64 mortality constraints)
Exacerbation risk (FEV1% predicted) CF registry data set65
Treatment effects: RRs transitioning out of FEV1 states RCT cumulative logit model
Treatment effects: RRR i.v. therapy-days RCT zero-inflated negative binomial model
Utility by FEV1% predicted strata Mixture model fitted to EQ-5D-5L data1
Exacerbation i.v. therapy day disutility RCT EQ-5D data (mapped from EQ-5D-5L to EQ-5D-3L)
i.v. therapy-days frequency (FEV1% predicted) CF registry data set65
Utility post transplant Anyanwu et al.66
Health state costs RCT resource use form (Dr Martin Wildman, personal
communication)
Nebulised treatment costs CF registry data set65
i.v. therapy day (hospital) cost NHS Reference Costs 2017/1858 (bronchiectasis)
i.v. drugs (hospital/home) costs Misbah Tahir, Sheffield Teaching Hospitals NHS Foundation
Trust, personal communication
Nebuliser costs Carola Fuchs, PARI GmbH, personal communication
Adherence intervention costs RCT (Dr Martin Wildman, personal communication) and
assumptions (see Appendix 13)
EQ-5D, EuroQol-5 Dimensions.
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Frequency of intravenous therapy-days: usual care
The expected number of i.v. therapy-days per year conditional on FEV1% predicted stratum under usual
care was estimated directly from the overall CF registry data set.65
Treatment effect models, risk ratios of transitioning between states
The FEV1% predicted states were modelled using a cumulative link logit model with a nominal treatment
group effect, baseline FEV1% predicted state and adjustment for the previous year’s i.v. therapy-days,
fitted to data from the RCT. The model was used to generate predicted probabilities for each follow-up
FEV1% predicted state, given baseline state and treatment allocation, from which RRs for between-state
transitions by treatment group were derived. A bootstrap approach was used to estimate the standard
errors (SEs) of the ratios on a log normal scale.
Treatment effect models, relative rate ratio for intravenous therapy-days
The i.v. therapy day counts in the 12-month period following consent into the RCT were modelled using
zero-inflated negative binomial regression with a treatment group factor, adjustment for baseline FEV1
status and the previous year’s i.v. therapy-days, and an offset for follow-up time. The treatment coefficient
was exponentiated to give the IRR and the SE estimated using the delta method.
Health-related quality of life
Health utility values for the FEV1% predicted states were estimated using a de novo function developed
to map from absolute FEV1% predicted scores to the EQ-5D-3L using data collected in the RCT
(Dr Martin Wildman, personal communication). The data used to estimate the mapping model included
repeated observations on 608 patients. Observations were not included in the analysis if EQ-5D-3L and
FEV1% predicted were missing or not measured in the same day/visit (2308 excluded observations).
The final number of observations used was 2386 (out of 4694), corresponding to 576 patients with a
mean of 3.4 clinic visits (SD 2.07). The mapping function developed by van Hout et al.57 was employed
to transform the EQ-5D-5L descriptive system into EQ-5D-3L utility values. The mean EQ-5D-3L and
FEV1% predicted values were 0.78 (SD 0.2) and 58.7 (SD 0.23). An adjusted limited dependent variable
mixture model67,68 (ALDVMM) was used to estimate the relationship between FEV1% predicted and the
mapped EQ-5D-3L values. The ALDVMM was developed specifically for mapping preference-based
measures and has been shown to outperform other models.69 Robust clustered SEs were used to take
into account the presence of repeated observations per patient. Models using two to four components
were estimated. On the basis the Akaike information criterion (AIC), the Bayesian Information Criterion
(BIC) and the mean absolute error (MAE), a model with three components was selected for inclusion in
the final economic model.70 An assessment of the goodness of fit of the alternative models is presented
in Appendix 15.
Utility values for patients undergoing transplantation and for patients receiving i.v. treatments were
excluded from the mapping analysis. The utility value for the transplant state was taken from Anyanwu
et al.66 QALY losses associated with receiving i.v. treatments were estimated non-parametrically using
the RCT data (using the same disutility applied in the EEACT; see Within-trial economic evaluation
alongside a clinical trial methods). Health utility values were age-adjusted using Ara and Brazier.71
Resource costs
The cost of the adherence intervention includes an initial cost associated with training and set-up
(year 1 only), ongoing annual costs (including data transfer, monitoring, maintenance and hosting of the data
platform), fidelity support and delivery of the intervention by interventionists. The model-based analysis
assumes that 30 interventionists can support 5900 adult CF patients receiving nebulised therapies.
Resource use estimates and unit costs were taken from NHS Reference Costs 2017/18,58 the PSSRU,58
the British National Formulary (BNF),72 the ACtiF RCT (Dr Martin Wildman, personal communication)
and personal communication (Misbah Tahir, Clinical Pharmacist, Sheffield Teaching Hospitals NHS
Foundation Trust; Carola Fuchs, PARI GmbH; Pauline Whelan, Farr Institute, and the ACtiF PMG).
Further details of the cost and resource use inputs are provided in Appendix 13.
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Model evaluation methods
The model estimates the incremental cost-effectiveness of the intervention compared with usual
care in terms of the incremental cost per QALY gained. Central estimates of cost-effectiveness were
based on the expectation of the mean derived from the probabilistic version of the model, based on
2000 Monte Carlo samples. Parameter uncertainty was evaluated using both deterministic sensitivity
analysis (DSA) and probabilistic sensitivity analysis (PSA). DSAs were used to identify key drivers of
the cost-effectiveness. PSA was used to estimate the probability that the intervention is cost-effective
across a range of willingness-to-pay (WTP) thresholds. Uncertainty was represented using cost-effectiveness
planes and cost-effectiveness acceptability curves.
Validation
A number of activities were undertaken to ensure internal validity and credibility of the model; these
are summarised in Appendix 16.
Model-based analysis: results
Table 11 presents the results of the base case analysis; the results of additional sensitivity analyses can
be found in Appendix 17. Based on the probabilistic version of the model, the intervention is expected
to generate 0.17 additional QALYs and cost savings of £1790 compared with usual care; therefore, the
adherence intervention is expected to dominate usual care (i.e. it is expected to be more effective and
less expensive). The results of the deterministic model are very similar. Assuming a WTP threshold of
£20,000 per QALY gained, the probability that the intervention generates more net benefit than usual
care is approximately 0.89.
The DSAs indicate that the conclusions of the economic analysis are sensitive to assumptions regarding:
l the duration over which health effects and costs of the adherence intervention apply
l the impact of the adherence intervention on the patient’s FEV1% predicted stratum
l increases in adherence to nebulised treatments and associated effects on drug-prescribing levels.
TABLE 11 Central estimates of cost-effectiveness










23.42 11.01 297,872 0.40 0.17 –1790 Dominating




23.37 10.96 299,107 0.40 0.17 –1637 Dominating
Usual care 22.97 10.79 300,743 – – – –
LYG, life-years gained.
a Undiscounted.
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We successfully developed an intervention and refined it during a feasibility study. In a full-scale RCT
of 608 PWCF, there was no statistically significant reduction in the primary outcome of incidence rate
of pulmonary exacerbations over a 12-month follow-up period. However, the RCT demonstrated a
clinically and statistically significant improvement in the secondary outcome of normative adherence
for PWCF. The magnitude of the increase in adherence, at 10% on average, may not have been large
enough to affect exacerbations. No significant difference was found between groups in lung function
at 12 months. There were statistically significant improvements in secondary outcomes that supported
the increase in adherence found, namely improvements in necessities and concerns, habit formation
and treatment effort. Only one of the eight domains of quality of life showed statistically significant
improvement: there was a reduction in treatment burden. There was a small average weight gain
(typically a positive outcome in CF).
The process evaluation identified that the level of implementation fidelity was high and that some of
the key expected mechanisms of action were in operation, including self-monitoring. PWCF in the RCT
valued the objective adherence data and the relationship they built with the interventionists, which
they perceived as helping them to change their behaviour. The process evaluation suggested that
adherence improvement might occur more in the baseline middle adherence level groups than the high
adherence level groups and the low adherence level groups. A statistical subgroup analysis supported
these findings.
The health economic model suggested that the intervention is expected to generate additional health
gains of 0.17 QALYs and cost-savings of £1790 over the patient’s remaining lifetime. In this modelling
the intervention is assumed to be given for 10 years and that treatment effects and costs accrue only
in the years the intervention is given.
Successes of the programme grant
The ACtiF programme set out to develop an intervention to help PWCF to increase adherence to
nebuliser adherence and subsequently reduce pulmonary exacerbations. Between February 2015 and
December 2019 objectives were achieved through a series of WPs. Each work package was delivered
on time and to plan. The intervention was evaluated in what was, to our knowledge, the largest CF
RCT conducted in the UK, which exceeded its participant recruitment targets and maintained a
sufficient sample size at follow-up. This contrasts with similar RCTs conducted in the CF population
that have failed to meet sample size requirements owing to research and intervention procedure
difficulties at recruitment and over the duration of the study.73–75 Extensive intervention development
and feasibility testing allowed the programme to develop a professional, theory-based, person-based
intervention that is both feasible and acceptable. Prior to this study there was insufficient evidence to
support the use of any individual self-management support strategy.76,77 A recent, large, well-conducted
RCT of strategies to improve adherence in CF had null findings.73 The legacy of the programme is a
digital platform for measuring objective adherence in PWCF that is being used in the NHS now, and a
manualised set of procedures for training and delivery of behaviour change techniques that improves
adherence to nebuliser treatments but does not reduce exacerbations.
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Challenges and methodological limitations
A major challenge for the whole programme was obtaining treatment costs for the RCT. Negotiating
treatment costs in the context of UK clinical research is a well-documented problem.78
The National Institute for Health Research (NIHR) funding panel members were keen that the RCT in
this programme focused on improvements in patient health. The primary outcome in the RCT was a
reduction in the number of exacerbations experienced by patients. The number of exacerbations is a
valid and sensitive outcome for the detection of change in blinded drug trials.79 However, we identified
problems with its use as a primary outcome in this open-label RCT of a complex intervention based in
routine care settings. The use of IVAB in clinical practice is essentially discretionary: about half of
those meeting objective criteria, and < 10% of people suffering acutely poor FEV1, decline to receive
them.80,81 Conversely, uptake in i.v. rescue antibiotics appears to increase as an individual becomes
more adherent with medication, with increased clinician contact allowing more exacerbations to be
detected.82,83 It is possible that our intervention and usual-care arms were subject to different levels
of surveillance, with the intervention arm experiencing greater contact time and perhaps being more
likely to self-present during exacerbations. Therefore, the estimated event rates may have been subject
to ascertainment bias, with under-reporting of exacerbations in the usual-care arm.
Improvement in normative adherence was a key secondary outcome on the proposed causal pathway
to reductions in exacerbations (see Figure 3). Some RCTs of adherence interventions use this as the
primary outcome, but our goal was more challenging. There was an improvement of 10% in this
outcome. It is clear (see Figure 6) that adherence rates were high in the first week of the RCT. Indeed,
our baseline adherence level was high (≈ 45%) compared with the average observed adherence in UK
CF centres (≈ 35%).16,84 This reduced in both arms for a few weeks before increasing in the intervention
arm. It was not possible to measure true baseline adherence; baseline adherence was measured when
PWCF entered the RCT and it is likely that the Hawthorne effect occurred in the first week of the RCT
as both intervention and usual-care arms reacted to being monitored in the RCT by trying to adhere
to their medication. It is possible that this was followed by a return to normal adherence before the
intervention began to help PWCF to improve their adherence.
The magnitude of the increase in adherence, at 10% on average and 15% in the low- to moderate-level
adherers, may not have been large enough to affect exacerbations and FEV1. Alternatively, detection
of change in exacerbations and FEV1 may be challenging within the time constraints of a 12-month
follow-up period. As depicted in the CFHealthHub logic model (see Figure 3), compared with increased
necessity, increased habit, decreased concern (immediate outcomes) and increased adherence
(intermediate outcome), improvements in exacerbation rates and lung function (FEV1) are longer-term
outcomes. It may be that further health benefits might be observed over longer periods of time, given
the window over which habits are thought to develop,85 although our extra analysis of longer-term
follow-up over 21 months for some RCT participants did not support this proposition. It is also possible
that the number of exacerbations is not a good indicator of patient health, and that quality of life may
be a better outcome in future studies, although other secondary outcomes such as quality of life also
showed little or no improvement.
A key limitation of the economic analysis is that the data collection mechanisms in the CFHealthHub
trial did not allow us to quantify the impact of the intervention on the number of packs of medicines
prescribed. As a consequence, there remains uncertainty regarding the relationship between improving
adherence on overall treatment costs incurred by the NHS. We undertook sensitivity analyses to
explore the potential impact of this factor on the cost-effectiveness of the intervention.
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Implications for practice and lessons learned
Effective chronic disease management with accurate diagnosis and medicines optimisation is reliant on
accurate adherence measures.15 Using state-of-the-art measurement tools to collect time- and date-
stamped inhalation data, this study has evidenced that level of objective adherence to nebulised
medications is lower than the patient themselves often realise.16 Poor calibration between subjective
and objective adherence may lead to inefficient clinical care for patients and consequent deteriorating
health. Clinicians may be unable to distinguish between patients who are deteriorating because of
untreated CF and patients whose CF is treated but who have complications requiring a change in
treatment. The digital platform component of the intervention provides objective adherence data that
may be useful in this context. A total of 19 UK CF centres now have access to the CFHealthHub
platform. The joint Chief Investigator Martin Wildman has established the CFHealthHub Data
Observatory and Improvement Collaborative (registered as ISRCTN14464661), which is using the
infrastructure and learning from the ACTIF programme to enable access to the CFHealthHub platform
for all PWCF and members of the MDT in routine care.
If used in practice, the expectation would be that the real-time measurement of adherence would be
continuous and that the interventionist-delivered part of the intervention would be used once or more
than once when someone’s adherence drops for any reason over their lifetime.
Recommendations for future research (in order of priority)
l Given the non-significant difference in the primary outcome, further research is required to explore
why an increase in objective normative adherence did not reduce exacerbations, and to develop
interventions that reduce exacerbations.
l The existing intervention could be adapted or tailored to address the needs of PWCF with different
levels of baseline adherence, including those with low levels of baseline adherence who often have
complex problems. That is, PWCF with low levels of motivation, who are disengaged from their
CF team or who inhabit adverse social situations as indicated by high self-reported life chaos
and low income. An enhanced, health and social care professional-led intervention to address the
wider complexity of individuals’ lives, as a precursor to adherence support, could be developed.
l The economic modelling indicates that the intervention is expected to dominate current care.
Future research would be valuable to better understand whether or not and how the effects of
the intervention change over time and whether or not improving adherence leads to increases in
prescribed CF medicines.
Conclusions
The CFHealthHub was successfully developed. In the full-scale RCT there was no statistically
significant reduction in the primary outcome of the number of pulmonary exacerbations at 12 months.
Clinically and statistically significant improvements in the key secondary outcome of normative
adherence were observed. The magnitude of the increase in adherence, at 10% on average, may not
have been large enough to affect exacerbations. The intervention was delivered with fidelity and key
mechanisms of action, including self-monitoring, were observed. The health economic model suggests
that the intervention is expected to generate additional health gains of 0.17 QALYs and cost-savings of
£1790 over the patient’s remaining lifetime. This finding is dependent on assumptions regarding the
duration over which costs and effects of the intervention apply, the impact of the intervention on
FEV1% predicted and the relationship between increased adherence and drug-prescribing levels.
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Appendix 1 Work package 1: developing
the technology and infrastructure to
collect adherence data
Introduction
A digital platform, CFHealthHub, was created to provide the technical components of the complex
intervention to support adherence to treatment in PWCF. CFHealthHub provided the front-end,
user-facing components of the intervention (a website and mobile app) and the back-end server
infrastructure for secure receipt and storage of adherence data. The technical development was
defined by two high-level phases: (1) technical scoping and configuration of the infrastructure and
(2) development of the digital BCI.
The platform was developed iteratively over an 18-month period, with a pre-pilot phase conducted with
27 participants from August 2015 to April 2016, followed by a two-centre feasibility study conducted
with 64 participants across two CF centres in 2016–2017. The digital platform was finalised and became
feature complete for the main RCT launch in October 2017. The first phase of the technical development
involved high-level requirements capture for the project. The top priority identified was to enable the
display of objective adherence data to the interventionists and PWCF through the CFHealthHub website.
Discussions with the nebuliser supplier led to the configuration of a secure data transfer mechanism,
enabling the devices to submit data in real-time through to the study server, hosted at the University of
Manchester. To display the adherence data in CFHealthHub it was necessary to develop a manual entry
point for the prescription information through the CFHealthHub website. The website was developed to
display the objective adherence data in a variety of graphical and tabular formats.
After the website was scaffolded to display the objective adherence data, an intensive co-design process
was launched to refine the display of data and to incorporate, develop and refine the BCI components.
This involved multiple project stakeholders reviewing successive prototypes and wireframes of designs,
and iterative website software releases. Input from the PPI group and from the qualitative research
contributed to the design and refinement process. Development of the mobile app drew heavily on the
earlier website development reviews, but designs were tailored for smaller screen sizes. Mobile-specific
engagement strategies (e.g. push notifications to encourage engagement with the CFHealthHub digital
platform) were also incorporated.
The software development was conducted by the mHealth team at the Health eResearch Centre,
University of Manchester, with design expertise provided by the Manchester-based user experience
company KeepItUsable. Later phases of the design work were completed in-house at the Health
eResearch Centre.
Methods
Agile software methodologies were used during the development cycles of the software.87,88 The
software team worked to regular sprint cycles, delivering successive software releases approximately
every 3 weeks. These iterative releases were reviewed by members of the research team, PWCF and
other project stakeholders for refinement and feedback. An intensive phase of co-design ran from
August 2015 until the launch of the feasibility study and involved weekly meetings with the software
team lead, external design lead, the health psychologist and the research physiotherapist leading the
intervention design. During these meetings key features were designed and refined through
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prototyping and wire-framing until project stakeholders were satisfied. PPI and feedback using
qualitative research with users were fed into these design meetings by research team members and if
areas were identified where further input was required from PWCF, these were highlighted to the PPI
lead of the project and taken to the PPI group for consultation.
Internally, the software team used agile scrum methodology, meeting at daily stand-ups to report and
plan progress, and delivering software in regular three-weekly sprint cycles.89,90 This agile process
allowed the software team to be responsive to changing requirements and flexible to the changing
needs of the platform as identified through PPI and qualitative feedback.
The MoSCoW91 (must have, should have, could have, won’t have) prioritisation system was used in the
later stages of the project to ensure that technical resources were directed to the critical areas of
feature development and enhancements.92 Using the MoSCoW91 system the team categorised each
feature or change request into must have, should have, could have or will not have at this time. This
was supported by effort estimates provided by the technical team and priorities as identified in the PPI
and qualitative feedback.
The digital platform CFHealthHub is hosted in a secure, ISO 27001-certified environment at the
University of Manchester.93
Results
Figure 2 outlines the technical architecture of the digital components of the intervention delivery and
shows (1) the nebulisers used by PWCF, which have electronic monitoring capabilities and transfer data to
the Qualcomm hub located in the participant’s home (nebuliser and hub provided by PARI GmbH), (2) how
data are received by the CFHealthHub server located at the University of Manchester, which stores
these inhalation data securely and combines them with prescription data entered manually through the
website, and (3) the user-facing components, website and mobile apps that are used by the clinicians
and participants in the trial to view adherence data and display the behaviour change components.
The website was designed to support role-based access to clinicians/interventionists (for viewing
adherence data), PWCF in the trial and members of the research team, who required access to the
data for further analysis. Features developed for the website and mobile app included the following:
l Adherence display in graphical (Figure 8) and tabular (Figure 9) format, supported by manual
prescription entry through the web interface and automatic real-time data transfer from the
nebulisers to the CFHealthHub.
l ‘My Education’ and ‘Problem-solving’ information, included for PWCF to view information and
support (e.g. to read about the reasons for taking medication, clarify concerns about antibiotic use
or to view information about how to clean the nebuliser) (Figure 10).
l ‘My Toolkit’ – a personalised space in the platform for PWCF to view information that had been
tailored specifically to them.
l Screening tool to support interventionists tailor the content delivered in the ‘My Toolkit’ section
towards the individual person with CF (Figure 11).
l Peer videos – an important aspect of our iterative response to patient feedback included the
incorporation of videos in which patients tell their own stories. The additional complexity of
indexing in the region of 20 interviews cut into short segments and tagged by identifiers (e.g.
managing CF at university) was likely to lead to around 80 or more individual video clips that
needed to be easily found on the CFHealthHub digital platform. Making this part of the website
compelling and easy to use required programming and graphic design input. Following consultation
with the Medicines and Healthcare products Regulatory Agency (MHRA) it was confirmed we did
not need to pay MHRA fees to support the evaluation of CFHealthHub.
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l ‘Action Planning’, ‘Coping Planning’, ‘Party Planning’ and ‘Day Planning’ to support the behaviour
change components of the trial.
l Push notifications to encourage engagement with the CFHealthHub tools.
l Push notifications informing participants of their adherence rates and encouraging an increase in
adherence to medication.
l Click and touch analytics – embedded in both the website and mobile apps, enabling the research
team to view engagement metrics (e.g. how often each element on the website and mobile apps
were visited and by whom).
l Export functionality to allow members of the quantitative research team to download the data in
secure encrypted format for further analysis.
FIGURE 8 Adherence display in tabular format.
FIGURE 9 Adherence display in graphical format.
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The technical design of the system employed a flexible, extensible, modular architecture to enable ease
of integrating features as the requirements developed over the lifetime of the project, and to future-
proof the system. The platform was designed to be as device agnostic as possible within the timelines
and budget available to enable the future integration of other kinds of medical devices and nebulisers.
(The system has subsequently integrated with another nebuliser device, demonstrating this capability.)
Mobile app development used a cross-platform development technology, Apache Cordova (Apache
Software Foundation, Forest Hill, MA, USA), and delivered both Android and iOS (Apple Inc., Cupertino,
CA, USA) versions.
Conclusions
The co-design and delivery of a digital platform to capture and display adherence data and to include
digital behaviour change tools was achieved for the launch of the main RCT. Agile software
development methods supported a co-design process of the digital platform and allowed input from
multiple stakeholders (PWCF, interventionists, members of the research team and members of the
technical teams) to shape the development of the digital platform CFHealthHub. To ensure optimal use
FIGURE 10 ‘My Education’ and ‘Problem-solving’ information on CFHealthHub.
FIGURE 11 Screening tool to support interventionists to tailor CFHealthHub.
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of resources, particularly in the later stages of the software refinement, the MoSCoW91 prioritisation
system for software requirements proved useful for determining which elements of the software were
critical to support the goals of the RCT and which elements could be saved for a future iteration of the
software. Inevitably, additional features and enhancements were identified for the system that could
have been implemented with additional time and resources. At the date of the main RCT launch,
CFHealthHub provided a professionally-designed, feature-rich website and mobile apps that supported
the digital components defined in the study protocol that were required by the complex intervention.
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Appendix 2 Work package 2.2: description
of the CFHealthHub intervention
This description follows the TIDieR checklist and guide.39
Aim
The CFHealthHub intervention aims to support adults with CF to increase and maintain their adherence to
prescribed nebulised medication to reduce exacerbations and improve or prevent decline in lung function.
Rationale
The CFHealthHub intervention is underpinned by the capability opportunity motivation – behaviour
(COM-B) model.37 It has been developed using the BCW approach alongside a PBA to intervention
development. This process is described in detail elsewhere but broadly consisted of the following stages:
l identification of barriers to and facilitators of nebuliser adherence using the TDF
l identification of appropriate intervention functions and behaviour change techniques to address
barriers identified
l iterative development of the CFHealthHub intervention with patients, using feedback from
interviews and ‘think aloud’ to refine the intervention
l creation of an intervention manual and training programme for interventionists
l pilot and feasibility trial including a process evaluation which was used to further refine the
intervention, manual and training process.
Conceptual framework and theory
The conceptual framework that describes the intervention is shown in Figure 12. Consistent with the
COM-B model, the framework considers issues of capability, opportunity and motivation, each of
which must be present for repetition of the behaviour (i.e. medication adherence) to occur. Initially,
we anticipate that repetition will require effortful self-regulation, but with repetition and strategies to
promote habit formation we aim for the behaviour to become more automatic.
The intervention addresses a range of different barriers and is tailored to meet the specific needs of
the person. The intervention draws on key theories to address different parts of the proposed process:
social cognitive theory,94 control theory95 and habit theory.96
Social cognitive theory94 proposes that behaviour is influenced by two core constructs: (1) perceived
self-efficacy (i.e. an individual’s beliefs in their capability to adhere to treatment) and (2) outcome
expectancies (i.e. an individual’s beliefs about the likely consequences of their actions). Self-efficacy can
be enhanced through (1) mastery, (2) vicarious experiences, where a role model similar to the individual
successfully achieves behavioural change in a similar situation, or (3) verbal persuasion. Outcome
expectancies include beliefs about the positive and negative and short- and long-term consequences
of adherence, and in this context include perceived necessities and concerns.97 According to social
cognitive theory outcome expectancies may result in intentions to change ones behaviour. Self-efficacy
then influences the translation of that intention into action through the pursuit of goals.
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Control theory95 explains the processes of self-regulation. When a behavioural standard or goal has
been set, an individual directs their attention through monitoring behaviour to the discrepancy
between their current behaviour and their goal. They then use this feedback to regulate their
behaviour to meet their goal through action control. This in the context of adherence; once an
adherence goal is set, self-monitoring of treatment-taking provides the feedback to prompt action to
enable self-regulation of behaviour.
A habit is where a behaviour is prompted automatically by a situational cue. Habits are created
through the repetition of a behaviour in a specific context,85 which over time results in a learned
cue–behaviour association.98 In the context of adherence, the repeated taking of treatment in a specific
context or in the presence of a specific cue should over time result in the formation of a habit. Habits
are particularly advantageous because theory predicts that, once formed, they do not rely on
motivational processes and, therefore, should persist even if motivation wanes.99 Therefore, they may
play a particularly important role in the promotion of long-term maintenance of behaviour,100 in this
case adherence, which is a key aim of the programme.
Materials
The CFHealthHub intervention includes a range of materials as follows:
1. eTrack nebuliser
2. Qualcomm hub
3. research procedures manual
4. CFHealthHub website
5. CFHealthHub app (available for Android and iOS devices)
6. COM-BMQ screening tool
7. CFHealthHub participant manual
8. CFHealthHub interventionist manual, including worksheets for intervention delivery
9. training slides and online resources [via the virtual learning environment (VLE) Blackboard
(University of Sheffield, Sheffield, UK)] for interventionist training


















FIGURE 12 Sustained behaviour conceptual framework: self-regulation or habit.
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Intervention providers
Intervention providers were recruited from each site. The majority of sites recruited individuals who
were already members of the MDTs working in CF at that site. Other sites recruited from other parts
of the hospital or recruited externally. Thus, interventionists had a range of backgrounds and included:
l physiotherapists working in CF or other respiratory conditions





Interventionist training, assessment and support
Interventionists received training in how to deliver the intervention in a variety of ways:
1. Training in use of equipment – interventionists received training in how to use the eTrack nebuliser
and Qualcomm hub, how to pair the devices and how to register a new participant onto the
CFHealthHub digital platform and eTrack system as part of their research procedures training.
This was delivered face to face by the study manager and PARI GmbH and supported with a
research procedures manual and ad hoc telephone support throughout the trial.
2. Training in delivery of CFHealthHub intervention – interventionists received training in how to use
the CFHealthHub digital platform and how they deliver the CFHealthHub intervention. Training was
delivered during a 2-day face-to-face training session followed by a schedule of online training to
be completed over the equivalent of 4 days hosted on the VLE. Training consisted of presentations,
with exercises in small groups or pairs, and supported use of CFHealthHub, role-play delivery of the
intervention and discussion. A training version of the CFHealthHub platform was provided for use
during training that included dummy data. Interventionists were paired to form buddies for support
and additional role play during the online part of the training.
3. Competency assessment – interventionists undertook two competency assessments during the
training period: (1) a theory test that assessed understanding of the content of the CFHealthHub
digital platform content and data. This test was delivered through an online survey on the VLE and
consisted of multiple choice and sort answer questions. The answers were marked according to a
pre-determined marking schedule. Interventionists passed if they received a mark of ≥ 80%. Individual
feedback was provided on the answers given and, where the first test was failed, additional tutorial
support was provided and the test retaken until passed. (2) A practical test that assessed delivery of
the first intervention visit of the CFHealthHub intervention. This was assessed through an audio-
recorded role play. The part of the participant was played by a member of the study team and the
interventionist role played their part. The intervention delivery was assessed using a competency
assessment sheet that consisted of sections on preparation, delivery of intervention components and
the quality of delivery. Two members of the training team looked at the completed worksheet for the
session and listened to the accompanying audio-recording. They discussed the marks and agreed
marks where there were any differences. Agreed marks for each section were averaged and the pass
threshold was 90%. Interventionists received individual feedback on their performance and tutorial
support where they had failed. The test was retaken until passed.
4. Competency to deliver a review visit and a phase review visit were assessed by listening to the first
audio-recorded visit of that kind for each interventionist.Two members of the training team looked at the
completed worksheet for the session and listened to the accompanying audio-recording.They discussed
and agreed marks. Agreed marks for each section were averaged and the pass mark threshold was 90%.
Interventionists received individual feedback on their performance and tutorial support where they
had failed. The next audio-recorded visit of that kind was assessed where the assessment was failed.
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5. Ongoing support – for interventionists this was delivered at a weekly teleconference, by e-mail and
telephone support with the training team and through technical support by telephone and e-mail.
The weekly teleconference provided a space where interventionists could discuss problems,
successes and case studies (anonymised) to aid group learning. Individuals could also access
members of the team individually and individual interventionists were targeted with support where
they had failed their earlier competency assessment or where there were any problems identified.
Intervention schedule of delivery
The intervention schedule of delivery is described in Figure 13. The content of each kind of intervention
session is described in this section. Within this schedule there were a number of different paths that
were determined during delivery.
Consent visit and set-up
All participants receive their eTrack nebuliser and Qualcomm hub at the consent visit. They also
complete the COM-BMQ screening tool at this visit. An account is created on CFHealthHub into which
is added the current prescription data for the participant and the data from the COM-BMQ screening
tool. The consent visit takes place at least 4 weeks prior to the first intervention visit. During this time
adherence data are transmitted automatically from the eTrack nebuliser via the Qualcomm hub, which
is plugged into their home, to the CFHealthHub platform. Figure 2 shows this process.
Intervention sessions received by all participants
All participants receive their first intervention visit at least 4 weeks following consent (so that the
consultation is based on at least 4 weeks’ worth of objective adherence data). This visit is always done
face to face, although it can be in a variety of locations, including at hospital (in-patient), a clinic or at
home. All participants receive an intermediate review telephone call 1 week later. Subsequent visits
depend on their adherence level. Participants with an objectively measured adherence level of ≥ 80%
follow the ‘very high level of adherence’ path and those with an adherence level of < 80% follow the
normal path.
Normal pathway (adherence level < 80%)
Participants on this pathway have intervention sessions over a 12-week period. In addition to the first
intervention session (at week 0) and an intermediate review (at week 1) they receive a review session
at week 4, an intermediate review at week 6, a second review session at weeks 8 or 9 and a phase
review at week 12. This pattern of delivery constitutes a phase. They then receive a phase review
session every 12 weeks, or every 6 weeks if their adherence level is < 25%.
Very high adherence level pathway (adherence level ≥ 80%)
Participants on this pathway have intervention sessions over a 4-week period. In addition to the first
intervention session (at week 0) and an intermediate review (at week 1) they receive a phase review at
week 4. They then receive a phase review session every 12 weeks.
Triggers
In addition to these pathways there are a number of criteria that, if met, trigger a new phase of
intervention delivery. These are:
l Participant-requested support. This can be a request for additional support at a phase review, in
which case an additional intervention delivery period is triggered without a break, or at any other
time. Additional periods of delivery are offered to participants if one or both of the following
triggers occurs following the first phase review.
l A drop of ≥ 20% in adherence since the phase review.
l An exacerbation requiring i.v. treatment.
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FIGURE 13 Schedule of intervention delivery.
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When there is a drop of ≥ 20% in adherence since the phase review or exacerbation requiring i.v.
treatment, participants are contacted and additional support is offered. If participants agree then the
triggered pathway commences with a review session at week 0, an intermediate review 1 week later,
a review visit 4 weeks later and a phase review 6 weeks later.
Participants then revert back to phase reviews at 12-week intervals (or 6 weeks if adherence is < 25%).
Access to the CFHealthHub digital platform
Participants had an individual login providing access to the CFHealthHub digital platform throughout
the intervention. It could be accessed on a laptop or through an app available for Android or iOS devices.
Participants were encouraged to access the site regularly and were provided with a participant guide
with instructions on how to access and information about what to find where.
Intervention modules
The CFHealthHub contains a number of distinct modules each of which focuses on a different aspect
using a range of specific behaviour change techniques (described using the definitions in the behaviour
change taxonomy)101 and modes of delivery. These are described in Table 12, which shows which
aspects of the intervention were delivered using the CFHealthHub digital platform and which were
delivered by the interventionist.
TABLE 12 Modules, behaviour change techniques and mode of delivery for the CFHealthHub intervention
Module BCTs101 Mode of delivery
My treatment l Information about
health consequences
l Credible source






l information about CF, the need for treatment, how each
treatment works and the importance of adherence
l information presented in a variety of ways though text, patient
stories, ‘talking heads’ and animation videos, with links to
external content including Cochrane reviews
l range of different credible information sources including PWCF,
clinicians and links to scientific papers
Interventionist:
l interventionist introducing and highlighting relevant content
on CFHealthHub








l charts and tables of objective adherence data
Interventionist:





l Focus on past success
CFHealthHub:
l ‘talking heads’ videos of coping stories
Interventionist:
l interventionist encouraging focus on periods of greater
adherence on charts
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Tailoring and personalisation
The CFHealthHub intervention is not one size fits all and is designed to be tailored and personalised
so that it can best meet the needs of a wide range of participants. Although the entire content of the
CFHealthHub website is available for participants to browse, tailored aspects are emphasised or added
into a specific personal ‘favourites’ area called ‘My Toolkit’. Table 13 described the ways in which the
intervention is tailored.
A number of features of the CFHealthHub digital platform are individually personalised for each
participant. These are described in Table 14.
Types of intervention visit
The intervention visits all have broadly the same aim, that is, to enable participants to look at their
data, reflect on why adherence is important, set goals to increase their adherence and make plans as to
TABLE 12 Modules, behaviour change techniques and mode of delivery for the CFHealthHub intervention (continued )












l indication of goal line on charts of adherence
l visual indication of goal met
l (optional) weekly push notifications indicating whether or not
goal was met
l (optional) reward messages sent when goal met
Interventionist:
l discussion and agreement of goals with interventionist
l review of goals
l suggested steady increase in goal as improvements are made
l feedback and social reward on progress




l ‘Action Planning’ tool and storage
Interventionist:
l help to focus on identifying consistent cues and linking to
behaviour (habit formation)
l discussion and identification of appropriate cues, and how to







l Social support (practical)







l solution bank (including advice on problem-solving,
restructuring the physical environment and engaging
social support)
l ‘Coping Planning’, ‘Day Planning’ and ‘Party Planning’ tools
and storage
l videos demonstrating correct use of nebulisers
Interventionist:
l tailored problem-solving guided by interventionist
l support to create day plans/party plans where appropriate
l support to construct if–then coping plans including identifying
self-talk where appropriate
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how they will achieve these, and problem-solve any barriers that are likely to get in the way. However,
the intervention visit types do differ somewhat in their set-up, focus and how in-depth they are as
follows. Detailed information about the structure of the delivery for each type of session is provided in
the intervention manual and the relevant worksheets.
First intervention visit
This session always occurs face to face, although this can be in a hospital/clinic setting or at home. It
lasts between 40 and 60 minutes. It is the first time that the participant accesses the CFHealthHub
digital platform and sees their data. Interventionists must prepare for this session by entering the data
from the COM-BMQ screening tool and checking that there is data coming through to CFHealthHub
from the nebuliser.
TABLE 13 Tailoring of the CFHealthHub intervention
Tailored component
How non-tailored components are
accessed How version is determined
Contents of ‘My treatment’ and
‘Problem-solving’ focus on
information relevant to current
prescription drugs
All generic information in available to
all participants to browse. Information
on treatments not currently prescribed
are available but minimised
Prescription is entered into
CFHealthHub at consent and altered
whenever there is a prescription
change. CFHealthHub automatically
tailors content based on this
information
Modules of ‘My treatment’ are
selected and placed into ‘My Toolkit’
based on the scores on the
COM-BMQ questionnaire
Participants can browse all modules
of ‘My treatment’
Participants responses to the COM-
BMQ questionnaire are entered into
CFHealthHub at consent. CFHealthHub
recommends the most relevant
modules based on a scoring algorithm.
If CFHealthHub recommends
more than three modules then
interventionists select three based on
the scores and their judgement based
on conversations with the participant.
Modules can be changed throughout
the intervention and these are
recorded on CFHealthHub
Modules of ‘Problem-solving’ are
selected and placed into My Toolkit
based on the barriers identified in
consultations with the interventionist
Participants can browse all modules
of ‘Problem-solving’
Interventionists can select modules of
‘Problem-solving’ content based on the
barriers identified in consultations.
Modules can be changed throughout
the intervention and these are
recorded on CFHealthHub
‘Talking heads’ videos are selected to
match key participant characteristics
and placed into ‘My Toolkit’. This is
optional
Participants can browse the entire
‘talking heads’ video library
Interventionists can select relevant
videos that match key characteristics
of the participant (e.g. age, gender,
occupation, life role, problems
experienced). Videos can be changed
throughout the intervention and
these are recorded on CFHealthHub
‘Goal-setting and review’ and
‘Treatment planning’ are utilised only
for participants who are motivated
(want to) take more treatment.
Participants with very low levels of
motivation do not receive these parts
of the intervention. Instead, they
spend more time focusing on the
content of ‘My treatment’ and
relationship building with the
interventionist
Participants can choose to set goals
and make plans at any point in a
consultation or by contacting the
interventionist
A very low level of motivation is
determined by a combination of a low
score on the COM-BMQ motivation
item and discussion with the participant
in a consultation. The identification of a
very low level of motivation is recorded
where this applies
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The key things that happen in this session are:
l participant receives their log-in details and accesses CFHealthHub
l participant (optionally) downloads the CFHealthHub app onto their smartphone









The intermediate review is a short session that is designed to trouble-shoot ‘quick’ and easy-to-solve
problems (e.g. an action plan that is not working). It is typically delivered by telephone and lasts
5–15 minutes. The review is less structured than other visits.
Ad hoc review
This follows the same structure as the intermediate review but is delivered where there is unplanned
face-to-face contact with a participant (e.g. in a clinic).
Review visit
This session typically lasts 30–45 minutes and can be delivered face to face or by telephone.
The session focuses on the data and what has happened in terms of adherence since the last visit.
TABLE 14 Personalisation of the CFHealthHub intervention
Personalised component How personalisation is achieved
Graphs and charts show personal data Participant’s eTrack nebuliser collects and send adherence data to
CFHealthHub via the Qualcomm hub for display
Target line on graph Participants determine their adherence goal in consultation with the
interventionist. This is displayed on their charts
Plans Participants make individual plans based on discussions with the
interventionist. These are made using the tools on the CFHealthHub digital
platform and recorded in ‘My Toolkit’. New plans can be added and
CFHealthHub records all plans for each participant
Home page Participants can select an image to display on their home page from a
default selection or can upload their own image
Notifications Participants can optionally choose to receive personalised notifications
using the CFHealthHub app. A message is sent to the participant if they
have met their goal in the previous week, or a messaging is sent to
encourage them to keep going if they did not
Reminders Participants can choose to receive reminders through the CFHealthHub
app. A reminder message is sent to the participant if they have not accessed
their CFHealthHub account for a period of 2 weeks
Reward messages Participants can optionally choose to receive reward messages through the
CFHealthHub app. A reward message is sent to the participant if they have
met their goal in the last week, 2 weeks or month
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The precise focus will vary depending on the individual participant, for example a session with a
participant who has met their goal would have a different focus to one with a participant who has not




l Goal-setting and review
l Treatment plan.
Problem-solving phase review
The focus of this appointment is to facilitate reflection on progress since the intervention (or the current
phase of delivery) began and to consider whether continued support is required or the participant
wishes to manage their adherence independently. Ideally, this should be delivered face to face but can






See Work packages 3.2, 3.3 and 3.4: full-scale randomised controlled trial with concurrent process evaluation.
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Appendix 3 Work package 2.3: intervention
training and fidelity assessment
Introduction
The Borrelli checklist54 was used as the framework to assess and monitor fidelity. In the feasibility
study the procedures for operationalising fidelity assessment in the main RCT were developed.
Fidelity was assessed across five domains.
Design
This explores whether or not the groups received the expected treatment (i.e. the CFHealthHub
intervention or usual care). For the intervention group, there is complexity in the flow of intervention
delivery where the next step in the intervention flow could change in response to events during the
trial. Therefore, we explored whether or not a participant received the minimum expected dose. This
was also complex because it differed depending on whether or not the participant was a high- or
low-level adherer. In general, there was reasonable agreement (74%) between expected versus actual
intervention in the treatment group. The control group participants received usual care, which for the
majority of sites did not include focused adherence support. For example, at trial initiation < 10% of
the centres used objective data such as MPR or I-neb adherence data to inform care.
Training
A blended programme of training was delivered to all interventionists that was supplemented
throughout the duration of the trial. Assessment of skill acquisition comprised two parts: (1) a written
theoretical competency test and (2) a practical competency test. To be fully certified as competent to
deliver this intervention, interventionists had to pass the theoretical competency test (pass mark
threshold 80%) as well as pass the competency threshold (90%) on fidelity assessments in all three
types of consultation: (1) first intervention visit, (2) review visit and (3) phase review visit. Certification
to deliver the first intervention visit was conducted as part of the initial intervention training.
Certification to deliver the review/phase review visits was conducted as they occurred in the main
RCT. Those achieving < 90% were given individual feedback and tutoring as well as direction to specific
learning materials provided on a VLE. All 30 interventionists completed the theory test. A total of
27 out of 30 interventionists achieved the pass mark (> 80%) on first attempt. Evaluation forms also
demonstrated that interventionists rated their competence to deliver the intervention at the end of
the training as high across a number of core domains involved in intervention delivery. A total of
27 interventionists completed first intervention certification prior to conducting any intervention sessions
in the RCT. For the assessments in which the participant was certified the mean score was 96% (SD 4%)
and the scores ranged from 88% to 100%. Each interventionist was given individual feedback, with
interventionists who failed given individualised retraining before reassessment. For review and phase
review certification 30 interventionists were certified. The mean score for the review was 96.2%
(SD 3.7%, range 90.7–100%] and for the phase review was 96.0% (SD 3.13%, range 91.7–100%].
Interventionists who failed were given individualised retraining before reassessment and also were
subsequently certified.
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Delivery of treatment
Assessment and monitoring of provider skill maintenance over time (fidelity drift) was assessed by
sampling from the different types of visits (first intervention visit, review visit or phase review visit).
We attempted to assess 20% of all visits with clear criteria to inform choice of assessments for drift
(18 targeted for high withdrawal rates, 37 for insufficient audio-recordings, 82 for having fewer visits
or action/coping plans created than expected and nine at random to ensure a total assessment sample
of ≥ 20% of all interventionist visits). A total of 110 assessments were assessed to explore drift in
fidelity over the duration of the trial and a pass mark threshold of 80% was set was drift assessments.
For both certification and drift, two people independently assessed each intervention, and agreement
between assessors was high. Of all paired assessments during the trial there was 97.2% agreement when
comparing pass/fail decisions at the 80% threshold (207 out of 213 assessments in agreement).
The trial had a high level of fidelity (overall fidelity by site, range 79–97%) with only one site not
achieving over the mean threshold (> 80%) on drift assessments.
Receipt
Setting of action and coping plans were assessed as a proxy for fidelity receipt. Receipt in this trial was
deemed to be satisfactory. Among the 265 participants who completed the 12-month trial, 205 (77%)
completed at least one action plan and 160 completed at least one coping plan.
Enactment
A total of 268 participants used web/app click analytics outside intervention sessions. In addition,
qualitative data provides evidence that participants were able to enact skills in real life settings.
Further details of fidelity findings are available in Report Supplementary Material 2.
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Appendix 4 Work package 3.3: usual-care
survey summary
A usual-care survey was conducted to examine the use and perceptions of the provision ofadherence monitoring and support in sites taking part in the full-scale RCT (WP 3.2).
Methods
All RCT sites were asked to complete a usual-care survey at study start and at 12-months. This was an
11-item questionnaire.
Questionnaires were to be completed by the site interventionist and/or other members of the MDT.
Median and interquartile ranges were used to summarise questionnaire items requiring a response
on 5-point nominal scales. Percentages by outcome response were also summarised for these items.
Key themes were extracted and summarised from free-text responses. Change scores were calculated
within sites by subtracting follow-up scores [time 2 (T2)] from baseline scores [time 1 (T1)] and
summarised overall.
Results
A total of 20 centres responded to the questionnaire. (Two centres share a CF service across the two
NHS trusts. For this reason, they were classed as a single site for the purposes of the full-scale RCT
but, because usual care could vary between the two sites, we collected a usual-care survey from both
sites.) Five sites responded outside the protocol window at baseline; all but one were within 3–18 days
of the expected response window (study start plus 1 month) and have been included in analyses. One
site was excluded at baseline and for comparison analyses between baseline and follow-up because the
questionnaire was not completed until a full-time interventionist replacement was confirmed, 9 months
post baseline.
Table 15 presents the results from nine questions, summarised quantitatively.
Change scores indicate consistency in all responses from baseline to follow-up, with the exception
of more frequent use of MPR at follow-up than at baseline (see question 1). Change scores should
be interpreted with caution because, in some cases, different members of the MDT completed
questionnaires at baseline and follow-up.
Question 3
Do you use any other motivational or behavioural strategies to promote adherence?
If so please specify
Use of behavioural strategies in routine care varied between sites. Some sites regularly used a range
of behavioural strategies in practice. One site did not state the use of any behavioural strategies in
routine care. At baseline, at least 63% of sites used MI or techniques derived from MI in usual care;
a further five sites (totalling 17 out of 19 sites over the course of the study) reported using MI
techniques with their patients at follow-up. The proportion of members of the MDT that were trained
in MI varied from some to all, but for the most part this was not specified. Goal-setting or use of specific,
measurable, achievable, relevant and time-bound (SMART) goals was used by at least five of 19 sites at
baseline. At least 26% of sites stated that they discussed barriers and/or used problem-solving to
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TABLE 15 Summaries by questionnaire item (excluding free-text questions)
Question T1 T2 Change Interpretation









l n = 20
l Median 3.5
(IQR 3.0–4.0)
l 20% = never
l 30% = rarely
l 35% = sometimes
l 15% = very often
l n= 19
l Median change in
score 1 (IQR 0–2)
l 21%= less frequent










58% of sites at
follow-up





l Median 3 (IQR 3–4)
l 5%= always




l n = 20
l Median 3 (IQR 2–4)
l 40% = very often
l 30% = sometimes
l 30% = rarely
l n= 19
l Median change in
score 0 (IQR 0–1)
l 16%= less frequent

























l Median 1 (IQR 1–2)
l 63%= always
l 32%= very often
l 5%= sometimes
l n = 20
l Median 1.5
(IQR 1.0–2.0)
l 50% = always
l 40% = very often




(IQR –1 to 0)
l 32%= less frequent



























l n = 20
l Median 1 (IQR 1–2)
l 65% = very
important
l 20% = important
l 10% =moderately




score 0 (IQR 0–0)
l 16%= less
important






















¢ question 6(1) –
2 (IQR 1–4)
¢ question 6(2) –
4 (IQR 1–6)
¢ question 6(3) –
6 (IQR 4.5–6.0)
¢ question 6(4) –
3 (IQR 2–4)
l n = 17d
l Median by items 2,
3, 4 and 7:
¢ question 6(2) –
4 (IQR 1–4)
¢ question 6(3) –
7 (IQR 5–7)
¢ question 6(4) –
5 (IQR 3–6)
¢ question 6(7) –
4 (IQR 2–6)
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TABLE 15 Summaries by questionnaire item (excluding free-text questions) (continued )



















¢ question 6(5) –
3 (IQR 2–4)
¢ question 6(6) –
4 (IQR 3–5)
¢ question 6(7) –
5 (IQR 3.5–6.0)










l n = 16*
l Median by items 1,
5 and 6:
¢ question 6(1) –
2.5 (IQR 1–4.5)
¢ question 6(5) – 3
(IQR 2.00–4.75)
¢ question 6(6) –
3.5 (IQR
2.25–5.75)























8. Do you use the
I-neb data to provide
objectively recorded
recent adherence














l n = 17
l Median 3 (IQR 2–5)
l 12% = always
l 18% = very often
l 29% = sometimes
l 12% = rarely
l 29% = never
l n= 14
l Median change
score 0 (IQR –0.25
to 1)
l 21%= less frequent





















9. Do you use
bespoke graphs
plotted from the




l Median 5 (IQR 5–5)
l 93%= never
l 7%= sometimes
l n = 17
l Median 5 (IQR 5–5)
l 82% = never
l 6% = rarely
l 6% = sometimes
l 6% = always
l n= 14
l Median 0 (IQR 0–0)
l 7%= less frequent










10. Do you sit with






l Median 5 (IQR 3–5)
l 64%= never
l 21%= sometimes
l 7%= very often
l 7%= always
l n = 17
l Median 5 (IQR 3–5)
l 53% = never
l 12% = rarely
l 24% = sometimes
l 12% = always
l n= 14
l Median 0 (IQR –1.0
to 0.5)
l 29%= less frequent
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overcome barriers with their patients, and at least 53% of sites had access to cognitive–behavioural
therapy and/or support from a trained psychologist. One site referenced the use of the COM-B model
and one site referenced discussing habit, both at follow-up.
Question 7
Do you use any objective measures of adherence? If so specify
Some method of objectively measuring adherence to inhaled medications was identified in 75% of
sites. This included general practitioner/home care/pharmacist prescription collections, downloads of
adherence data from the I-neb, checking of drug levels, visual analogue scales of adherence, dosset
boxes and tick charts. Collection and utilisation of these data varied in frequency; most sites reported
using objective measures on an ad hoc or relatively infrequent basis, often in selected groups of
patients whom they had concerns about and only by specific members of the MDT. In 25% of the sites,
no formal measures were identified over the course of the study.
Summary
Adherence support was mostly considered very important and adherence was discussed with patients
at least sometimes, across all sites. Some method of objectively measuring adherence to inhaled
medications was identified in 75% of sites. Qualitative data highlighted that implementation of
adherence support varied between RCT sites. Collection and utilisation of adherence data varied in
frequency and formality; many sites reported using objective measures on an ad hoc or relatively
infrequent basis. Change scores indicated that, on the whole, practice was consistent in usual care over
the follow-up period.
TABLE 15 Summaries by questionnaire item (excluding free-text questions) (continued )
Question T1 T2 Change Interpretation











l Median 3 (IQR 2–5)
l 9%= always
l 36%= very often
l 18%= sometimes
l 36%= never
l n = 12
l Median 3 (IQR 2–4)
l 33% = very often
l 33% = sometimes
l 17% = rarely
l 17% = never
l n= 9
l Median 0 (IQR –1
to 2)
l 33%= less frequent
























a The number of prescriptions issued compared with the number cashed.
b For example, agree that a patient with chronic Pseudomonas will aim to achieve 1 × DNase and 1 × tobramycin per
day rather than 2 × tobramycin per day.
c Sites that did not respond stated that they could not rank these items because they are all considered to
be important.
d Sites that did not respond stated that they could not rank these items as different patients have different priorities.
Coding questions 1, 2, 4 and 8–11: 1= always; 2= very often; 3 = sometimes; 4= rarely; 5= never.
Coding question 5: 1 = very important; 2= important; 3 =moderately important; 4= slightly important;
5= not important.
Question 6: answers indicate order of priority [e.g. a question 6(1) score of three means that encouraging airway
clearance was scored as third most important].
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Appendix 5 Work package 3.3: user
satisfaction survey
A survey was conducted to evaluate satisfaction with the CFHealthHub intervention, delivered inthe full-scale RCT (WP 3.2).
Methods
All participants allocated to the intervention arm and who completed the 12-month follow-up were
asked to complete an 11-item survey. This was completed as part of the 12-month follow-up
questionnaire battery. Interventionists were usually present during the completion of the survey.
All questionnaire items asked participants to rate how helpful they found specific parts of the
intervention. Each item required responses on a 4-point nominal scale, from very helpful to not helpful
at all. Responses have been summarised as percentages for each response category.
Results
A total of 257 out of the 305 participants randomised to the intervention arm responded. Summaries
by response category are presented in the main report (see Table 7). The intervention element rated as
most helpful was the first intervention visit and exposure to CFHealthHub.
There was variation in overall satisfaction between sites. Summaries of scores averaged across all
intervention elements by site are shown in Table 16.
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TABLE 16 User satisfaction, averaged across all intervention elements, by site
Site code Very helpful (%) Quite helpful (%) Not very helpful (%) Not helpful at all (%)
1 52.3 41.5 6.2 0.0
2 70.0 25.0 5.0 0.0
3 33.0 53.7 12.7 0.6
4 59.4 34.3 6.3 0.0
5 34.9 44.1 11.8 9.1
6 41.6 45.5 8.4 4.5
7 55.8 22.4 8.5 13.3
8 66.2 27.3 6.5 0.0
9 53.0 32.0 12.4 2.7
10 48.1 34.5 15.2 2.3
11 45.5 41.6 10.4 2.6
12 32.8 52.3 9.6 5.2
13 24.2 48.5 18.2 9.1
14 55.2 30.1 9.8 4.9
15 41.1 38.2 20.8 0.0
16 70.8 23.0 4.3 1.9
17 44.9 46.4 8.7 0.0
18 28.2 28.7 40.0 3.0
19 73.3 24.4 2.3 0.0
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Appendix 6 Work package 3.3:
adverse events
TABLE 17 Detailed list of adverse events in RCT
Adverse event
Usual care
(n= 303), n (%)
Intervention





All AEs 301 (46.9) 341 (53.1) 642 (100.0)
Participants experiencing at least one AE 125 (41.3) 139 (45.6) 264 (43.4)
AEs by category
Expected or common eventa 242 (80.4) 263 (77.1) 505 (78.7)
01 Acute FEV1 drop > 15% after first dose of medication 1 (0.4) 2 (0.8) 3 (0.6)
02 Increased productive cough 62 (25.6) 73 (27.8) 135 (26.7)
03 Nasal congestion or stuffy nose 12 (5.0) 10 (3.8) 22 (4.4)
04 Chest congestion 8 (3.3) 15 (5.7) 23 (4.6)
05 Wheezing 8 (3.3) 10 (3.8) 18 (3.6)
06 Chest pain or chest discomfort 18 (7.4) 11 (4.2) 29 (5.7)
07 Voice alteration/change 4 (1.7) 2 (0.8) 6 (1.2)
08 Dyspnoea (breathlessness) 17 (7) 14 (5.3) 31 (6.1)
09 Haemoptysis (coughing blood) 26 (10.7) 40 (15.2) 66 (13.1)
10 Rhinitis 1 (0.4) 2 (0.8) 3 (0.6)
11 Headache 3 (1.2) 4 (1.5) 7 (1.4)
12 Crackles in lung 9 (3.7) 6 (2.3) 15 (3.0)
13 Throat irritation/sore throat 15 (6.2) 12 (4.6) 27 (5.3)
14 Upper respiratory tract infection 6 (2.5) 8 (3.0) 14 (2.8)
15 Sinusitis 3 (1.2) 3 (1.1) 6 (1.2)
16 Deafness 0 (0.0) 1 (0.4) 1 (0.2)
17 Indigestion/reflux 2 (0.8) 0 (0.0) 2 (0.4)
18 Tonsillitis 0 (0.0) 1 (0.4) 1 (0.2)
19 Joint pain 2 (0.8) 5 (1.9) 7 (1.4)
20 Decreased appetite 5 (2.1) 1 (0.4) 6 (1.2)
21 Fatigue 12 (5.0) 6 (2.3) 18 (3.6)
22 Headache 0 (0.0) 3 (1.1) 3 (0.6)
23 Distal intestinal obstructive syndrome 0 (0.0) 1 (0.4) 1 (0.2)
24 Fever 2 (0.8) 3 (1.1) 5 (1.0)
25 Otitis media or ear infection 1 (0.4) 2 (0.8) 3 (0.6)
26 Conjunctivitis 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 17 Detailed list of adverse events in RCT (continued )
Adverse event
Usual care
(n= 303), n (%)
Intervention




27 Pneumothorax 2 (0.8) 2 (0.8) 4 (0.8)
28 Decreased exercise tolerance 1 (0.4) 1 (0.4) 2 (0.4)
29 Pyrexia 1 (0.4) 0 (0.0) 1 (0.2)
30 Abdominal pain 4 (1.7) 14 (5.3) 18 (3.6)
31 Influenza 3 (1.2) 4 (1.5) 7 (1.4)
32 New Pseudomonas infection since recruitment in
patient who was previously Pseudomonas free
6 (2.5) 2 (0.8) 8 (1.6)
33 Vomiting 4 (1.7) 4 (1.5) 8 (1.6)
34 New diagnosis of diabetes 4 (1.7) 1 (0.4) 5 (1.0)
35 Pneumonia 0 (0.0) 0 (0.0) 0 (0.0)
New depression requiring treatment 1 (0.3) 5 (1.5) 6 (0.9)
Other 58 (19.3) 73 (21.4) 131 (20.4)
Serious adverse events
All SAEs 64 (47.4) 71 (52.6) 135 (100.0)
Participants experiencing at least one SAE 43 (14.2) 56 (18.4) 99 (16.3)
SAEs by category
Expected or common eventa 21 (32.8) 28 (39.4) 49 (36.3)
01 Acute FEV1 drop > 15% after first dose of medication 0 (0.0) 0 (0.0) 0 (0.0)
02 Increased productive cough 2 (9.5) 2 (7.1) 4 (8.2)
03 Nasal congestion or stuffy nose 0 (0.0) 0 (0.0) 0 (0.0)
04 Chest congestion 0 (0.0) 0 (0.0) 0 (0.0)
05 Wheezing 0 (0.0) 1 (3.6) 1 (2.0)
06 Chest pain or chest discomfort 1 (4.8) 1 (3.6) 2 (4.1)
07 Voice alteration/change 0 (0.0) 0 (0.0) 0 (0.0)
08 Dyspnoea (breathlessness) 0 (0.0) 3 (10.7) 3 (6.1)
09 Haemoptysis (coughing blood) 1 (4.8) 5 (17.9) 6 (12.2)
10 Rhinitis 0 (0.0) 0 (0.0) 0 (0.0)
11 Headache 0 (0.0) 0 (0.0) 0 (0.0)
12 Crackles in lung 0 (0.0) 0 (0.0) 0 (0.0)
13 Throat irritation/sore throat 0 (0.0) 1 (3.6) 1 (2.0)
14 Upper respiratory tract infection 0 (0.0) 0 (0.0) 0 (0.0)
15 Sinusitis 0 (0.0) 0 (0.0) 0 (0.0)
16 Deafness 0 (0.0) 0 (0.0) 0 (0.0)
17 Indigestion/reflux 0 (0.0) 0 (0.0) 0 (0.0)
18 Tonsillitis 0 (0.0) 0 (0.0) 0 (0.0)
19 Joint pain 0 (0.0) 0 (0.0) 0 (0.0)
20 Decreased appetite 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 17 Detailed list of adverse events in RCT (continued )
Adverse event
Usual care
(n= 303), n (%)
Intervention




21 Fatigue 0 (0.0) 0 (0.0) 0 (0.0)
22 Headache 0 (0.0) 0 (0.0) 0 (0.0)
23 Distal intestinal obstructive syndrome 3 (14.3) 5 (17.9) 8 (16.3)
24 Fever 0 (0.0) 0 (0.0) 0 (0.0)
25 Otitis media or ear infection 0 (0.0) 0 (0.0) 0 (0.0)
26 Conjunctivitis 0 (0.0) 0 (0.0) 0 (0.0)
27 Pneumothorax 2 (9.5) 0 (0.0) 2 (4.1)
28 Decreased exercise tolerance 0 (0.0) 0 (0.0) 0 (0.0)
29 Pyrexia 0 (0.0) 0 (0.0) 0 (0.0)
30 Abdominal pain 9 (42.9) 2 (7.1) 11 (22.4)
31 Influenza 1 (4.8) 1 (3.6) 2 (4.1)
32 New Pseudomonas infection since recruitment in
patient who was previously Pseudomonas free
0 (0.0) 1 (3.6) 1 (2.0)
33 Vomiting 2 (9.5) 5 (17.9) 7 (14.3)
34 New diagnosis of diabetes 0 (0.0) 1 (3.6) 1 (2.0)
35 Pneumonia 0 (0.0) 0 (0.0) 0 (0.0)
New depression requiring treatment 0 (0.0) 0 (0.0) 0 (0.0)
Other 41 (64.1) 42 (59.2) 83 (61.5)
Unknown 2 (3.1) 1 (1.4) 3 (2.2)
a Expected events by type are presented as percentage of total expected events.
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Appendix 7 Work package 3.3: the
benefits of objective nebuliser adherence
data as ‘proof’ in the management of cystic
fibrosis in adults – a qualitative study
Background
Low rates of adherence or non-adherence to nebuliser treatment in CF are linked to poor clinical
outcomes. With advances in technology there has been an increase in electronic monitoring of
nebuliser usage in CF clinical practice. There is little understanding of how objective data, when used
as evidence of adherence, is perceived by PWCF and health-care professionals, and whether or not it
can facilitate discussions surrounding the reasons for adherent or non-adherent behaviours.
Methods
A qualitative study as part of a RCT evaluating the effectiveness of a new intervention to promote
adherence. The intervention comprised feedback of real-time, objective adherence data to PWCF and
an interventionist – usually a health-care professional from the CF MDT – offering a BCI. During
intervention sessions between interventionists and PWCF the objective adherence data were discussed
and targets for improvement agreed on and set. A total of 22 PWCF and 26 interventionists took part
in individual semistructured interviews; a framework approach was used for analysis.
Results
Objective adherence data were welcomed by both interventionists and PWCF in the intervention arm
of the RCT. PWCF were able to choose how to display their data, for example different types of graphs
(bar/line) and daily, weekly or specific times. Interventionists suggested that these easy-to-read graphs
provided a focus for discussions with PWCF about their adherence patterns. Details about how the
data were displayed were significant. In particular, using a traffic light system of red, amber and green
enabled PWCF to see at a glance if they were meeting targets set by themselves and the interventionist.
‘Gamification’ of the data, encouraging PWCF to achieve green graphs signifying meeting targets, was key
to engaging PWCF, acting as a motivator to meet targets. Technological issues did not appear to affect
PWCFs’ trust in the data.
The objective data were used as ‘proof to self’, offering reassurance to high-level adherers who
believed they were adhering to their nebuliser treatments but nevertheless appreciated external proof
of this belief. By contrast, some PWCF with lower adherence levels could be shocked by the proof of
the number of treatments they had missed in previous weeks and months. PWCF from all adherence
groups used the data to keep track of their progress, and seeing patterns of adherence helped them to
consolidate their routines to improve adherence. The data as ‘proof to self’ provided both motivation
to improve for lower-level adherers and motivation to maintain high levels for higher-level adherers.
The data were used as a platform to initiate sometimes difficult discussions about adherence, and were
perceived as promoting honesty between PWCF and clinicians. When patients could see improvements,
this increased their motivation to continue to meet targets set.
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The objective data could also act as ‘proof to others’. The ability to prove what they were doing to
others was very important to PWCF, regardless of adherence grouping, because they often perceived
that their clinical team – and in some cases their close family members – did not believe their
subjective reports of adherence. Some PWCF in the sample had objective adherence rates that
matched their subjective adherence rates and were considerably higher than their clinical team or
family members believed. In these cases the proof offered by the objective data could radically change
the PWCF’s identity as a low-level adherer, improving relationships with clinicians and family. It could
even affect future clinical care when clinicians understood that the health problems experienced by the
PWCF could not be due to lack of adherence to nebuliser medication, and that alternative reasons
needed to be investigated.
Most interventionists and PWCF viewed the objective data, and the proof it offered, positively.
However, interventionists pointed out that it needed to be used carefully, particularly with those
PWCF not achieving high levels of adherence. They stressed that it was important that this proof
was used to instigate a discussion, not as a reason to castigate PWCF. At times there was disparity
between the objective data, and PWCF’s perceptions of their adherence, which had to be addressed
with sensitivity.
Conclusion
In this study of PWCF who chose to participate in a RCT of an intervention to improve adherence,
objective nebuliser adherence data appeared to facilitate honest discussions around reasons for non-
adherence, and helped with identification of strategies to resolve barriers to adherence. In addition,
the data offered proof to both PWCF and their clinical team that both motivated and rewarded
improvements in adherence.
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Appendix 8 Work package 3.3:
mechanisms of action based on the
perceptions of people with cystic fibrosis
and interventionists
Background
The logic model (see Figure 3) and prior research33 identified a number of mechanisms of action
important to increasing adherence in the CFHealthHub intervention. We explored whether or not
and how these mechanisms of action operated in patient and interventionist accounts of using the
CFHealthHub intervention.
Methods
We analysed the perceived mechanisms of action identified in 22 patient and 26 interventionist interviews.
We grouped patients into four categories of baseline levels of objectively measured adherence
(very low: 0.0–24.9%; low: 25.0–49.9%; moderate: 50.0–74.9%; high: ≥ 75%) as part of this analysis.
Results
Perceived changes in adherence
Most patients in this sample (20/22) believed that they had increased their adherence. Some patients
made connections between changes in health and doing their nebuliser treatments, which reinforced
the need for treatment. Small adjustments to routines allowed high-level adherers to maintain
adherence. Participants perceived that moderate-level adherers increased adherence by establishing
routines for additional treatments by making informal or formal action plans with the interventionist.
For those with lower levels of adherence, there were more barriers to overcome, which interventionists
sometimes struggled to address.
Expected mechanisms of action in different groups of baseline adherence
Self-monitoring was acceptable in this sample of PWCF and was the most used aspect of the
intervention, usually accessed through the app. Self-monitoring seemed less important to high-level
adherers who knew how they were doing and very low-level adherers who sometimes did not see the
need to look at their adherence.
Tailored education and problem-solving were used successfully by some interventionists and PWCF
to address individual issues for low- and moderate-level adherers such as unhelpful beliefs about
treatments. The videos about how treatments worked were seen as particularly useful to patients and
interventionists, with the exception of high-level adherers.
Tailored patient videos were useful to some patients provided that they found someone like them.
However, some patients disliked seeing other PWCF.
Personalised goal-setting, goal review and rewards were acceptable and used in visits to set targets
acceptable to patients. Lower- and moderate-level adherers often lowered their targets initially to hit
their target. Some then increased their target and maintained it, although this could be sporadic to
begin with.
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Personalised action plans were sometimes problematic as patients did not understand their purpose
and struggled to write them in the intervention format. High-level adherers did not need action plans;
however, these plans were sometimes successful in forming habits for low- and moderate-level
adherers through trial and error and tackling assumptions about when treatments could happen.
Additional mechanisms of action
The patient–interventionist relationship gave PWCF someone to talk to about adherence issues,
someone who believed in them, and made them accountable to someone about adherence progress.
Most PWCF and interventionists in the sample believed that visits needed to happen face to face and
outside clinic visits to enable time to talk through issues with someone who cared.
Others (interventionists and MDT members) monitoring adherence was reassuring and motivating for
most participants in the sample, particularly when the interventionist or MDT members praised PWCF.
The right time to receive the intervention was important for some PWCF who increased their
adherence; for example, during a time of change, such as a new job, house or relationship, a recent
hospital admission or a sense of getting older.
Conclusion
Where the intervention helped PWCF to increase adherence, a combination of mechanisms of action
came together at the right time for patients. Key mechanisms were self-monitoring, others monitoring
nebuliser adherence, the relationship between the patient and the interventionist, and action plans.
In some cases, the intervention was unable to address all the barriers in the individual’s life.
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Appendix 9 Work package 3.3: variation
in context between randomised controlled
trial sites
Introduction
Understanding the relationship between intervention and context is essential to determine the factors
involved in the success and failure of interventions, causal mechanisms and variation in effects.102
In addition, decision-makers need to understand the role of context so that they can have confidence
that the intervention will work well in other settings.103
The UK Medical Research Council Guidance definition of context includes ‘anything external to the
intervention that may act as a barrier or facilitator to its implementation, or its effects’.45 It ‘interacts,
influences, modifies and facilitates or constrains the intervention and its implementation’.104
Methods
We considered context at the macro (CF community), meso (CF unit size, culture, attitude to medication
adherence) and micro (interventionists’ skills, backgrounds, practices) levels.104 We focused only on the
meso and micro levels in our analysis because we were interested in variation between RCT sites.
We brought together data from a range of sources in the process evaluation: qualitative interviews
with interventionists (patients and MDT were not included because we did not have interviews for all
RCT sites), trial management reports, fidelity scores, the usual-care survey and the acceptability of
intervention survey (focusing on items relating to interventionists only). We displayed data in a grid,
with sites in rows and variables in columns. We colour coded each cell as red if problems were
identified and as blue if the site looked very good compared with other sites. We then undertook
‘pattern matching’ used in multiple case study analysis, with each site acting as a case.105
Results
We found variation between sites in all the variables we included. For example, some sites used
different nebulisers to the type used in the RCT, interventionists had different disciplinary backgrounds
and experience with CF (e.g. physiotherapist, pharmacist), interventionists had different reasons to get
involved in the RCT, interventionists had different levels of communication with the MDT about the
intervention and about specific patients in the intervention arm, interventionists organised their work
differently, some sites did not allow home visits and so all assessments had to occur on site when the
intervention specified home, some sites had different cultural alignment with the intervention, MDT
attitudes to the RCT varied from receptive to indifferent to hostile, and some interventionists found it
easier to deliver patient-centred communication.
A key finding was that potential barriers did not hinder the intervention but potential facilitators could
enhance the implementation of the intervention. The extent to which the interventionist was embedded
in the MDT appeared to be very important to implementation of the intervention.
Conclusions
A key contextual factor of how embedded interventionists were in the MDT may have enhanced the
implementation of the intervention.
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Appendix 10 Work package 3.3:
mediation analysis
A mediation analysis was conducted to examine the mechanisms of change in relation to thosehypothesised in an a priori logic model.
The mean adherence between 6 to 12 months was primarily mediated by awareness of medication usage
(37% of the total effect mediated, 95% CI 24% to 51%), with habit formation (9%, 95% CI 3% to 16%)
the second most important factor (Table 18). Other mediating effects were reduced concerns, increased
self-efficacy and ease of effort, resulting in a total mediated effect of 51%. There was some evidence
that the intervention increased awareness among patients who used several nebulisers at baseline.
As shown in Figure 14, better awareness seems to be associated to better normative medication adherence.
As shown in Figure 15, increase in baseline prescription seems to reduce awareness in the usual-care
arm but not in the intervention group.
As shown in Figure 16, increase in effort seems to improve normative medication adherence but this
effect varies for males and females.
Figure 17 and Tables 19–21 and provide additional information and data from this analysis.





Cohen’s d (95% CI) Mediator selected?
Awareness 570 0.45 (0.38 to 0.51) 0.61 (0.44 to 0.77) Yes
Motivation 534 0.06 (–0.03 to 0.14) 0.11 (–0.06 to 0.28) No
Habit 532 0.17 (0.08 to 0.25) 0.29 (0.12 to 0.46) Yes
Concerns 534 0.13 (0.05 to 0.22) 0.40 (0.22 to 0.56) Yes
Necessity 534 0.04 (–0.05 to 0.12) 0.19 (0.02 to 0.36) No
Self-efficacy 534 0.16 (0.078 to 0.25) 0.17 (0.002 to 0.34) Yes
Barriers 607 0.10 (0.02 to 0.18) –0.01 (–0.17 to 0.14) No
Chaos 535 0.10 (0.01 to 0.19) 0.06 (–0.11 to 0.22) No
Effort 530 0.18 (0.1 to 0.27) 0.25 (0.08 to 0.42) Yes
Burden 539 0.03 (–0.06 to 0.11) 0.17 (–0.003 to 0.34) No
a Awareness was calculated as the difference between self-reported adherence and observed normative medication
adherence from the data collected closest to 6 months post consent. Mediating effect for motivation, necessity,
concerns, self-efficacy, chaos, habit, effort and barriers were calculated as the change from baseline to 12-month
follow-up. All values were converted so that increase in mediation can be interpreted as positive treatment effect.
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FIGURE 14 Normative medication adherence vs. baseline prescription by randomisation group: (a) usual care; and
(b) intervention.
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FIGURE 15 Awareness vs. baseline prescription by randomisation group interaction graph: (a) usual care; and
(b) intervention.
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FIGURE 16 Effort vs. gender by randomisation group interaction graph: (a) usual care, female; (b) usual care, male;
(c) intervention, female; and (d) intervention, male.
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FIGURE 17 Mediation pathway DAG. Model fit of the model with concerns affecting self-efficacy was similar to self-efficacy
affecting concerns but both models produced similar estimates.
TABLE 19 Association between mediators
Mediator 1a Mediator 2a Correlation (95% CI)
Awareness Self efficacy –0.01 (–0.10 to 0.08)
Awareness Concerns 0.06 (–0.03 to 0.14)
Awareness Habit –0.05 (–0.13 to 0.04)
Awareness Effort –0.05 (–0.14 to 0.04)
Self efficacy Concerns 0.16 (0.07 to 0.24)
Self efficacy Effort 0.20 (0.12 to 0.28)
Self efficacy Habit 0.20 (0.12 to 0.28)
Concerns Habit 0.21 (0.12 to 0.29)
Concerns Effort 0.23 (0.15 to 0.31)
Habit Effort 0.32 (0.24 to 0.39)
a All values were converted so that increase in mediation can be interpreted as a positive
treatment effect.
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TABLE 20 Final mediation model result
Effect Mediator Indirect effect estimate (95% CI) Proportion mediated (%)
Indirect effects Awareness (prescription 0.5) 2.40 (–0.56 to 5.36) 18.00
Awareness (prescription 2) 3.85 (1.79 to 5.91) 28.90
Awareness (prescription 4) 5.79 (3.76 to 7.81) 43.43
Awareness (prescription 6) 7.72 (4.45 to 10.99) 57.97
Self-efficacy 0.21 (–0.31 to 0.73) 1.58
Concerns 0.21 (–0.29 to 0.71) 1.55
Habit 1.26 (0.36 to 2.15) 9.44
Effort (females) 0.37 (–0.23 to 0.98) 2.80
Effort (males) –0.03 (–0.34 to 0.28) –0.24
Direct effect 6.07 (2.65 to 9.48)
Total effect 13.32 (9.60 to 17.04)
TABLE 21 Final mediation model result
Effect Mediator Indirect effect point estimate (95% CI) Proportion mediated (%)
Indirect effects Awareness (prescription 0.5) 1.88 (–0.99 to 4.74) 14.08
Awareness (prescription 2) 3.65 (1.64 to 5.67) 27.43
Awareness (prescription 4) 6.02 (4.08 to 7.97) 45.23
Awareness (prescription 6) 8.40 (5.30 to 11.49) 63.03
Self-efficacy 0.20 (–0.31 to 0.71) 1.54
Concerns 0.18 (–0.33 to 0.68) 1.32
Habit 1.26 (0.36 to 2.15) 9.45
Effort (females) 0.38 (–0.23 to 0.98) 2.83
Effort (males) –0.03 (–0.35 to 0.28) –0.25
Direct effect 6.17 (2.74 to 9.61)
Total effect 13.33 (9.60 to 17.06)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
Appendix 11 Work package 3.3: process
evaluation triangulation table
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TABLE 22 Process evaluation triangulation table
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm













patients to do things they
were supposed to do to
hit fidelity targets,
specifically action plans




some of the behaviours
such as action plans








facilitators – also helped
people link treatments to
aspects of daily routine
l Preference for different
aspects of intervention –
mainly the interventionist
knowing more about them
l Enactment – successes in
establishing new routine
and habits. Using cues and
triggers was popular but
did not always work
– 1. High levels of fidelity





as well as clicks on
CFHealthHub







































Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
Adaptations l Interventionists adapted
timing of visits around
patient availability
l Sometimes wanted
patients to have more
visits than patients
wanted
l Some did not stick to








rearranged, to suit them –
adapting the flow of visits
– – – –
Access to
intervention
l Technical issues l Patients were generally
not put off by technical
issues as long as they
could be explained
– – 1. CFHealthHub went down
for 5 weeks near the end
of the RCT, affecting a
subset of patients
2. Four new interventionists
recruited




Dose l Some patients were hard
to get hold of and may
not have had the
expected number of visits
l Interventionists
sometimes used the flow
chart of visits in a flexible
way but generally stuck
to the overall flow of
intervention visits
l Patients spoke about
having to rearrange
appointments and so
there was longer between
sessions than there should
have been, or visits
were missed
l No one mentioned that
they would have liked
more sessions
– 1. Fidelity to minimum
sessions was high

































































































































































































































































































































TABLE 22 Process evaluation triangulation table (continued )
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
Feasibility l The intervention was
feasible to deliver by the
interventionists and by
the sites in the RCT
l The intervention
was feasible
– – – 1. Feasible
Reach l Self-selecting sample of
people who are happy to
be monitored?






they thought would sign up
(at least initially). Some
interventionists had
patients with learning
disabilities who found the
written aspects of the
intervention difficult. Some
interventionists reported
hard to reach populations
with no fixed abode,
nowhere to plug a hub in
l Better for ‘middle’
adherers – people who
are not ill enough to see
team regularly but are not
high-level adherers with
established routine
l Good for some but ‘not
for me’ (very low-level
baseline adherers)
l Good for people who are
online quite often, for
people who need more
knowledge; reassurance
for high-level adherers
– – 1. 1581/3510
(45% of eligible)
2. 607/1581 (38% of eligible
recruited to RCT)
3. 125 unwilling to change
nebuliser (8% of eligible)












































Qualitative Quantitative Acceptability questions











PWCF in intervention arm







to prefer home visits but
not allowed in some
RCT sites
2. Creating long-term
continuity of care in
relationship important








2. Patients liked choice of
venue for meetings
3. Preferred face-to-face
visits than telephone visits
but if away from CF
centre, telephone visits
could also work
– – 1. 60% found interventionist
support very helpful and
7% unhelpful, so a largely
acceptable component
2. 287/305 (94%) got first
intervention visit. A total
of 77% patients found
first meeting very helpful.
No one not finding it
helpful, so a universally
acceptable component.
But note that only 257
out of 305 people
completed this item
owing to loss to follow-up




helpful, again with few
finding it unhelpful
4. Helpfulness ratings of
interventionists differed
by site with three sites
having higher levels of
dissatisfaction/saying not
helpful (24–33%)




why – emphasis on
relationship building.
Likely to be a key
mechanism of action

































































































































































































































































































































TABLE 22 Process evaluation triangulation table (continued )
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm










3. Proof of adherence or
proof of non-adherence
1. Key mechanisms of
self-monitoring and
self-regulation
2. Patients used this part
of the intervention
outside visits
3. Liked traffic light aspect
4. Main aspect of
CFHealthHub that was
looked at or used by











– 1. 68% of patients found
graphs very helpful and
only 4% not helpful, so
universally acceptable
component
1. Agreement from a
number of sources
that this was a key
mechanism of action










1. Not often used
outside meetings
– – 1. 44% found toolkit very
helpful, 16% not helpful,
so not helping every one





1. Some people doing
actions plans
2. Need to revisit and
tweak plans, so not a
one-off exercise
3. It is sometimes a
box-ticking exercise
in terms of completing
actions plans
1. If action plans do not
work at first, some were
reluctant to try again,
whereas others did
try again
2. Difficult to formulate
plans on CFHealthHub
– – 1. 216 participants with
push notifications
enabled
2. 227 participants made
action plans
3. 118 participants made
coping plans
4. 39% very helpful and
20% not helpful
1. Action plans were
used and found to be












































Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
4. Difficult to set them and
encourage people to do
it themselves
5. Happening informally in
that patients do not want
to put them down
on paper





plans and use them with
patients. Easier when
renamed as backup plans
and further training from
research team
3. Some patients found these
worked straightaway,
whereas others tweaked
them to make them work




1. Helped to increase
knowledge
1. Patients understood better
how treatments worked
even if they already
thought they knew
2. Thought they would be
good to share with others
(e.g. family)
– – 1. 38% found them very
helpful and 26% not, so






1. Patients either loved or
hated them
2. Some interventionists
showed them during visits
rather than leaving
patients to look at them
alone after visits
1. Some patients liked to
see people in similar
circumstances (i.e. with
children) and some did not
want the reminder that
they had CF
– – 1. 29% very helpful and
34% not helpful. The love-






































































































































































































































































































































TABLE 22 Process evaluation triangulation table (continued )
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
My treatment – – – – 1. 48% very helpful and
11% not helpful





1. Could be picked up during
conversation to address
an issue (e.g. going on
holiday or cleaning
nebulisers)
1. Not looked at much by
patients in this sample but
described as a useful
source of information if
they had an issue before
contacting interventionist





App – Preferred way to access
CFHealthHub
Not everything was
accessible on the app and
tricky to see some aspects of
the graphs
Could not see times on app
but quick and easy







1. Some difficulties if MDT
gave different advice
to patients
2. Engagement of MDT
varied across RCT sites
3. Concerns that others in
MDT would use graphs
information in the
wrong way
1. Key mechanism of action
was that others were
monitoring, including MDT
and interventionists
2. Feeling of not being
believed by MDT in the
past but objective data
could offer proof
of adherence














































Qualitative Quantitative Acceptability questions











PWCF in intervention arm




1. Training was well received.
Some gap between training
and delivering the
intervention. Some issues
around the way the
intervention is delivered in
terms of MI-informed
approach. More could have


















2. Only of benefit to some
patients? Depends on
baseline adherence level.




and family and friends
1. Reported examples of
improvements: increase in
FEV1, less hospital visits,
cough stopping
2. Able to show proof to MDT
and family that they were
doing their treatment
3. High-level adherers already
had habit formation, so no
improvements there, but
could see patterns and
check, use monitoring for
reassurance
4. Some patients liked
routine and habit forming,
and others disliked it, so
resisted habit forming
































































































































































































































































































































TABLE 22 Process evaluation triangulation table (continued )
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
4. Can change identity of
patient toMDT if patient
had been known as a low-
level adherer but the
objective data showed they
were a high-level adherer
5. Interventionists found
that the approach to
communicating with
people stimulated
reflection on their own
practice even if they had
had MI training in
the past
5. Appreciated the more
in-depth relationships
with interventionists –









worrying to some patients
because they fixated on
the data and withdrew
owing to felling the
pressure to improve
2. If there was no praise from




of action plan completion
may have contributed to
some interventionists
setting inappropriate
action plans or with
patients who were not
sufficiently motivated
1. The intervention was
successful for some
patients when it was













































Qualitative Quantitative Acceptability questions











PWCF in intervention arm





1. Baseline adherence rate is
very important in terms
of how patients use the
intervention and benefit
from it
2. Adherence can be
inconsistent owing to
life events
3. Needs to be the right
time for someone for
them to engage fully
with intervention
1. Chaotic lives hindered
habit formation
2. Low levels of literacy or
dyslexia could prohibit
writing action plans







1. Usual-care arm feel
monitored in the RCT,
so may increase their
adherence rates so not
just receiving usual care
2. Differences between
RCT sites in how much
adherence and MI
communication style was
embedded in usual care
1. Intervention seen by
patients as opportunity
for interventionists to get
more insight into their
lives than usual care –
opportunity to discuss
more things, and in more
depth, as had longer time
with interventionists than
usually have with MDT
2. Differences between sites
in how intervention was
delivered (in a clinic or
at home)
3. Variation in how
integrated the
intervention was
perceived to be with
usual care




increased over time, and
did not use bespoke
graphs of I-neb plots, but
some used Insight Online.
Majority said they used
some objective adherence
measurement but in an
ad hoc way
2. A minority of sites tended
to reduce the target
prescription and this
increased over time (21%
then 37% always/often),
and tended not to use
I-neb data to inform
consultations (21%
then 25%)
1. There did not seem
to be a high level of
action similar to the
intervention at play
in usual care







4. Not much changed in
usual care over the
time of the RCT





































































































































































































































































































































TABLE 22 Process evaluation triangulation table (continued )
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity




4. 63% used MI at baseline
and a further five sites
used it at follow-up






and this could have
increased adherence
Nebuliser type 1. Patients had preferences
that influenced
participation in RCT and
withdrawal from RCT




1. Some found the new
nebuliser issued in the
RCT quicker, quieter,
smaller and more effective
2. Others found it harder to
use because they had to
use it at different times
from their old nebuliser
and they had to change
established systems/habits
– – 1. 4 people withdrew from
the RCT owing to
preference for
another nebuliser
1. The types of
nebulisers offered











































Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
RCT sites/CF
centres
1. There are differences
between RCT sites in
terms of implementation,
context, interventionists,





visits or had to see





culture of the CF centre,
how the CF centre
reacted to the CQUIN




prescribed, links to MDT,
and interventionist
skills/background



































































































































































































































































































































TABLE 22 Process evaluation triangulation table (continued )
Type/source
of data
Qualitative Quantitative Acceptability questions











PWCF in intervention arm
of RCT interviews Mediation analysis Fidelity
RCT 1. Some usual-care arm
patients believed that
the interventionist








3. Motivation questions on
RCTquestionnaire did not
pick up who was not
motivated to do treatment.
This could be picked up by
the interventionist in their
first meeting
4. Paperwork and data
collection burden
5. The site principal
investigator was more
involved in the RCT in
some sites
6. CTRU monitoring of sites
influenced which aspects
of the intervention were
focused on
1. Lots of questionnaires
to answer – sometimes
confusing as to what
rating to give as could not
remember how they had
rated things last time
and thought this might
cause problems
– – – 1. May see increase in
adherence in the
usual-care arm





































Appendix 12 Work package 3.4:
triangulation of randomised controlled trial
and process evaluation findings
TABLE 23 Triangulation of RCT and process evaluation findings
Outcomes and




Exacerbations l Primary outcome
l Difference = 0.14 lower
in intervention
l IRR 0.96 (95% CI 0.83 to
1.12; p = 0.638)
l Subgroup analyses
identified no patterns
l Examples of individuals
seeing reductions in
exacerbations/hospital visits
in the qualitative research,
but much more discussion
about improvements
in adherence
The intervention may have
helped some PWCF reduce
exacerbations but the size of





l Key secondary outcome
l 9.5 percentage points




identified that those with
low to moderate levels of
baseline adherence had
improvements of 15%
compared with lower rates
of improvement for very
low (10%) or high levels
of baseline adherence
(3%) (p < 0.001)
l Interventionists and PWCF




of action planned in the
intervention (e.g. self-
monitoring) as well as others
such as the importance of
the relationship between
interventionist and PWCF,
timing of the intervention in
the context of their wider
lives and the importance
of time spent with
interventionists
l Calibrating adherence using
objective adherence data
were associated with
increases in adherence in
the mediation analysis
l In the qualitative research,
PWCF with high levels of
baseline adherence were
often reassured by the
intervention; PWCF with
low to moderate levels
of baseline adherence
discussed improvements;
PWCF with very low
baseline adherence often
had complex lives that






and potentially a range of
other mechanisms
continued
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TABLE 23 Triangulation of RCT and process evaluation findings (continued )
Outcomes and




FEV1 l Key secondary outcome




l Examples of PWCF in
qualitative research
perceiving improvements in
lung function, reduction in
cough and related benefits
such as being able to hold
a conversation, do more
exercise or feel better
while exercising
Possible small improvement in
lung function
BMI l Key secondary outcome
l 0.3 kg/m2 (95% CI 0.1 kg/m2
to 0.6 kg/m2) improvement
in BMI
l Maintenance in controls
and increase in
intervention arm
l Weight gain was identified
in the qualitative research
by some interventionists
and reported by one PWCF.




adherence, or PWCF feeling
better when their adherence
rates increased




l Reduction in concerns and
increase in necessities







the need for treatment,
particularly through the
videos of what the
treatments do in the lungs
Positive changes in beliefs
about medication through
discussion with interventionists
and videos in CFHealthHub
Habit l Increase in habit forming l Interventionists and PWCF
in the qualitative research
described patients creating
habits or treatment becoming
more automatic. Habit
forming was associated with
improvements in adherence
in the mediation analysis
Improvement in habit forming
HRQoL l CF questionnaire showed
that all changes in domains
of HRQoL were in a positive




l PWCF in the qualitative
research described benefits
that could improve quality of
life, some of which were not
measured here, such as
better relationships with the
MDT, better relationships
with family, having a sense of
doing everything they can,
being able to do more
exercise because it was easier
and being able to do daily
tasks more easily (such as
taking children to school).
This could come from
interventionists addressing
wider life issues that got in
the way of being able to
adhere, as well as addressing
nebuliser adherence
Possibly some improvements
in quality of life. Reduction in
treatment burden caused by a
range of issues
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TABLE 23 Triangulation of RCT and process evaluation findings (continued )
Outcomes and




l There were examples of
reduction of perceived and
actual treatment burden in
the qualitative research that
came from new nebulisers
offered in the RCT being
more efficient than older
ones, removal of fear and
dread of the treatment
burden, understanding how
medication worked in theory,
helping to reduce sense of
burden, making a personal
cost–benefit analysis of the
time put into treatment vs.
benefits actually experienced,
being advised to use
daily activities for their
physiotherapy (not related
to medication) and having
numbers of treatments
reduced to encourage
adherence with the intention
to increase treatments later
Effort l Improvement in that
treatment was less effort
l See discussion of treatment
burden above
Less perceived effort to take
treatments
PAM l Increase in
patient activation
l A PWCF in the qualitative
research reported feeling




Depression l No change l Interventionists in the
qualitative research felt
that the intervention was
challenging for a minority of
patients with depression.
One interventionist felt that
the intervention had helped
her patient’s depression
but not their adherence.
The intervention was
not designed to deal
with depression
No change in depression
Anxiety l No change l Some interventionists
described a small number of
PWCF who were anxious
about achieving 100%
adherence or using the
intervention. This was low-
level anxiety around a specific
issue, not the more generic
anxiety measured in the RCT
No change in general anxiety
Implementation – l Level of fidelity was high in





Safety l No serious adverse events – No serious adverse events
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Appendix 13 Work package 3.5: resource
and cost inputs economic evaluation
alongside a clinical trial




component Unit cost (£) Assumptions Source
i.v. drugs:
hospitala






15.16 14 doses in 14 days
Sodium
chloride, 0.9%
0.06 28 doses in 14 days
Heparin, 50
units in 5 ml


























44.82 14 doses in 14 days
Sodium
chloride, 0.9%
0.60 28 doses in 14 days
Heparin, 50
units in 5 ml
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component Unit cost (£) Assumptions Source
Adherence
intervention















312.72 Costs of running CFHealthHub
for 12 months; 305 trial patients






72.13 Costs for 12 months; 305 trial





34.93 One programme manager
(1 hour/3 weeks), one research
assistant (1.5 hours/3 weeks),
two data specialists (0.5 days/
week + 6 weeks full and 1 hour/
3 weeks); includes overheads for
academic staff; 305 trial patients
in the intervention arm
University of Sheffield (yearly
ages); Chin Maguire, ACTIF
Project Manager, University






58.50 15 interventionists, one
programme manager, one data
specialist, two research
assistants, one trainer; includes
overheads for academic staff;
305 trial patients in the
intervention arm






345.45 Three trainers (2 × 180.5 hours
and 61 hours for developing
training, delivering face-to-face
and competency assessment),
30 interventionists (grade 7
physiotherapists); includes
overheads for academic staff;
305 trial patients in the
intervention arm






58.50 Assumed the same costs as
TMG; telephone calls with all
interventionists every 3 weeks;
305 trial patients in the
intervention arm












257.00 Data from the intervention log;
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Annualised cost per patient;
equipment lifetime of 5 years






Annualised cost per patient,
equipment lifetime of 5 years,
20% of patients would receive a







406.03 Cost per non-elective bed-day,
weighted by FCEs and average
length of stay, assumed
interventions for bronchiectasis
(codes DZ12C to DZ12F)





337.36 Cost per non-elective excess
bed-day weighted by FCEs;
weighted average across all
interventions




4.06 Assumed that each surgery
consultation lasts 9.22 minutes;
unit costs of GP includes direct
care staff costs, qualification





165.98 Costs of consultant-led services
for respiratory medicine (service
code 340) from total outpatient
attendances data




119.64 Costs of non-consultant led
services for respiratory medicine
(service code 340) from total
outpatient attendances data
NHS Reference Costs 2017/1858
Nurse (minutes) 0.75 Unit costs of hospital or
community-based nurses,





54.91 Costs of total services for
physiotherapy (consultant and
non-consultant led, service code
650) from total outpatient
attendances data
NHS Reference Costs 2017/1858
Dietitian (n) 82.64 Costs of total services for
dietetics (consultant and
non-consultant led, service code
654), from total outpatient
attendances data
NHS Reference Costs 2017/1858
Telephone
contact (call)
10.45 Unit costs of telephone triage –
assumed the average between
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component Unit cost (£) Assumptions Source
Psychologist
visits (n)
170.27 Costs of total services for clinical
psychology (consultant and non-
consultant led, service code 656)
from total outpatient
attendances data




73.25 Costs of total services for
occupational therapy (consultant
and non-consultant led, service
code 651) from total outpatient
attendances data
NHS Reference Costs 2017/1858
Radiographer
visits (n)
57.73 Assumed the costs of total
services for diagnostic imaging
(consultant and non-consultant
led, service code 812) from total
outpatient attendances data
NHS Reference Costs 2017/1858
Social worker
(minutes)
1.00 Unit costs of telephone triage –
assumed the average between
the GP-led and nurse-led
services
PSSRU report 2018106
Other visits (n) 121.34 Assumed all interventions for
total outpatient attendances,
excluding paediatric (and related)
items; costs were weighted by
FCEs
NHS Reference Costs 2017/1858
A&E (n) 135.80 Costs of total services for A&E
(consultant and non-consultant
led, service code 180) from total
outpatient attendances data
NHS Reference Costs 2017/1858
Transplant 45,458.41 Assumed the costs of total
services for lung and heart and
lung transplants (elective
inpatient, elective inpatient
excess bed-days and non-elective
long stay, codes DZ01Z and
ED01Z); costs weighted by FCEs
NHS Reference Costs 2017/1858
A&E, accident and emergency; FCE, finished consultant episode; GP, general practitioner; ScHARR, School of Health
and Related Research.
a Unit costs presented by dose.
Any queries regarding the redacted costs should be sent to the corresponding author.
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Appendix 14 Work package 3.5: health
economic model parameters
Transition probabilities: usual care
TABLE 25 Initial health state distribution: both arms pooled (ACtiF RCT data)
Health state FEV1 ≥ 70% FEV1 ≥ 40–69% FEV1 < 40% Transplant Dead
n 212 242 152 0 0
Probability 0.35 0.40 0.25 0 0
TABLE 26 Annual transition probabilities estimated from multistate models fitted to CF registry data: usual care
(CF Registry data set, 2006–15)
From/to FEV1 ≥ 70% FEV1 ≥ 40–69% FEV1 < 40% Transplant Dead
Aged 30–34 years
FEV1 ≥ 70% 0.8749 0.1138 0.0074 0.0001 0.0038
FEV1 ≥ 40–69% 0.0806 0.8047 0.1045 0.0029 0.0073
FEV1 < 40% 0.0044 0.0879 0.7804 0.0441 0.0832
Transplant 0.0000 0.0000 0.0000 0.9450 0.0550
Dead 0.0000 0.0000 0.0000 0.0000 1.0000
Aged 35–39 years
FEV1 ≥ 70% 0.8545 0.1322 0.0068 0.0001 0.0065
FEV1 ≥ 40–69% 0.0775 0.8291 0.0849 0.0015 0.0070
FEV1 < 40% 0.0045 0.0961 0.7906 0.0285 0.0803
Transplant 0.0000 0.0000 0.0000 0.9672 0.0328
Dead 0.0000 0.0000 0.0000 0.0000 1.0000
Aged 40–44 years
FEV1 ≥ 70% 0.8599 0.1245 0.0081 0.0001 0.0074
FEV1 ≥ 40–69% 0.0624 0.8216 0.1064 0.0015 0.0081
FEV1 < 40% 0.0033 0.0879 0.7944 0.0222 0.0921
Transplant 0.0000 0.0000 0.0000 0.8875 0.1125
Dead 0.0000 0.0000 0.0000 0.0000 1.0000
Aged 45–49 years
FEV1 ≥ 70% 0.8892 0.0927 0.0062 0.0000 0.0119
FEV1 ≥ 40–69% 0.0770 0.8025 0.1078 0.0010 0.0116
FEV1 < 40% 0.0045 0.0938 0.7792 0.0149 0.1075
Transplant 0.0000 0.0000 0.0000 0.9465 0.0535
FEV1 ≥ 70% 0.0000 0.0000 0.0000 0.0000 1.0000
continued
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Treatment effects: risk ratios of switching state, intervention versus control
TABLE 26 Annual transition probabilities estimated from multistate models fitted to CF registry data: usual care
(CF Registry data set, 2006–15) (continued )
From/to FEV1 ≥ 70% FEV1 ≥ 40–69% FEV1 < 40% Transplant Dead
Age ≥ 50 years
FEV1 ≥ 70% 0.8291 0.1527 0.0129 0.0001 0.0052
FEV1 ≥ 40–69% 0.0837 0.7466 0.1271 0.0020 0.0406
FEV1 < 40% 0.0060 0.1077 0.7465 0.0241 0.1158
Transplant 0.0000 0.0000 0.0000 0.9558 0.0442
Dead 0.0000 0.0000 0.0000 0.0000 1.0000
Shaded cells reflect non-permitted state transitions.
TABLE 27 Annual i.v. therapy day frequencies, proportion of year spent with i.v. therapy and probability of i.v. therapy in
hospital, conditional on FEV1% predicted stratum: usual care (CF registry data set, 2006–15)
Parameter FEV1 ≥ 70% predicted FEV1 40–69% predicted FEV1 < 40% predicted
i.v. therapy-days in hospital 72,891 187,183 195,998
i.v. therapy-days at home 79,617 192,393 179,325
Total i.v. therapy-days 152,508 379,576 375,323
Patient-years in FEV1% category 17,178 16,210 7964
i.v. therapy-days per year 8.88 23.42 47.13
Proportion of year on i.v. therapy 0.02 0.06 0.13
Probability i.v. therapy given in hospital 0.48 0.49 0.52
TABLE 28 Risk ratios of switching FEV1% predicted stratum: cumulative logit model (ACtiF RCT data)
Transition p1 p2 Point estimate (95% CI) Log SE
Bootstrap back-
transformed mean
FEV1 ≥ 70% : FEV1 40–69% 0.17 0.27 0.65 (0.40 to 1.04) 0.25 0.64
FEV1 ≥ 70% : FEV1 < 40% 0.01 0.01 1.18 (0.69 to 2.04) 0.28 1.18
FEV1 40–69% : FEV1 ≥ 70% 0.09 0.05 1.65 (0.95 to 2.94) 0.29 1.67
FEV1 40–69% : FEV1 < 40% 0.24 0.21 1.14 (0.74 to 1.75) 0.22 1.14
FEV1 < 40% : FEV1 ≥ 70% 0.01 0.00 1.71 (0.95 to 3.15) 0.31 1.73
FEV1 < 40% : FEV1 40–69% 0.15 0.17 0.86 (0.53 to 1.36) 0.24 0.85
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Treatment effects: relative rate ratio for intravenous therapy-days,
intervention versus control
Health-related quality of life mapping
TABLE 29 Relative rate ratio for i.v. therapy-days, intervention versus control:
negative binomial model (ACtiF RCT data)
Parameter Mean (95% CI) SE
RRR i.v. therapy-days 0.92 (0.80 to 1.06) 0.07
TABLE 30 The FEV1% predicted to EQ-5D mapping model coefficients: three-component ALDVMM (ACtiF RCT data)
Component EQ-5D Coefficient SE z p> |z|a Lower 95% CI Upper 95% CI
Comp_1 FEV1% 0.1499 0.0667 2.2484 0.0246 0.0192 0.2806
Comp_1 _cons 0.7068 0.0360 19.6061 0.0000 0.6361 0.7774
Comp_2 FEV1% 0.4843 0.1341 3.6127 0.0003 0.2216 0.7470
Comp_2 _cons 0.4168 0.1479 2.8179 0.0048 0.1269 0.7066
Comp_3 FEV1% 1.2016 0.3618 3.3213 0.0009 0.4925 1.9106
Comp_3 _cons 0.3371 0.1102 3.0585 0.0022 0.1211 0.5532
Prob_C1 FEV1% 4.9465 2.1909 2.2577 0.0240 0.6524 9.2407
Prob_C1 _cons –1.4490 1.1952 –1.2123 0.2254 –3.7915 0.8936
Prob_C2 FEV1% 7.1422 2.0871 3.4221 0.0006 3.0516 11.2329
Prob_C2 _cons –3.8112 0.9412 –4.0491 0.0001 –5.6560 –1.9664
lns_1 _cons –1.9981 0.0737 –27.1154 0.0000 –2.1425 –1.8537
lns_2 _cons –1.1134 0.1014 –10.9779 0.0000 –1.3122 –0.9146
lns_3 _cons –1.6441 0.1257 –13.0789 0.0000 –1.8905 –1.3977
_diparm1 sigma1 0.1356 0.0100 – – 0.1174 0.1567
_diparm1 sigma2 0.3284 0.0333 – – 0.2692 0.4007
_diparm1 sigma3 0.1932 0.0243 – – 0.1510 0.2472
EQ-5D, EuroQol-5 Dimensions.
a p-value from the hypothesis test for the regression coefficient from the model.
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Costs




component Unit cost (£) Assumptions Source
i.v. drugs:
hospitala






15.16 14 doses in 14 days
Sodium chloride,
0.9%
0.06 28 doses in 14 days
Heparin, 50 units
in 5 ml




1 x 100 Sani-
cloth® wipes
– 1 unit












44.82 14 doses in 14 days
Sodium chloride,
0.9%
0.60 28 doses in 14 days
Heparin, 50 units
in 5 ml




1 × 100 Sani-
cloth® wipes
24.00 1 unit









2380.45 Daily dose of 600 mg;
tobramycin, 300 mg/5 ml; drug
tariff price; weighted by the
proportion of patients in CF
registry
BNF; CF registry; Misbah







5.89 Daily dose of 160 mg;
gentamicin, 80 ml/2 ml; NHS
indicative price; weighted by the
proportion of patients in CF
registry
Colistin 442.19 Daily dose of 2 million units;
colomycin, 2 million units
powder; NHS indicative and drug
tariff prices; weighted by the
proportion of patients in CF
registry
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1158.39 Daily dose of 4 million units
(average); Promixin, 1 million
units powder; NHS indicative
and drug tariff prices; weighted
by the proportion of patients in
CF registry
Aztreonam 1506.06 Daily dose of 225 mg; Cayston,
75 mg powder; NHS indicative
and drug tariff prices; weighted




923.62 Daily dose of 3.32 million units;
Colobreathe (Teva UK Ltd,
Castleford, UK), 1.6 million units
powder capsules; NHS indicative
and drug tariff prices; weighted




1212.22 Daily dose of 224 mg;
tobramycin, 28 mg powder
capsules; drug tariff price;
weighted by the proportion of
patients in CF registry
Azithromycin 69.44 Daily dose of 250 mg;
azithromycin, 250 mg tablets;
drug tariff price; weighted by




6.76 Daily dose of 1 g; flucloxacillin
250 mg or 500 mg capsules; NHS
indicative or drug tariff prices;
weighted by the proportion of
patients in CF registry
Mannitol 341.18 Daily dose of 800 mg; Bronchitol
(Pharmaxis Europe Limited,
Dublin, Ireland), 40 mg inhalation
powder capsules; NHS indicative
price; weighted by the proportion
of patients in CF registry
DNase 4160.35 Daily dose of 2.5 mg; Pulmozyme
(Roche Products Limited,
Welwyn Garden City, UK),
2.5 mg; NHS indicative and
drug tariff prices; weighted by
the proportion of patients in
CF registry
Hypertonic saline 91.33 Daily dose of 8 ml; 6% or 7%
inhalation solution; NHS
indicative price; weighted by
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component Unit cost (£) Assumptions Source
Adherence
intervention





Same costs as in the trial;








16.17 Same annual cost as in the trial;







3.73 Same annual cost as in the trial;









0 Not applicable –
Interventionists
training
17.86 Same number of trainers,
interventionists and costs as in
the trial; 305 trial patients in the
intervention arm; applicable only
for the first year of the model






3.02 Assumed the same annual costs
as the TMG meetings in the trial;
5900 patients eligible for the
intervention






159.00 Same cost and assumptions as in
the trial; applicable only for the





257.00 Assumed the same average per















Annuitised cost per patient;
equipment lifetime of 5 years





Annuitised cost per patient,
equipment lifetime of 5 years





406.03 Same cost and assumptions as in
the trial





337.36 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
APPENDIX 14
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128













165.98 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Non-consultant
hospital visits (n)
119.64 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858





54.91 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Dietitian (n) 82.64 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Phone contact
(call)





170.27 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Occupational
therapist visits (n)
73.25 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Radiographer
visits (n)
57.73 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Social worker
(minutes)
1.00 Same cost and assumptions as in
the trial
PSSRU report 2018
Other visits (n) 121.34 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
A&E (n) 135.80 Same cost and assumptions as in
the trial
NHS Reference Costs 2017/1858
Transplant 45,458.41 Same cost and assumptions as
in the trial. Applied once on
transition into the transplant
health state
NHS Reference Costs 2017/1858
A&E, accident and emergency; GP, general practitioner; ScHARR, School of Health and Related Research.
a Unit costs presented by dose.
Any queries regarding the redacted costs should be sent to the corresponding author.
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Appendix 15 Work package 3.5: forced
expiratory volume in first second (per cent)
predicted to EuroQol-5 Dimensions,
three-level version, mapping function –
assessment of goodness of fit of
alternative models
TABLE 32 Summary measures of fit for ALDVMMs
Summary measure Two components Three components Four components
AIC 588.55 564.26 568.39
BIC 634.76 639.37 672.38
MAE 0.1495 0.1486 0.1487
RMSEA 0.1922 0.1909 0.1909
0.70







95% CI mean prediction
95% CI mean data
(a)
0.70







95% CI mean prediction
95% CI mean data
(b)
FIGURE 18 Plots of mean prediction vs. data group means for ALDVMMs: (a) two components; (b) three components;
and (c) four components. (continued )
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FIGURE 19 Plots of the cumulative percentage of actual data vs. model for ALDVMMs: (a) two components; (b) three
components; and (c) four components. (continued )
0.70







95% CI mean prediction
95% CI mean data
(c)
FIGURE 18 Plots of mean prediction vs. data group means for ALDVMMs: (a) two components; (b) three components;
and (c) four components.
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FIGURE 19 Plots of the cumulative percentage of actual data vs. model for ALDVMMs: (a) two components; (b) three
components; and (c) four components.
DOI: 10.3310/pgfar09110 Programme Grants for Applied Research 2021 Vol. 9 No. 11
Copyright © 2021 Wildman et al. This work was produced by Wildman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
133

Appendix 16 Work package 3.5:
validation of model outputs
The following activities were undertaken to ensure the internal validity and credibility of the model:
l consideration of key items contained in published economic evaluation and health economic
modelling checklists107,108
l discussion of the proposed model structure with members of the ACtiF PMG
l double programming of the deterministic version of the model to ensure that the model is not
subject to programming errors
l checking the model parameter values against their original data sources
l checking the integrity of the distributions sampled in the PSA
l using expert clinical input to determine alternative plausible assumptions
l comparing the observed and model-predicted state sojourn times for the age-specific registry data
sets (Figures 20–24)
l comparing the model-predicted survival against previously published estimates (Figure 25)8
l comparing the model-predicted health state occupancy estimates by age against recent estimates















































FIGURE 20 msm prevalence plots, aged 30–34 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
(continued )
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FIGURE 20 msm prevalence plots, aged 30–34 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
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FIGURE 21 msm prevalence plots, aged 35–39 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
(continued )
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FIGURE 22 msm prevalence plots, aged 40–44 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
(continued )
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FIGURE 23 msm prevalence plots, aged 45–49 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
(continued )
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FIGURE 24 msm prevalence plots, aged ≥ 50 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
(continued )
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FIGURE 24 msm prevalence plots, aged ≥ 50 years: (a) state 1; (b) state 2; (c) state 3; (d) state 4; and (e) state 5.
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40–69%; CF registry




FIGURE 26 The FEV1% predicted by age category: model predicted vs. 2015 CF registry estimates.
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Appendix 17 Work package 3.5: model-
based analysis sensitivity analysis results


























































































FIGURE 28 Cost-effectiveness acceptability curves: ACtiF adherence intervention vs. usual care, 10-year treatment
effect duration.
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Treatment effect duration
FIGURE 29 Incremental net montary benefit by treatment effect duration: ACtiF adherence intervention vs. usual care
(assuming a WTP threshold of £20,000 per QALY gained).











1. Discounted results 0.20 0.09 –1065 Dominating 2854
2. Undiscounted results 0.20 0.18 815 4610 2721
3. Increase in adherence increases
nebulised drug costs
0.20 0.09 3198 35,749 –1409
4. Nebulised drugs costs halved 0.20 0.09 –1660 Dominating 3449
5. Increase in adherence increases
nebulised drug costs plus nebulised
drugs costs halved
0.20 0.09 472 5273 1317
6. No treatment effect on transition
probabilities
0.00 0.00 119 46,927 –68
7. No treatment effect on i.v.
therapy-days
0.20 0.09 1207 13,868 534
8. i.v. therapy-days treatment effect
doubled
0.20 0.09 –3338 Dominating 5175
9. Utilities based on Bradley et al.109 0.20 0.11 –1065 Dominating 3283
10. i.v. disutility halved 0.20 0.09 –1065 Dominating 2804
11. i.v. disutility doubled 0.20 0.09 –1065 Dominating 2956
12. Health state resource costs halved 0.20 0.09 –1094 Dominating 2883
13. Health state resource costs
doubled
0.20 0.09 –1009 Dominating 2798
14. Intervention cost 25% higher 0.20 0.09 –497 Dominating 2286
15. Intervention cost 25% lower 0.20 0.09 –1634 Dominating 3423
16. Transplant costs halved 0.20 0.09 –1033 Dominating 2822
17. Transplant costs doubled 0.20 0.09 –1130 Dominating 2919
18. Remove survival constraints 0.24 0.09 –892 Dominating 2782
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10-year treatment effect duration
1. Discounted results 0.40 0.17 –1637 Dominating 4991
2. Undiscounted results 0.40 0.35 2026 5729 5047
3. Increase in adherence increases
nebulised drug costs
0.40 0.17 5477 32,657 –2123
4. Nebulised drugs costs halved 0.40 0.17 –2787 Dominating 6141
5. Increase in adherence increases
nebulised drug costs plus nebulised
drugs costs halved
0.40 0.17 770 4592 2584
6. No treatment effect on transition
probabilities
0.00 0.00 93 21,671 –7
7. No treatment effect on i.v.
therapy-days
0.40 0.16 2121 12,957 1153
8. i.v. therapy-days treatment effect
doubled
0.40 0.17 –5394 Dominating 8829
9. Utilities based on Bradley et al.109 0.40 0.21 –1637 Dominating 5772
10. i.v. disutility halved 0.40 0.16 –1637 Dominating 4904
11. i.v. disutility doubled 0.40 0.18 –1637 Dominating 5164
12. Health state resource costs halved 0.40 0.17 –1712 Dominating 5066
13. Health state resource costs
doubled
0.40 0.17 –1487 Dominating 4841
14. Intervention cost 25% higher 0.40 0.17 –697 Dominating 4051
15. Intervention cost 25% lower 0.40 0.17 –2576 Dominating 5930
16. Transplant costs halved 0.40 0.17 –1578 Dominating 4932
17. Transplant costs doubled 0.40 0.17 –1753 Dominating 5107
18. Remove survival constraints 0.50 0.18 –1218 Dominating 4813
20-year treatment effect duration
1. Discounted results 0.69 0.26 –1812 Dominating 6937
2. Undiscounted results 0.69 0.59 4360 7336 7526
3. Increase in adherence increases
nebulised drug costs
0.69 0.26 8841 34,499 –3716
4. Nebulised drugs costs halved 0.69 0.26 –3624 Dominating 8750
5. Increase in adherence increases
nebulised drug costs plus nebulised
drugs costs halved
0.69 0.26 1702 6643 3423
6. No treatment effect on transition
probabilities
0.00 0.01 –7 Dominating 137
7. No treatment effect on i.v.
therapy-days
0.69 0.25 3751 14,985 1255
8. i.v. therapy-days treatment effect
doubled
0.69 0.26 –7374 Dominating 12,619
9. Utilities based on Bradley et al.109 0.69 0.31 –1812 Dominating 8065
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10. i.v. disutility halved 0.69 0.25 –1812 Dominating 6812
11. i.v. disutility doubled 0.69 0.27 –1812 Dominating 7188
12. Health state resource costs halved 0.69 0.26 –1952 Dominating 7077
13. Health state resource costs
doubled
0.69 0.26 –1532 Dominating 6657
14. Intervention cost 25% higher 0.69 0.26 –415 Dominating 5540
15. Intervention cost 25% lower 0.69 0.26 –3209 Dominating 8334
16. Transplant costs halved 0.69 0.26 –1727 Dominating 6853
17. Transplant costs doubled 0.69 0.26 –1981 Dominating 7107
18. Remove survival constraints 0.93 0.29 –806 Dominating 6507
LYG, life-years gained.
a Undiscounted.
b WTP threshold of £20,000 per QALY gained.
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